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SUMMARY 
 
Staphylococcus aureus is the most common cause of hospital-acquired infection and 
contributes significantly to patient morbidity and mortality. The ability of S. aureus to switch 
to an alternative phenotype in the presence of antimicrobial agents is clearly favourable. One 
of these alternatives are small colony variants (SCVs). The novel phenotypes include changes 
to colony morphology, antibiotic susceptibility, haemolytic activity and many other 
physiological activities.  It is now recognised that SCVs have a deficiency in electron 
transport, owing to mutations affecting its efficacy. 
 
This study investigated SCVs in various ways. In the evolution component changes 
(mutations) occurring sequentially in successive cycling (15 cycles), were identified.  In this 
experiment selection was made for sequentially SCV mutants and wild type revertants. Two 
sequenced clinical MRSA strains COL and N315 were chosen so changes in sequence in 
SCVs and wild type revertants could be compared. Selection for SCVs was made 
independently for triclosan and gentamicin for both strains. The final SCV and WT strains 
isolated were compared physiologically and genetically and showed differences in frequency, 
biochemical profiles, pigment production, haemolysis, catalase, coagulase, levels of 
intracellular ATP and phage yield. The genomic sequence of the final 4 cycle isolates 
(SCV15) showed numerous and diverse mutations occurred COL and N315 SCVs.  Over 70 
mutations were found and 33 were determined as historic mutations and the rest were termed 
novel mutations.  The novel mutations occurred during the cycling process. The historic 
mutations occurred prior to the experiment and these mutations were acquired during growth 
in laboratory culture.  Only one mutation was found to be common between COL and N315 
and this was in the fabI gene. These data indicate mutations occurring in ~1.3% of the 
genome (~ 40 Kb) can generate mutants with the SCV phenotype. 
 
Susceptibility to phage 80α and transduction of S. aureus wild type and their SCVs 1-3 was 
studied. Wild type strain of S. aureus and SCV3 both yielded a high number of lysogens 
(~68%) the remaining being resistant mutants. SCV 1 and SCV 2 provided a much lower 
proportion of lysogens (4-10%). There was no obvious relationship between cellular ATP 
levels and lysogen formation. Consequently the frequency of lysogen formation (or that of 
resistance mutants) cannot be related to energy status. 
 
Transduction of ciprofloxacin resistance (grlA) was observed into COL wild type at a 5-10-
fold higher frequency than into SCV1. Transduction of rifampicin resistance (rpoB) into 
SCVs was reduced almost 10-fold. As transduction was significantly decreased into SCVs it 
is hypothesised this process was influenced by ATP levels. The data thus suggests that SCV 
strains will be less efficient in gene exchange by transduction in vivo.  
Three SCVs previously isolated from S. aureus COL on the basis of different growth rate 
were further studied. Results clearly support the hypothesis that there is a physiological 
diversity in SCV populations. 
Sensitivity of S. aureus wild type and SCVs strains to various antimicrobial was determined. 
The SCV strains were more sensitive to some antibiotics and heavy metals than the wild type 
strain.  
  
VII 
LIST OF FIGURES 
 
 Page 
Figure 1.1 Shape and arrangement of S .aureus  3 
Figure 1.2 Relationship between electron transport and the small colony 
variants phenotype in S. aureus 
19 
Figure1.3 Summary of characteristics of (A) wild type S. aureus (B) S. 
aureus SCV 
22 
Figure 1.4 Transfer of DNA between bacteria cells 26 
Figure 2.1 The chemical structure of gentamicin 32 
Figure 2.2 The chemical structure of triclosan 34 
Figure 2.3 A schematic of the steps for isolating SCV mutants and wild 
type revertants.  
40 
Figure 2.4 The number of wild type revertants, recorded at each cycle, 
from the SCV isolates of S. aureus COL and S. aureus N315. 
46 
Figure 2.5 Shows the distribution of reversion isolates with respect to 
triclosan isolated SCVs (a-p, red symbols) and gentamicin SCVs (1-15).  
The initial count is represented by @ 
47 
Figure 2.6 The number of SCV mutants, recorded at each cycle, from the 
wild type strains S. aureus COL and S. aureus N315. 
48 
Figure 2.7 A comparison of the frequency of SCV formation by COL and 
N315 at each cycle after selection by triclosan (a-m) and gentamicin (1-
15) 
49 
Figure 2.8 The frequency of reversion to wild type plotted against the 
mutation frequency to SCV 
51 
Figure 2.9 The frequency of strains from triclosan agent plotted against 
the mutation frequency to strains from gentamicin 
52 
Figure 2.10 Extracellular DNase activity 55 
Figure 2.11 Pigment production 55 
Figure 2.12 Intracellular ATP concentrations 56 
  
VIII 
Figure 2.13 Shows the ratio phage yield of S. aureus 56 
Figure 2.14 Growth curves of COL and N315 58 
Figure 2.15 Maximum cell count of COL and N315 58 
Figure 2.16 Summarises S. aureus COL and N315 wildtype test results 
with those of wildtype 15 and SCV 15 each of GEN and TRI 
60 
Figure 2.17 Characteristics associated with S. aureus SCVs 61 
Figure 2.18 Multiplex PCR of SCV isolates from gentamicin and triclosan 62 
Figure 3.1 A schematic of generalized transduction 68 
Figure 3.2 A schematic of generalized bacteriophage replication 71 
Figure 3.3 A comparison of transduction frequency of rifampicin 
resistance into S. aureus COL wildtype and SCV 1, 2 and 3 by Φ 80α-
MRSA COL
Rif-r
 
80 
Figure 3.4 An illustration of bacteriophage 80α release by COL lysogens 
and lysis of the indicator lawn 
82 
Figure 3.5 A comparison of the frequency of formation of phage 80 α 
lysogens and resistant mutants of S. aureus COL and SCV strains 1, 2 and 
3 
83 
Figure 3.6 Comparison of the average viable counts of S. aureus COL and 
SCV strains and their lysogens 
86 
Figure 3.7 A comparison of the phage yield from a lysate and lysogen 
strains of COL and SCV 1-3 
86 
Figure 3.8 Distribution of phage yields obtained from temporally separate 
A) lysogen and B) lysate cultures 
88 
Figure 4.1 Extracellular DNAase activity 100 
Figure 4.2 Pigment production by COL wildtype and SCV strains 101 
Figure 4.3 Intracellular ATP concentrations of COL wildtype and SCV 
strains  
101 
Figure 4.4 Growth curves of COL wildtype and SCV strains 103 
Figure 4.5 Maximum cell count of COL & and SCV strains 1; 2 & 3 103 
  
IX 
L 
wild type and SCV strains 1, 2 and 3 
104 
Figure 4.7 RAPD profiles of COL wild type and SCV strains  104 
Figure 4.8 Multiplex PCR of S. aureus 105 
Figure 4.9 A comparison of S. aureus COL wildtype test results with SCV 
strains 
107 
Figure 4.10 Morphological differences between  S. aureus wildtype and 
SCVs strains  
108 
Figure 4.11 Magnified morphological differences between S. aureus 
wildtype and SCVs colonies 
108 
Figure 4.12 A schematic of differentially expressed phenotypes common 
to S. aureus and SCVs strains. 
109 
Figure 5.1 Chemical structure of antimycin A, oligomycin A and CCCP 115 
Figure 5.2 Metabolic pathways affected in respiratory-deficient cells as 
inferred from transcript profiling 
116 
Figure 5.3 The relative % differences in sensitivity to antimycin, 
oligomycin and CCCP of S. aureus strain COL and SCV 1-3. 
122 
Figure 5.4 The relative % differences in sensitivity to cadmium, 
chromium and copper salts of S. aureus parent strain and their SCVs. 
124 
Figure 7.1 A composite of the chromosomes of COL and N315 showing 
the locations of the mutations conferring the SCV phenotype 
157 
Figure 7.2 Composite chromosomes of COL and N315 showing the 
locations of the historic mutations. 
157 
  
X 
LIST OF TABLES 
 
 Page 
 
Table 1.1  Virulence  and related factors   contributing to the 
pathogenicity of S. aureus 
4 
Table 1.2  Relationship between the clinical introduction of an antibiotic 
and appearance of resistance 
8 
Table 1.3 Mechanism of resistance to several antibiotics and genetic 
location in S. aureus  
9 
Table 1.4. General differences in phenotypic characteristics between 
wildtype S. aureus and small colony variants (SCVs) 
12 
Table 2.1 The concentrations of gentamicin and triclosan used to isolate 
SCVs  
39 
Table 2.2 Primers used in multiplex PCR for species confirmation of 
SCVs 
45 
Table 2.3 A summary of the average of forward and reverse mutation 
frequencies 
50 
Table 2.4 A comparison of physiological tests between SCVs and wild 
type strains 
59 
Table 3.1 Bacterial strains and bacteriophage used in this study of transfer 
of antimicrobial resistance amongst staphylococci. 
75 
Table 3.2 Transduction of ciprofloxacin resistance into S. aureus COL 
and SCV strains by Φ 80α-EMRSA 16 
78 
Table 3.3  Transduction of rifampicin into S. aureus COL and SCVs by Φ 
80α COLRif-r 
79 
Table 3.4 S. aureus strains used in an attempt to transfer gfpuvr by Φ 80α-
ALC1437
 
81 
Table 3.5 A comparison of phage 80α yields from lysogens and parental 
strains of COL and SCVs 1, 2 and 3 
85 
Table 3.6 The average phage titre from several lysates. 87 
  
XI 
Table 3.7 A summary of the transduction frequencies for ciprofloxacin 
and rifampicin resistance. 
90 
Table 3.8 Comparison antibiotic resistance transduction frequencies 
between an earlier study and this investigation 
90 
Table 3.9 A comparison of ATP levels and lysogen formation 91 
Table 4.1 MIC (mg/L) for S. aureus MRSA COL-wildtype and SCVs  100 
Table 4.2 Summary of the characteristics of S. aureus COL wildtype and 
SCV strains 
106 
Table 5.1 The concentration of antibiotics used 120 
Table 5.2 The concentration of chloride salts of heavy metals used 120 
Table 5.3 Relative sensitivities of S. aureus wildtype strain and their 
SCVs to CCCP, antimycin and oligomycin. 
121 
Table 5.4 Relative sensitivities of S. aureus wildtype strain and their 
SCVs to heavy metal chloride salts 
123 
Table 6.1 Bacterial strains used in this study 135 
Table 6.2 Characteristics of the genes associated with SCV formation in 
N315   
142 
Table 6.3   Characteristics of the genes associated with SCV formation in 
COL   
143 
Table 6.4 Total the mutation types and proportion in both strains 146 
Table 6.5  27 genes associated with SCV formation and their metabolic 
roles 
150 
 
  
XII 
TABLE OF ABBREVIATIONS 
 
A adenine 
AAC aminoglycoside acetyltransferase 
ADP adenosine diphosphate 
Ag argent 
agr accessory gene regulator 
Al aluminium 
AMEs aminoglycoside modifying enzymes 
Amp ampicillin 
ATCC American Type Culture Collection 
ATP adenosine triphosphate 
BHI Brain Heart Infusion 
bp base pairs 
BSAC British Society for Antimicrobial Chemotherapy 
C cytosine 
CAMHB cation adjusted Muller Hinton broth 
CCCP carbonyl cyanide m-chlorophenylhydrazone 
Cd cadmium 
CF cystic fibrosis 
CFS chronic fatigue syndrome 
CFU colony forming unit 
Cip-r ciprofloxacin resistance 
CLSI Clinical Laboratory and Standards Institute 
CoNS coagulase negative staphylococci 
CoPS coagulase-positive staphylococci 
Cr chromium 
CRE catabolite responsive element 
Cu copper 
DHFR dihydrofolate reductase 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
EDTA ethylenediaminetetraacetic acid 
EES ethyl ethane sulphonate 
EF-G elongation factor 
EMRSA epidemic methicillin-resistant Staphylococcus aureus 
Ery erythromycin 
ETC electron transport chain 
FADH2 flavin adenine dinucelotide 
  
XIII 
G guanine 
GEN gentamicin 
GFP green fluorescent protein 
GMP guanine monphosphate synthetase 
Hg mercury 
HGT horizontal gene transfer 
HQNO 4-hydroxy-2-heptylquinoline-N-oxide 
HX hypoxanthine 
Kan kanamycin 
kb kilo base 
LSD least significant difference 
M molar 
MeC methylcytosine 
MGEs mobile genetic elements 
mg/L milligrams per litre 
MIC minimum inhibitory concentration 
MH Mueller Hinton 
µL microliter 
MLS macrolide–lincosomide–streptogramin B 
MLST multilocus sequence typing 
MMR methyl-directed mismatch repair 
MRSA methicillin-resistant Staphylococcus aureus 
MSSA methicillin-sensitive Staphylococcus aureus 
Mup mupirocin 
NADH nicotinamide adenine dinucelotide 
NCBI National Center for Biotechnology Information 
NCTC National Collection of  Type Cultures 
Neo neomycin 
nm nanometer 
Nov novobiocin 
OD optical density 
ORFs open reading frames 
Oxa oxacillin 
Pb lead 
PBP 2a penicillin binding protein 2a 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PFGE pulse field gel electrophoresis 
  
XIV 
PFU Plaque forming unit 
PMF proton Motive Force 
qPCR quantitative PCR 
QRDR quinolone resistance-determining region 
RAPD random amplified polymorphic DNA  
Rif-r rifampicin resistance 
RLU relative light units 
rpm rotation per minute 
sar staphylococcal accessory regulator 
SCCmec staphylococcal cassette chromosome mec 
SCVs small colony variants 
SCV-GEN SCV selected for in the presence of gentamicin 
SCV-TRI SCV selected for in the presence of triclosan 
SD standard deviation 
SE standard error 
SEM Scanning electron microscopy 
SEPHCHC 2-succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylate 
Sn tin 
ST sequence type 
SXT trimethoprim-sulphamethoxazole 
T thiamine 
TAE  tris-acetate EDTA  
TCA cycle tricarboxylic acid cycle 
Tec teicoplanin 
Tet tetracycline 
TF transduction frequency 
TRI triclosan 
TSST toxic shock syndrome toxin 
U uracil 
UV ultraviolet 
Van vancomycin 
WT wild type 
XMP xanthosine monophosphate 
ΔΨ membrane potential 
σB sigma B factor 
  
XV 
CONTENTS 
 
DECLARATION ............................................................................................................ IV 
ACKNOWLEDGEMENTS ............................................................................................... VI 
SUMMARY ................................................................................................................... VI 
LIST OF FIGURES ..................................................................................................... VIII  
LIST OF TABLES ............................................................................................................ X 
TABLE OF ABBREVIATIONS ....................................................................................... XII 
CONTENTS ................................................................................................................. XV 
1 CHAPTER 1: GENERAL INTRODUCTION ............................................................. 1 
1.1 Phenotypic characteristics of Staphylococcus aureus parental strains............ 1 
1.2 Pathogenicity of Staphylococcus aureus ......................................................... 2   
1.3 Multi-antibiotics resistant Staphylococcus aureus .......................................... 5 
1.3.1 Appearance of Methicillin-Resistant Staphylococcus aureus (MRSA) ... 6 
1.3.2 Mechanisms of methicillin-resistance in S. aureus.................................. 7 
1.4 General features of Small Colony Variants................................................... 11 
1.4.1 S. aureus small colony variants  ............................................................ 11 
1.4.2 Antibiotic selection for S. aureus SCVs  ............................................... 13 
1.4.3 Infections associated with S. aureus SCVs  ........................................... 13   
1.4.4 The survival advantage of the SCV condition to S. aureus .................. 14 
1.4.5 Reduced antibiotic susceptibility in S. aureus SCVs ............................. 14 
1.5 Isolating and identifying SCVs ..................................................................... 15 
1.6 Biochemical basis of SCVs ........................................................................... 16 
1.6.1 Menadione and haemin SCVs ................................................................ 16 
1.6.2 Thymidine biosynthesis deficient SCVs  ............................................... 17 
1.6.3 Prototrophic SCVs  ................................................................................ 18 
1.6.4 SCV formation  ...................................................................................... 20 
1.7 Molecular identification techniques for S. aureus SCVs .............................. 21 
1.8 Gene transfer in Staphylococcus aureus  ..................................................... 23 
1.8.1 Transformation ...................................................................................... 23 
1.8.2 Phage-mediated conjugation  ................................................................ 23 
1.8.3 Conjugation  .......................................................................................... 24 
1.8.4 Transduction  ........................................................................................ 24 
1.9 The susceptibility of S. aureus strains to bacteriophage 80α ........................ 25 
1.10 Aims .............................................................................................................. 27 
2 CHAPTER 2: MUTATION IN STAPHYLOCOCCUS AUREUS  .. 28ERROR! BOOKMARK 
NOT DEFINED. 
2.1 Introduction  .................................................................................................. 28 
2.1.1 History of mutation ................................................................................ 28 
2.1.2 Causes of mutation ................................................................................. 28 
2.1.2.1 Spontaneous mutation ................................................................................. 28 
2.1.2.2 Induced mutation ...................................................................................... 29 
2.1.2.2.1   Chemical mutagens ............................................................................. 29 
2.1.2.2.2   Radiation ............................................................................................. 30 
2.1.2.2.3  Transposon insertion ...........................................................................  30 
2.1.3 Effects of mutation ................................................................................. 30 
2.1.4. Antibiotic and biocide selection for S. aureus SCVs ............................. 31 
2.1.4.1 Gentamicin selection for S. aureus SCVs ................................................... 31 
2.2.4.2 Triclosan selection for S. aureus SCVs ....................................................... 33 
2.1.5 Identification characteristics mecA gene and nuc gene.......................... 34 
  
XVI 
2.1.6 The experimental strategy and design of the cycling experiment .......... 35 
2.1.7 Aims ....................................................................................................... 36 
2.2. Materials and methods3 ................................................................................ 37 
2.2.1 Bacterial strains and bacteriophage ....................................................... 37 
2.2.2      Preparation of gentamicin and triclosan stock solutionss ...................... 37 
2.2.3 Determination of minimum inhibitory concentrations .......................... 37 
2.2.4 Storage of wild type and SCV cultures .................................................. 38 
2.2.5 Isolation of SCV mutants ....................................................................... 38 
2.2.6 Isolation of wild type revertants ............................................................ 38 
2.2.7 Characterisation of SCVs isolates .......................................................... 41 
2.2.7.1 Determination of auxotrophy ............................................................. 41 
2.2.7.2 Coagulase activity .............................................................................. 41 
2.2.7.3 Haemolysis activity ..................................................................................... 41 
2.2.7.4 Catalase activity ........................................................................................... 42 
2.2.7.5 DNase activity ............................................................................................. 42 
2.2.7.6 Pigment production ..................................................................................... 42 
2.2.7.7 Quantification of intracellular ATP ............................................................. 43 
2.2.7.8 Phage sensitivity and phage yield  by Φ 80 ................................................. 43 
2.2.7.9 Growth rate .................................................................................................. 43 
2.2.7.10 DNA extraction ........................................................................................... 44 
2.2.7.11 Species confirmation ................................................................................... 44 
2.2.8 Statistical analysis .................................................................................. 45 
2.3 Results ........................................................................................................... 46 
2.3.1 Wild type revertants ............................................................................... 46 
2.3.2 SCV formation ....................................................................................... 48 
2.3.3 Mutation frequency ................................................................................ 50 
2.3.4 The rates of reversion between wild type and SCV ............................... 50 
2.3.5 Characterisation of gentamicin and triclosan selected SCV15 isolates . 53 
2.3.5.1 DNase activity  ............................................................................................ 53 
2.3.5.2 Pigment production ..................................................................................... 53 
2.3.5.3 Intracellular ATP concentrations ................................................................. 53 
2.3.5.4 Phage sensitivity and phage yield by Φ 80α  ............................................... 54 
2.3.5.5 Growth rate and maximum cell density   ..................................................... 57 
2.3.6 Identification of SCVs as S. aureus using multiplex PCR  ……..…….57 
2.3 Discussion  .................................................................................................... 63 
2.3 Conclusions   ................................................................................................. 65 
3 CHAPTER 3: BACTERIOPHAGE 80 ALPHA STUDIES ............................ 66 
3.1 Introduction ................................................................................................... 66 
3.1.1 Gene transfer in staphylococci ............................................................... 66 
3.1.2 Features of the rpoB, grlA and sarA genes ............................................ 66 
3.1.3 Transduction in S. aureus ...................................................................... 67 
3.1.4 Temperate bacteriophages of S. aureus ................................................. 67 
3.1.5 Bacteriophage-host interaction .............................................................. 69 
3.1.6 Aims ....................................................................................................... 72 
3.2 Materials and methods .................................................................................. 73 
3.2.1 Bacterial strains ...................................................................................... 73 
3.2.2 Transduction related protocols ............................................................... 73 
3.2.2.1 Preparation rifampicin and ciprofloxacin stock solutions ........................... 73 
3.2.2.2 Minimum inhibitory concentrations ............................................................ 73 
  
XVII 
3.2.2.3 Bacteriophage propagation and titration ...................................................... 73 
3.2.2.4  Viable bacterial cell count ........................................................................... 74 
3.2.2.5  Transduction procedure .............................................................................. 74 
3.2.2.6  Preparation of lysogens .............................................................................. 74 
3.2.2.7  Preparation of lysates from lysogens strains .............................................. 77 
3.2.2.8   Preparation of lysates from parental strains................................................ 77 
3.2.2.9  Calculation of transduction frequency ......................................................... 77 
3.2.3  Statistical analysis .................................................................................. 77 
3.3 Results ........................................................................................................... 78 
3.3.1 Transduction experiments ...................................................................... 78 
3.3.1.1 Transduction of ciprofloxacin resistance (cip-r; grlA gene) .......................  78 
3.3.1.2 Transduction of rifampicin resistance (rpoB gene) ....................................  79 
3.3.1.3 Transduction of sarA P2 by Φ80α-ALC1437 .............................................. 80 
3.3.2 Lysogeny of S. aureus COL................................................................... 82 
3.3.2.1 Rates of resistance to and lysogen formation by bacteriophage 80α ........... 82 
3.3.2.2 Viable cell counts of lysogens and parental strains ..................................... 83 
3.3.2.3 Phage 80α yield from lysogens.................................................................... 84 
3.3.2.4 Lysate reproducibility .................................................................................. 87 
3.4 Discussion ..................................................................................................... 89 
3.5 Conclusions ................................................................................................... 92 
4 CHAPTER 4: CHARACTERIZATION OF STAPHYLOCOCCUS AUREUS COL SCV 1, 2 
AND 3 ........................................................................................................................... 93 
4.1 Introduction ................................................................................................... 93 
4.1.1 Small colony variants of bacterial species ............................................. 93 
4.1.2 Molecular typing of MRSA ................................................................... 94 
4.1.2.1  Random amplified polymorphic DNA ....................................................... 94 
4.1.2.2 DNA sequence analysis-based typing methods ........................................... 94 
4.1.3 Aims ....................................................................................................... 95 
4.2 Materials and methods .................................................................................. 96 
4.2.1 Bacterial strains and growth medium .................................................... 96 
4.2.2 Preparation of antimicrobial agents ....................................................... 96 
4.2.3 Determination of minimum inhibitory concentrations .......................... 96 
4.2.4 Characterisation of S. aureus COL SCV 1, 2 & 3 ................................. 96 
4.2.4.1 Determination of auxotrophy....................................................................... 96 
4.2.4.2 Coagulase production .................................................................................. 96 
4.2.4.3 Haemolysis activity ..................................................................................... 96 
4.2.4.4 Catalase production ..................................................................................... 97 
4.2.4.5 DNase production ........................................................................................ 97 
4.2.4.6 Pigment production ..................................................................................... 97 
4.2.4.7 Quantification of intracellular ATP ............................................................. 97 
4.2.4.8 Phage sensitivity .......................................................................................... 97 
4.2.4.9 Growth curve ............................................................................................... 97 
4.2.4.10 DNA extraction ........................................................................................... 97 
4.2.4.11 Aerobic and anaerobic growth ..................................................................... 97 
4.2.4.12  Species confirmation .................................................................................. 98 
   4.2.4.12.1     Random amplified polymorphic DNA PCR (RAPD-PCR) ........  98 
   4.2.4.12.2     Multiplex PCR ............................................................................. 98 
4.3 Results ........................................................................................................... 99 
  
XVIII 
4.3.1 Minimum Inhibitory Concentrations ..................................................... 99 
4.3.2 Characterisation of COL and SCV 1, 2 & 3 .......................................... 99 
4.3.2.1  Catalase, haemolysis and auxotrophy ......................................................... 99 
4.3.2.2 DNase activity ............................................................................................. 99 
4.3.2.3 Pigment production ..................................................................................... 99 
4.3.2.4 Intracellular ATP concentrations ................................................................. 99 
4.3.2.5 Growth rate and maximum cell count ....................................................... 102 
4.3.3 Aerobic and anaerobic growth ............................................................. 102 
4.3.4 Species confirmation - RAPD .............................................................. 102 
4.3.5 Species confirmation - multiplex PCR ................................................ 102 
4.4 Discussion ................................................................................................... 110 
4.5 Conclusions ................................................................................................. 112 
5 CHAPTER 5: SUSCEPTIBILITY AND RESISTANCE OF STAPHYLOCOCCUS AUREUS 
COL AND THEIR SMALL COLONY VARIANTS TO INHIBITORY AGENTS ...................... 113 
5.1 Introduction ................................................................................................. 113 
5.1.1 Brief history of resistance in Staphylococcus aureus .......................... 113 
5.1.1.1 The susceptibility of S. aureus strains to antimycin, oligomycin and 
carbonyl cyanide m-chlorophenylhydrazone (CCCP) ..............................................  114 
5.1.1.2 Susceptibility to heavy metals ................................................................... 117 
5.1.2 Aims ..................................................................................................... 118 
5.2 Material and methods .................................................................................. 119 
5.2.2 Preparation of antibiotics stock solutions ............................................ 119 
5.2.3 Preparation of chloride salts of heavy metals stock solutions ............. 119 
5.2.4 Disc diffusion ....................................................................................... 119 
5.3 Results ......................................................................................................... 121 
5.3.1 Disc diffusion ....................................................................................... 121 
5.3.1.1 The activity of antimycin, oligomycin and carbonyl cyanide m-
chlorophenylhydrazone (CCCP) ..............................................................................  121 
5.3.1.2 The activity of chloride salts of cadmium, chromium, copper and mercury ... 
  ................................................................................................................... 122 
5.4 Discussion ................................................................................................... 125 
5.5 Conclusions ................................................................................................. 127 
6 CHAPTER 6: SEQUENCING OF THE S. AUREUS GENOME ................................ 128 
6.1 Introduction ................................................................................................. 128 
6.1.1 Structure of the S. aureus genome ....................................................... 128 
6.1.2 Relevant biochemical features in staphylococci .................................. 129 
6.1.2.1 dnaC gene .................................................................................................. 129 
6.1.2.2 mecA gene (penicillin binding protein A2) ...............................................  129 
6.1.2.3 fusA gene (Elongation factor-G "EF-G") ................................................... 130 
6.1.2.4  ccpA (catabolite control protein A) .........................................................  130 
6.1.2.5  fabI (enoyl acyl carrier protein reductase) ...............................................  130 
6.1.2.6 mnh gene (Na+/H+ antiporter) .................................................................  131 
6.1.2.7 menD gene (Menaquinone biosynthesis) ..................................................  131 
6.1.2.8 atl or nag gene (Autolysin gene) ..............................................................  131 
6.1.2.9  folD gene (coenzyme transport and metabolism) ....................................  132 
6.1.2.10 isdA or stbA gene (iron-regulated surface determinant proteinA) ............. 132 
6.1.2.11 trmFO or gid gene (methylenetetrahydrofolate--tRNA-(uracil-5-)-
methyltransferase) ....................................................................................................  132 
6.1.2.12 spl gene (serine protease) .........................................................................  133 
  
XIX 
6.1.2.13 fmtA gene (autolysis and methicillin resistance related protein) ..............  133 
6.1.2 Aims ..................................................................................................... 134 
6.2 Materials and methods ................................................................................ 135 
6.2.1 Bacterial strains  ................................................................................... 135 
6.2.2 Genome sequence analysis .................................................................. 135 
6.2.2.1 Selection of strains for sequencing ............................................................ 135 
6.2.2.2 Rationale of the sequencing strategy ......................................................... 136 
6.2.2.3 The genome comparison ............................................................................ 136 
6.2.2.4 Electronic genome structure ...................................................................... 136 
6.3 Results ......................................................................................................... 137 
6.3.1 Genes effected in S. aureus N315 SCVs ............................................. 139 
6.3.2 Genes effected in S. aureus COL strain ............................................... 140 
6.3.3 A mutations occurring in both S. aureus COL and N315 .................... 141 
6.4 Discussion ................................................................................................... 147 
6.5 Conclusions ................................................................................................. 151 
7 CHAPTER 7: GENERAL DISCUSSION, CONCLUSIONS AND FUTURE WORK ..... 152 
7.1 General discussion....................................................................................... 152 
7.1.1 Selection and identification of SCVs ................................................... 152 
7.1.2 Transduction and lysogen formation in S. aureus and SCVs .............. 153 
7.1.3 Physiological variety in small colony variants .................................... 154 
7.1.4 Phenotypic switching ........................................................................... 154 
7.1.5  Antibiotic susceptibility ...................................................................... 155 
7.1.6 The cycling experiment ....................................................................... 155 
7.1.7 How many SCV genes are there?  ....................................................... 156 
7.2 Conclusions ................................................................................................. 158 
7.3  Future work  ............................................................................................... 159 
REFERENCES: ...........................................................................................................  160 
APPENDIX ................................................................................................................... 197 
 
1 
 
CHAPTER 1:  
GENERAL INTRODUCTION 
1.1  Phenotypic characteristics of Staphylococcus aureus parental strains  
Staphylococcus aureus is Gram-positive coccus which forms large golden yellow colonies 
on agar, and it is often haemolytic on blood agar. The bacteria are catalase-positive and 
oxidase-negative. Nearly all strains of S. aureus produce the enzyme coagulase (Todar, 
2005). The cell wall contains peptidoglycan and teichoic acid. S. aureus is resistant to 
temperatures as high as 50°C, to high salt concentrations, and to drying. It is perfectly 
spherical cells about 1 micrometer in diameter and grows in clusters. 
Paster and Koch (1878) were the first to observe and culture staphylococci, but the 
earliest detailed studies on staphylococci were performed by Ogston in 1881 and 
Rosenbach in 1884 (Ogston, 1882; Cookson et al., 2003). Ogston coined the name 
Staphylococcus to describe grape-like clusters of bacteria (Figure 1.1). He observed in pus 
from human abscesses and by 1884 a scientist named Rosenbach was able to isolate and 
grow these microorganisms in pure culture and described two pigmented colony types of 
staphylococci and proposed the appropriate nomenclature: Staphylococcus aureus 
(golden) and Staphylococcus albus (white) (Kloos & Schleifer, 1986) the latter species is 
now known as Staphylococcus epidermidis. The data there are 35 recognised species of 
staphylococci all of which are Gram-positive non-motile, non-spore and grow optimally 
under aerobic conditions (Peacock, 2005). The production of coagulase is an important 
characteristic that allow differentiation from other bacterial genera and species. 
Staphylococci are generally divided in two main groups, coagulase-positive staphylococci 
(CoPS) and coagulase-negative staphylococci (CoNS) such as S. epidermidis based on the 
production of coagulase, an enzyme-like factor that causes fibrin to coagulate and form a 
clot, a trait which is generally associated with pathogenicity (Bannerman & Peacock, 
2007). Catalase production differentiates S. aureus from streptococcal species. 
Those Staphylococcus aureus strains resistant to antimicrobial agents are clinically 
significant since they commonly cause problems, both in developing and industrial 
countries (Wenzel et al., 1981).  S. aureus is the most common staphylococcal pathogen 
while S. epidermidis is not pathogenic but may cause infections in some circumstances. 
Since both are inhabitants of the skin, most lesions are superficial and develop as boils, 
pustules, pimples, furuncles, carbuncles, or impetigo contagiosa (Sun, 1996). 
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1.2 Pathogenicity of Staphylococcus aureus 
S. aureus is an opportunistic pathogen and the major causative agent of numerous 
hospital- and community-acquired infections. As such it is of the most intensively studied 
bacterial species (Plata et al., 2009). S. aureus infections have been linked to a diverse 
range of medical conditions including skin, soft-tissue, respiratory, bone, joint and 
endovascular disorders (Lowy, 1998) and are associated with prolonged hospital stay, 
increased morbidity and mortality, as well as increased healthcare costs (Que & 
Moreillon, 2010). S. aureus infection generally occurs in those who are immunodeficient 
and have provided a means of entry into the body, i.e. a cut or wound (Lowy, 1998). It is 
for this reason that S. aureus is prevalent within post-operative infections. S. aureus 
possesses some of the various virulence factors as shown in Table 1.1. Pathogenesis 
requires the combination of various virulence factors including; secreted proteins, cell 
surface-bound proteins and cell surface components (Tenover & Gorwitz, 2000). Some 
global regulatory genes that coordinate the expression of various groups of S. aureus 
virulence genes have been identified (Peng et al., 1988; Dufour et al., 2002; Lindsay et 
al., 2006). Of the most extensively studied is agr, which induces the expression of 
extracellular protein whilst suppressing the expression of surface protein. agr and other 
regulators appear to coordinate the pathogenesis of staphylococcal infection in a 
sequential  nature; surface protein are predominantly synthesized during the exponential 
growth phase and secreted proteins during the stationary phase. Thus different stages of 
infection require differential expression of virulence determinants (Lowy, 1998). 
In addition staphylococci have proven very successful at developing and acquiring 
antimicrobial resistances through mutation and gene exchange (World Health 
Organisation, 2011). Section 1.8 discusses the potential for gene exchange to contribute to 
evolution in staphylococci. 
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    (A)       
 
 
(B) 
 
 
Figure 1.1 Shape and arrangement of S. aureus (A) - Light microscopy shows Gram-
positive S. aureus, arranged in grape-like clusters and magnified about 100x. (B) - 
Scanning electron microscopy (SEM) shows a higher resolution image of S. aureus. 
Magnified about 10,000x (Seaman, 2007). 
 
2 µm 
 
  10 µm 
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Table 1.1  Virulence  and related factors contributing to the pathogenicity of S. aureus 
The genes encoding for S. aureus pathogenicity functions are located in a variety of genomic locations, with mobile genetic elements being 
significant repositories. 
 
Virulence factor Role Example References 
Adhoidanesins 
Adhesins 
Surface proteins that promote attachment to host 
proteins such as laminin and fibronectin. 
Coagulase and fibronectin-binding protein. Moreillon et al., 1995 
& Menzies, 2003. 
 
 
 
Invasins 
Enable invasion by damage of host membranes. α-toxin, β-toxin, δ-toxin, γ-toxin and leukocidin. Novick, 2003a & 
Gillet et al., 2002 
Promote bacterial spread by dissolution of fibrin 
clots. 
Staphylokinase. Collen, 1998 
Enhance survival through nutrient provision. Proteases, lipases, haemolysins and 
deoxyribonucleases. 
Urban et al., 2006 
Avoidance of host 
defences 
Prevention of opsonization and phagocytosis by 
immunological disguise. 
Enhance survival in phagocytes. 
Capsule polysaccharide, protein A and 
leukocidin.  
Carotenoids, catalase production 
O'Riordan & Lee, 
2004; Peterson et al., 
1977 
 
 
Exotoxins 
 Disrupt host membranes or otherwise promote 
symptoms of disease. 
Toxic shock syndrome toxin (TSST-1), 
enterotoxins A-M and other superantigen toxins. 
 
(Novick et al., 2001 
Cleave desmoglein 1, a cadherin that is found in 
desmosomes in the epidermis. 
Scalded skin syndrome .Exfoliative toxin (A & 
B) 
Raygada et al., 2009 
 
Intrinsic and acquired 
antimicrobial resistance  
 
Prevent infection by chemotherapeutics. 
 
 
β-lactamases, penicillin binding protein 2a 
(PBP2a)  
Matsuhashi et al., 
1986 & Kaatz et al., 
2005; Ojo et al., 2006 
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1.3 Multi-antibiotic resistant Staphylococcus aureus  
Resistance to penicillin was reported in S. aureus within 5 years of its introduction in 
1943. Currently it is estimated that more than 90% of S. aureus isolates worldwide are 
resistant to this antibiotic (Lyon & Skurray, 1987; Swartz, 1997).  The incidence of 
penicillin-resistant S. aureus in clinical isolates was less than 1% in 1940, increased to 
14% in 1946 and approximately 60% by 1948 in UK hospitals (Barber & Rozwadowska-
Dowzenko, 1948). Levels of penicillin-resistance S. aureus continued to rise (Table 1.2), 
and owing to the high incidence of penicillin-resistance it was necessary to introduce 
other antibiotics to control the infections. Antibiotics such as streptomycin, tetracycline, 
chloramphenicol and erythromycin were introduced but these similarly followed by the 
emergence of resistant strains (Shanson, 1981). Resistance to several different antibiotics, 
such as tetracycline, chloramphenicol, streptomycin, neomycin, kanamycin and the MLS 
group that were introduced in the late 1940s and early 1950s, (Novick, 1989). Multi-
resistant S. aureus was first reported in the UK in 1961 (Parker & Hewett 1970). It was 
also responsible for outbreaks of nosocomial infection in several other countries 
(Rountree & Beard 1968; King et al., 1982; Naidoo et al., 1984). 
Resistance to the ß-lactamase-resistant penicillins, such as methicillin, arose in the mid 
1960s and is associated with the mecA gene (Koch, 2003). Early in the 1980s methicillin-
resistant S. aureus (MRSA) strains re-emerged and many showed additional resistances to 
several antimicrobial agents including gentamicin and unrelated agents such as 
antiseptics. Several strains of S. aureus have shown resistance to as many as 20 
antimicrobial agents, including antiseptics and heavy-metal ions (Lyon & Skurray 1987). 
Resistance to gentamicin first arose in the mid 1970s and is mediated by the aacA-aphD 
gene, which also confers resistance to other aminoglycosides kanamycin and tobramycin 
(Casman & Bennett, 1963). Emerged after some 10 years use and was associated with its 
extensive use as a topical antibiotic (Noble & Naidoo 1978).  
Tetracycline, erythromycin and chloramphenicol-resistant strains of S. aureus were 
detected between 1951-1960 in Australian hospitals (Horinouchi & Weinblum 1982) 
Resistance to amikacin, chloramphenicol, erythromycin, tetracycline,arsenate, cadmium 
and mercury was reported from Australia between 1940-1974 (Lacey, 1975). 
Trimethoprim resistance was first reported in 1980, more than 15 years after it is clinical 
introduction (Young et al., 1987; Amyes & Towner, 1990). Although the use of 
trimethoprim for more than 15 years, the incidence of trimethoprim-resistant 
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staphylococci has since remained almost stable (Young et al., 1987; Amyes et al., 1989; 
Amyes & Towner, 1990). 
Mupirocin was first prescribed in 1986 and resistance strains were reported immediately 
following its clinical use (Rahman et al., 1990). Reduces susceptibility can be achieved 
via spontaneous mutation and alteration of the target gene, the majority of antibiotic 
resistance genes are acquired through horizontal gene transfer (HGT). Antibiotic 
resistance genes are commonly carried by mobile genetic elements such as bacteriophage, 
plasmids and transposons, allowing them to transferred among bacteria. HGT has 
facilitated the spread of antibiotic resistance genes via gene exchange processes such as 
conjugation, transduction and transformation (Wise, 2002; Wright, 2007). 
1.3.1. Appearance of Methicillin-Resistant Staphylococcus aureus (MRSA) 
Methicillin-Resistant Staphylococcus aureus MRSA was first described in 1961, shortly 
after the introduction of penicillinase-resistant β-lactams antibiotics into clinical practice.  
Since then, hospitals worldwide have reported varying proportions of MRSA among S. 
aureus isolates (de Lencastre, 1998). The incidence of methicillin resistance of S. aureus 
after clinical treatment of aminoglycoside antibiotics decreased in the UK. After the 
clinical introduction of new penicillin and cephalosporin derivatives, the MRSA strains 
re-emerged in UK in the early 1980s (Marples and Reith 1992).  Gentamicin resistance 
began to emerge in S. aureus, in the late 1970s and early 1980s gentamicin-resistant 
MRSA became a problem by the mid-1980s and a strain designated epidemic MRSA 1 
was widely distributed in the UK, the Irish Republic and Australia (Ayliffe, 1997).  
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1.3.2. Mechanisms of methicillin-resistance in S. aureus  
There are two principle mechanisms by which MRSA exhibit resistance to ß lactams, 
namely altered PBPs and penicillinases. The first is achieved through a mutation in 
penicillin-binding protein (PBP; mecA). The gene mecA and regulatory sequences that 
encode for production of a low-affinity penicillin-binding protein (PBP-2a) are not 
present in methicillin sensitive strains (Greenwood 1995). This enzyme can continue to 
catalyse the formation of cross-bridges in bacterial cell wall peptidoglycan in the presence 
of β-lactams (Berger-Bachi & Rohrer, 2002; Hartman & Tomasz, 1984). PBPs are the 
target for β lactam antibiotics, so in the case of MRSA by altering PBP, it is not allowing 
the drug to target it, therefore it is insensitive to ß lactams. For a drug to be effective the 
affinity between the PBP and the drug must be high (Mulligan et al, 1993). Thus in 
sensitive strains methicillin binds to PBP and inhibits cross linking of peptidoglycan, 
resulting in cell lysis (Wise & Park, 1965). S. aureus has several PBPs that are responsible 
for catalysing cross-linking reactions between peptidoglycan polymers, one of final steps 
in bacterial cell wall assembly (Chambers, 1988).  
The gene encoding PBP is mecA, and mutations in mecA modify the PBP. The widespread 
presence of MRSA is thus partially due to the lateral gene transfer of mecA (Ghuysen, 
1991). The mec gene is believed to have originated in the animal related staphylococcal 
species S. fleurettii, as the sequence is nearly identical to the mecA region found in MRSA 
strains (Tsubakishita et al., 2010). 
 
The second mechanism is the enzymatic degradation of the penicillin by ß-lactamase.  
The enzyme was termed it a penicillinase (Wise, 1982). The importance to MRSA strains 
was recognised by de Lencastre (1998).   
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Table 1.2  Relationship between the clinical introduction of an antibiotic and appearance of resistance 
 
 
 
Antibiotic 
Date of 
 
 introduction 
Delay prior to 
Appearance of 
resistance 
                      Date of  
 
References 
Clinical 
problem 
% Strains 
 Resistance (date) 
Chloramphenicol 1950 8 1958 2-34 (1953-1958) Kock, 1960; Lowbury & Ayliff, 1974 
Erythromycin  1952 1 1953 43 (1952) Ministry Health 1959 
Fusidic acid 1962 8 1970 1-2 Godtfredson et al., 1962; Ayliff et al., 1979 
Gentamicin 1950 25 1975 27 (1976-1980) Rountree & Beard 1965; Richardson & Marple 
1982 
Kanamycin 1950 25 1975 4 (1976-1980) Rountree & Beard 1965; Richardson & Marple 
1982 
Methicillin 1960 1 1961 37 (1976-1980) Jevons 1961; Richardson & Marple 1982 
 
Mupirocin 
 
1986 
 
1 
 
1987 
 
0.01-3 
 
Rahman et al., 1987; Cookson 1990 
 
Neomycin 
 
1950 
 
10 
 
1960 
 
40 
 
Waisbren, 1958; Rountree & Beard 1965; 
Parker & Hewitt, 1970 
Penicillin 1941 9 1948-1950 60 Barber 1947; North & Christie 1946; Barber & 
Rozwadoska, 1948 
Tetracycline 1940 9 1949 60 Finland et al., 1950; Ministry Health 1959 
Trimethoprim 1980 1 1985 26 Lyon et al., 1983; Archer et al., 1986 
Vancomycin 1958 24 1982 20 Kirby et al., 1959; Cafferkey et al., 1982; 
Watanakunakorn, 1984 
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Table 1.3 Mechanism of resistance to several antibiotics and their  genetic location in S. aureus 
( Adapted from al Masaudi et al., 1991, Jensen & Lyon, 2009 and Woodford, 2005) 
Antibiotics Mechanism of action Main resistance mechanism Gene(s) Genomic location 
β-lactam 
(penicillins & 
cephalosporines) 
Peptidoglycan synthesis-inhibits cell 
wall synthesis enzymes 
Enzymatic hydrolysis of 
β-lactam ring. 
blaZ 
Plasmids & 
transposons 
Semisynthetic  β-lactams 
(Methicillin) 
Peptidoglycan synthesis-inhibits cell 
wall synthesis enzymes 
Modified PBP2a with 
reduced affinity to 
β -lactams antibiotics 
mecA Chromosome 
Aminoglycosides Protein synthesis-inhibit translocation AMEs-inactviation of antibiotic aac, aph, ant 
Chromosome, 
plasmids & 
transposons 
MLS antibiotics 
Protein synthesis-stimulatesdissociation 
of peptidly-tRNA during elongation 
Enzymatic methylation of adenine on 23S 
rRNA rduced affinity for antibiotics 
ermA, ermB, ermC 
Plasmids & 
transposons 
Quinolones DNA synthesis-inhibit DNA gyrase 
Alteration in QRDR, reducing affinity of 
enzyme-DNA complex for fluroquinolones 
grlA/B Chromosome 
Oxazolidinones 
Protein synthesis-prevent formation of 
the 70S ribosomal initiation complex 
Alteration of domain V component of the 23S 
rRNA 
23S rRNA Chromosome 
Chloramphenicol Protein synthesis-inhibit transpeptidation 
Chloramphenicol acetyl transferase-
inactivation of antibiotic 
cat Plasmid 
 
Fusidic acid 
 
 
 
Protein synthesis-forms a stable complex 
with elongation factor G and ribosome 
inhibiting translocation 
 
Decreased affinity of the G factor for the 
antibiotic. Impermability and efflux also 
implicated 
 
fusA, fusB 
 
Chromosome & 
plasmid 
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Mupirocin 
Protein synthesis-inhibits isoleucyl-
tRNA synthestase preventing 
incorporation of isoleucine into nascent 
peptides 
Alteration of target site 
 
Acquisition of novel isoleucyl-tRNA 
synthetase 
ileS 
 
 
mupA 
Chromosome 
 
 
Plasmid 
Rifampicin 
RNA polymerase-binds to β-subunit of 
DNA dependant  RNA polymerase 
Alteration of target site ropB Chromosome 
Tetracycline 
Protein synthesis-inhibit binding of 
aminoacyl-tRNAs 
Tetracycline efflux proteins-energy dependent 
efflux of tetracycline 
 
Ribosomal protection protein-promotes 
release of bound tetracycline 
tet(K), tet(L) 
 
 
 
tetA(M) 
Chromosome & 
plasmid 
 
 
Transposons 
Trimethoprim 
Tetrahydrofolic acid synthesis-competes 
with DHFR inhibiting reduction of 
dihydrofolate acid to tetrahydrofolic acid 
Chromosomal mutations, reduced affinity for 
trimethoprim 
 
Acquisition of unique DHFR with reduced  
affinity for trimethoprim 
dfrB 
 
 
dfrA 
Chromosome 
 
 
Plasmid 
 
PBP, penicillin-binding protein; AMEs, aminoglycoside modifying enzymes; QRDR, quinolone resistance determining region; DHFR, dihydrofolate reductase 
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1.4. General features of Small Colony Variants 
Small colony variants (SCVs) constitute a slow-growing subpopulation
 
of bacteria with 
distinctive phenotypic and pathogenic traits.
 
Since their first description in 1910 (Proctor 
et al., 2001), SCVs have been described
 
in a wide range of bacterial
 
species, including 
Staphylococcus aureus, Staphylococcus epidermidis,
 
Escherichia coli, Salmonella 
enterica, Pseudomonas aeruginosa,
 
and Burkholderia cepacia (Proctor et al., 2006). 
SCVs all display a small
 
colony size, a slow growth rate, and atypical colony morphology. 
Since their discovery S. aureus SCVs have been associated with persistent, recurrent and 
antibiotic resistant infections (Proctor et al., 2006). 
 
1.4.1. S. aureus small colony variants 
SCVs of S. aureus arise as a drug-resistant sub-population during exposure to 
antimicrobial chemotherapeutics (Proctor et al., 2006). In contrast to the normal S. aureus 
phenotype typical SCV colonies are non-pigmented colonies and also about 10-fold 
smaller (von Eiff et al., 2001). S. aureus SCVs exhibit many other atypical characteristics 
including reduced susceptibility to a range of antimicrobial compounds, lack of coagulase 
and haemolytic activity. Table 1.4 summarises the general characteristics reported for 
many SCVs.  
Although their microscopic morphology and Gram staining of SCVs are normal, clinical 
microbiologists may fail to detect them because of their atypical biochemical 
characteristics and very slow growth (Proctor et al., 2001). This makes them a challenge 
for clinical microbiologists to identify. Further characteristics include altered expression 
of virulence genes; intracellular persistence in vitro systems; auxotrophy for growth 
factors, such as thymidine, hemin, and/or menadione; and the ability to revert to the 
normal phenotype (Kahl et al., 2005 & Proctor et al., 2006).  
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Table 1.4. General differences in phenotypic characteristics between wildtype S. aureus 
and small colony variants (SCVs) 
Differences   Wild type SCVs    References 
Colony size 
(approx.) 
2 mm 0.2 mm 
Bergoge-Berezin, 2000; 
Roggenkamp  
et al., 1998 
lag phase 
(mean) 
2.8 hours 4.5 hours  Kahl et al., 2005 
Cell Wall Thin Thick Peschel, 2002 
Coagulase 
production 
Positive Negative  Seifert et al., 2003 
Haemolytic Positive Negative Balwit et al., 1994 
Pigmentation Golden yellow Non pigmented 
Balwit et al., 1994; Proctor et al.,  
1998 
Auxotrophy for 
hemin and/or 
menadione 
Negative  
 
Positive  
 
Kahl et al., 2003;  
Proctor & Peters 1998 
Intracellular 
survival 
Poor Increased  
Kahl et al., 1998; Vaudaux et al.,  
2002; von Eiff et al., 2001 
Amino 
glycoside 
antibiotics 
Sensitive 
Reduced  
susceptible 
Rusthoven et al., 1979; Proctor &  
Peters 1998 
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1.4.2 Antibiotic selection for S. aureus SCVs 
Aminoglycosides such as gentamicin have been shown to select for S. aureus SCVs in 
patients receiving treatment for osteomyelitis (Musher et al., 1977). Other antibiotics such 
as chloramphenicol, streptomycin and a number of different quinolones have also 
displayed ability to select for S. aureus SCVs (Seligman, 2006; Mitsuyama et al., 1997). 
Recently, triclosan (commercially know as Irgasan; 2,4,4'-trichloro-2'-hydroxydiphenyl 
ether) is a synthetic
 
bisphenol antimicrobial agent, has been shown to select for S. aureus 
SCVs (Seaman et al., 2007). Interestingly in 1998 it was recommended
 
for the control of 
methicillin-resistant S. aureus
 
(MRSA) (Duckworth, 1998). Triclosan has been used in 
some skin care products for over 30 years and has been employed as surgical scrubs, hand 
washes and body washes to control MRSA (Russell, 2004). Thus the topical use of 
triclosan against staphylococci is widespread, but the fact it selects for SCVs (Seaman et 
al., 2007) appears not to be considered a health risk. 
 
1.4.3 Infections associated with S. aureus SCVs   
S. aureus SCVs have been associated with relapsing or persistent infections, in particular 
in osteomyelitis, some foreign body-associated infections (Sendi et al., 2006) and 
attributed to the pathogenesis of relapsing or persistent infections in cystic fibrosis 
patients (Kahl et al., 1998; Abele et al., 2000 & Gilligan et al., 1987). Further 
investigation has revealed that patients infected with S. aureus SCVs were more likely to 
undergo relapses of osteomyelitis and the MICs for gentamicin were up to 32-fold greater 
for the SCVs when compared to the wild type strain MIC (von Eiff et al., 1997). The 
ability of SCVs to enter into and persist within host cells that are not naturally phagocytic, 
such as epithelial cells and endothelial cells provides a source for these persistent 
infections (Schroder et al., 2006).  A study in CF patients isolated S. aureus SCVs and 
showed SCVs to persist for extended periods in comparison to the wildtype (Kahl et al., 
2003). Of further concern is that S. aureus SCVs were shown to persist in CF patients 
after antibiotic therapy was halted (Kahl et al., 2003). 
One study has demonstrated the virulence of a site-directed hemin-auxotrophic S. aureus 
SCV mutant in a murine model of septic arthritis (Jonsson et al., 2003). The study 
concluded that the small colony variants of S. aureus were more virulent on a per 
organism basis than its isogenic parental strain in the model of septic arthritis. This can at 
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least in part be explained by the ability of SCV to produce high amounts of destructive 
proteases (Jonsson et al., 2003). 
The study included normal and SCV strains from CF patients as well as control strains 
were tested for the susceptibility to defences, killing activity of professional phagocytes 
and adhesion to A549 cell line (Sadowska et al., 2002). 
Thus the SCV state is obviously of clinical significance, but establishing a clear link 
between recurrent infection and SCVs is clearly hampered by diagnostic failures on 
occasion.  
 
1.4.4 The survival advantage of the SCV condition to S. aureus  
There are many advantages to be gained by growing in the cytoplasm of host cells, inside 
non-professional phagocytes, such as endothelial cells and osteoblasts (Hudson et al., 
1995 & von Eiff et al., 2000). These rewards include protection from antibodies, 
complement and antibiotics that penetrate poorly into mammalian cells and a highly 
nutritious environment.  S. aureus SCVs have a reduced production of cytotoxins and this 
may down-regulate the induction of cell lysis or apoptosis (Proctor et al., 2006). 
Consequently and unlike the wild type, they do not kill the cells because they produce 
very little α-toxin (von Eiff et al., 2000). They are thus in a safe haven and can multiply 
without obvious limitation. S. aureus SCVs can revert to the highly virulent rapidly 
growing wild type form and lyse the host cell.  If the host immune response has dropped 
and antibiotic therapy is complete (von Eiff et al., 2000) then an infection results.  The 
continued persistence of the SCV strain and its phenotype indicates a survival advantage 
compared to strains with their normal phenotype (von Eiff 2008). It has also been 
demonstrated that the intracellular location itself can trigger the emergence of SCVs in S. 
aureus (Vesga et al., 1996). Intracellular bacteria were shown to develop the SCV 
phenotype at a much greater rate than bacteria not exposed to an intracellular environment 
in bovine endothelial cells, suggests that SCVs are induced by the intracellular milieu 
(Vesga et al., 1996).   
 
1.4.5 Reduced antibiotic susceptibility in S. aureus SCVs  
The ability to form a variant sub-population affords S. aureus a number of survival 
advantages. SCV do persist intracellularly, within non-professional phagocytes, and this 
shields them from host defences and decreases exposure to antimicrobial agents (Balwit et 
al., 1994).  S. aureus SCVs also show reduced antimicrobial susceptibility.  Seaman et al. 
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(2007) showed S. aureus SCVs have raised minimum inhibitory concentrations (MICs) to 
several antimicrobials including gentamicin, erythromycin and linezolid. However, 
resistance in SCVs does not result from the classical mechanisms of resistance such as 
production of β-lactamases (to break β-lactam based antibiotics) or efflux pumps (to 
pump antimicrobials out from the cell) (al Masaudi et al., 1991). Resistance to 
antimicrobials in SCVs is a direct consequence of the defects in the ETC and the SCV 
phenotype itself (Proctor 1998). Interruption of the ETC reduces the electrochemical 
gradient across the bacterial membrane, which in turn decreases the uptake of 
antimicrobial agents such as aminoglycosides, which require a charge differential to be 
present (von Eiff et al. 2006). Limits on ATP production reduce the growth rate of S. 
aureus SCVs, and this reduction is associated with a four-fold increase in the MICs of cell 
wall specific antibiotics. The decrease in energy bestows a characteristic
 
pleiotropic 
phenotype including slow growth (hence small colonies),
 
lack of pigmentation, non-
production of virulence factors and
 
reduced spectrum of carbohydrate utilization 
(McNamara & Proctor 2000). The survival of S. aureus SCVs within host cells reduces 
the effectiveness of antibiotics that have a limited ability to cross eukaryotic membranes 
(Darouiche & Hamill, 1994). This reduced susceptibility of S. aureus SCVs to 
antimicrobial agents is the main factor why SCVs have the ability to produce persistent 
and reoccurring infections. Antimicrobial agents that penetrate host cells and exert 
optimal intracellular bactericidal activity, especially against slow growing bacteria, have 
been suggested for use against S. aureus SCVs (Vaudaux et al. 2006). Rifampin is the 
single antistaphylococcal agent considered to be effective for treating intracellular 
infections (Sendi et al., 2006). 
 
 
1.5 Isolating and identifying SCVs  
It is recognised that the recovery and identification of SCVs by clinical microbiologists 
can be difficult (Proctor, 1994 & von Eiff et al., 1997). SCVs and parents S. aureus have 
the same appearance when Gram stained and SCVs are morphologically identical and 
often in a mixed population with parents S. aureus. Additionally and even when present as 
a small proportion of the total number of bacteria, normally growing organisms rapidly 
overgrow SCVs in liquid medium in an overnight culture. Thus rendering SCV isolation 
and susceptibility testing difficult (Kipp et al., 2005). Also the slow growth rate of SCVs 
and revertability makes standardization of testing difficult, because the slow growth rate 
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alters diffusion tests and times for measuring susceptibility. Lastly irrespective of their 
auxotrophism, errors can occur when these variants are resistant to oxacillin and are tested 
by disc-diffusion tests, Etests (AB Biodisk), microdilution tests, automated susceptibility 
testing systems, as well as anti-penicillin-binding-protein-2a (PBP2a) latex agglutination 
tests (MRSA-Screen, Denka Seiken) (Kipp et al., 2004). 
Since their colonial morphology is atypical, their biochemical reactions are unusual, such 
as reduced coagulase activity (often SCVs are only coagulase positive in the tube test after 
incubation for 18 hours) their identification is difficult (Kahl et al,. 1998).   
The failure to recover SCVs results in a major susceptibility reporting error, in that the 
more resistant of the two populations of organisms exhibited by a strain will be missed.  
Similarly, in instances where S. aureus SCV is misidentified, physicians may not be 
alerted to the possibility of recurrent infections or treatment failures (Proctor & Peters, 
1998).   
Thus SCVs are characterized by a strong reduction in growth rate, an atypical colony 
morphology, and unusual biochemical characteristics. All characteristics which have 
clinical health care issues (Proctor et al 2006) 
 
1.6. Biochemical basis of SCVs  
SCVs have a deficiency in electron transport, owing to mutations in the bacterial electron 
transport chain (ETC), or in thymidine biosynthesis (Proctor et al., 2006).  
  
1.6.1 Menadione and haemin SCVs 
Clinical isolates of SCVs are commonly auxotrophic for menadione and haemin, two 
compounds that are each crucial to the functioning of the electron transport chain (ETC; 
von Eiff et al., 1997, Proctor & Peters 1998). Both haemin and menadione have roles in 
bacterial electron transport.  Menadione is isoprenylated to form menaquinone and is the 
acceptor of electrons from nicotinamide adenine dinucelotide (NADH) and flavin adenine 
dinucelotide (FADH2) (Bates et al. 2003). Haemin is required for the biosynthesis of 
cytochromes, which accepts electrons from menaquinone and completes the ETC. Haemin 
and menaquinone are used both by aerobic electron transport. Mutations in the genes 
encoding these components of the ETC chain therefore interrupted ATP generation 
(Proctor et al. 2006).   
Thus mutations in genes that result in the SCV phenotype include menD (Bates et al. 
2003) and hemB (von Eiff et al. 1997). Other mutations occur in catA block the 
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biosynthesis of haemin, and therefore catA mutants also display the SCV phenotype 
(Clements et al. 1999).  
von Eiff et al. (1997) showed that laboratory constructed hemB mutants display 
characteristics typical of SCVs (micro colonies, reduced coagulase activity and increased 
resistance to aminoglycosides), indicating that mutations in hemB result in the SCV 
phenotype.  Interestingly all characteristics of the SCV phenotype in this mutant were 
reversed by growing in the presence of haemin or by complementing the mutant with 
intact hemB (von Eiff et al. 1997).  Without oxidative respiration SCVs can only produce 
ATP through fermentation, which is significantly less efficient resulting in severe ATP 
reduction, by 92%. ATP production is directly linked to cell wall biosynthesis, the 
generation the electrochemical gradient and also carotenoid biosynthesis. The reduction of 
ATP production in SCVs results in slower growth (hence smaller colonies), reduced 
uptake of aminoglycosides and cationic peptide transport and also decreased pigment 
formation in SCVs.  
 
1.6.2 Thymidine biosynthesis deficient SCVs  
The other group of SCVs that are constantly recovered from clinical specimens are those 
deficient in thymidine biosynthesis (Proctor et al. 2006). SCVs that are auxotrophic for 
thymidine have been commonly isolated from cystic fibrosis (CF) patients after long-term 
treatment with trimethoprim sulphamethoxazole (SXT) (Kahl et al. 1998). A further study 
by Kahl et al. (2005) showed S. aureus SCVs auxotrophic for thymidine to display two 
distinct colony morphologies: pin point colonies (one tenth the size of wildtype S. aureus) 
and ‘fried egg’ type colonies, with translucent edges that surround an elevated pigmented 
centre. Thymine auxotrophic SCVs have similar characteristics to SCVs deficient in 
electron transport; however the two morphological variants tested by Kahl et al. 2005 
showed the pinpoint colonies to exhibit an even longer doubling time and did not reach as 
high cell densities as the ‘fried egg’ colonies. Procter et al. (2006) suggest that thymidine 
auxotrophic SCVs may have a mutation in the nupC gene, which as Figure 1.2 shows is 
involved in the thymidine uptake from the environment. This is supported by the notion 
that B. subtilis nupC mutants, were shown to have a thymidine uptake 5 times slower than 
the wildtype (Saxild et al. 1996). Recently Beiser et al. (2007a) have shown mutations in 
the thymidylate synthestase gene, may be responsible for the formation of thymidine 
auxotrophic SCVs in S. aureus. Defects in thymidylate synthestase causes metabolic 
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impairments in the cell (Beiser et al. 2007a), which correlates with features of SCVs, such 
as reduced ATP production.  
Reduced thymidine uptake, ensures that the SCV phenotype is maintained, however 
supplementation with thymidine results in phenotypic reversion to the wildtype in S. 
aureus SCVs isolated from CF patients (Kahl et al. 1998). In thymidine auxotrophic 
SCVs there is also down regulation of the virulence regulators agr and sarA, and 
dependent virulence genes such as hla and spa (Kahl et al. 2005). Also showed that 
thymidine auxotrophic SCVs displayed decreased expression of agr and sarA, although 
supplementation of thymidine increased the transcription
 
of the agr locus and the agr-
dependent virulence genes spa and
 
hla to full or partial transcription. Similarly to the 
hemB mutant supplementation of the compound the SCVs are deficient in this case 
thymidine, results in reversion to the wildtype and restores transcription of virulence 
associated genes (Kahl et al. 2005).  
 
1.6.4 Prototrophic SCVs  
In all of the discussions of SCVs, phenotypes and genotypes there is an absence of 
analysis of where the mutations in non-auxotrophic mutants are. Clearly if these are not 
shown to become wild type by supplementation then their mutations are in other genes. 
There is no conjecture in the literature. Logically therefore these mutations must be in 
genes not related to the biosynthesis of precursor chemicals but in the structural 
composition of an active ETC. Since there are many components, which comprise the 
ETC one could estimate crudely auxotrophs are a small subset of potential mutations 
accusing the SCV phenotype. 
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Figure 1.2 Relationship between electron transport and the small colony variants 
phenotype in S. aureus (Proctor et al. 2006).  Defects in electron transport reduce the 
yield of ATP (92 %) effecting all metabolism including that available for cell-wall 
biosynthesis, which leads to a slower growth rate and production small colonies. Since 
ATP is required for carotenoid biosynthesis and maintaining membrane potential.  Thus 
SCVs produce non-pigmented colonies and decreased uptake of cationic compounds. 
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1.6.4   SCV formation 
The molecular mechanisms behind the emergence of SCVs are not well understood and 
regulatory as well as genetic mechanisms seemed conceivable to Schaaff et al (2003).  
This was due to the fact many SCVs are unstable and form wild type revertants (Becker et 
al. 2007), although this seems a little naive as many mutations revert at high frequencies. 
Schaaff et al. (2003) have examined whether an increased mutation rate favours the 
formation of SCVs by comparing an E. coli strain with mutS gene knocked out with 
wildtype strains. mutS along with mutH and mutL make up the dam-directed mismatch 
repair system in E. coli which is crucial in proofreading during DNA replication (Horst et 
al. 1999).  The results of Schaaff et al. (2003) showed that the emergence of spontaneous 
SCVs was 556-fold higher in the mutS mutant than in the wildtype strain, demonstrating 
that a higher mutation rate favours the emergence of SCVs, and suggest that point 
mutations play a substantial role in the formation SCV populations.  The widely reported 
ability of antimicrobials such as aminoglycosides and triclosan to select for SCVs 
(Musher et al. 1977, Balwit et al.  1994 Seaman et al. 2007) suggests that the presence of 
antimicrobials may induce SCV formation. Recently, aminoglycoside-induced SCV 
formation has been linked to the activity of an alternative sigma factor in S. aureus. 
Formation of the SCV phenotype in S. aureus can be viewed as a phenotypic switching 
system which appears to be strongly influenced by the alternative sigma factor, σB 
(Mitchell et al., 2010a). Alternative sigma factors in bacteria are involved in regulating 
gene expression in response to environmental signals such as changes in temperature or 
pH shifts (Hecker et al., 2007; Kullik et al., 1998).  Three alternative sigma factors have 
been identified in S. aureus: sigma A (Deora & Misra, 1996) sigma B (Wu et al., 1996) 
and sigma H (Morikawa et al., 2003), all of which are closely related to their respective 
forms in Bacillus subtilis. Regulation of B is modulated by rsbU, rsbV, rsbW gene 
products which sit in a chromosomal cluster along with sigB (Bronner et al., 2004). Under 
non stress conditions RsbW acts as an anti-sigma factor and holds B in an inactive 
complex (Pane-Farre et al., 2006). Under stress conditions RsbV is dephosphorylated by 
RsbU and forms a RsbV–RsbW complex. This permits the release of free B, which binds 
to RNA polymerase to form an active σB-holoenzyme (Bronner et al., 2004). Microarray 
based analysis has shown that B influences the expression of 251 genes, 198 of which are 
positively influenced (Bischoff et al., 2004). Cell envelope biosynthesis, signalling 
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pathways and various virulence factors were among some of the diverse cellular processes 
influenced by B.  
Recently B has been implicated in the emergence of SCVs following exposure to 
aminoglycosides (Mitchell et al., 2010a). Sub-inhibitory concentrations of gentamicin and 
tobramycin significantly increased the frequency SCV formation in S. aureus strains with 
B+ background, where-as fewer SCVs were recovered from a B- constructed mutant 
Quantitative PCR (qPCR) also demonstrated that sub-inhibitory concentration of 
gentamicin and tobramycin induced B activity (Mitchell et al., 2010a). 
 
1.7   Molecular identification techniques for S. aureus SCVs  
Identification of clinical strains S. aureus SCVs is difficult because of their slow growth 
rate and unusual colony morphology (Proctor et al. 1994). Thus SCVs cause numerous 
problems for diagnosis and treatment, and are also rapidly overgrown (Proctor, 2000). 
Population sizes as low as 0.01% of wildtype S. aureus will overgrow S. aureus SCVs in 
an overnight culture without selection (von Eiff et al., 2001a). The standard biochemical 
tests for identification of S. aureus are made obsolete by changes in carbon source 
utilisation and virulence factors, and their lack of coagulase production and reduced 
haemolytic activity meaning staphylococcal SCVs are difficult to recognise and are often 
misidentified as coagulase negative staphylococci (CoNS) (Seaman et al. 2007, 
McNamara and Proctor 2000). Standardisation testing for S. aureus SCVs is difficult; as 
their slow growth rate lengthens times for measuring antimicrobial susceptibility and 
errors can also occur when SCVs are tested via automated susceptibility testing systems 
(Kipp et al. 2004).  Rapid identification of S. aureus SCVs had been demonstrated by the 
use of multiplex polymerase chain reaction (PCR), targeting the 16S rRNA 
(Staphylococcus genus specific), and
 
nuc (S. aureus species specific) genes (Seaman et al. 
2007and Zhang et al. 2004). The identification of microorganisms based on their 16S 
rRNAs has many advantages; each bacterial cell contains multiple copies of the 16S 
rRNA in its ribosomes. Hence, the technique is sensitive enough to detect single bacterial 
cells and 16S rRNA genes are highly conserved throughout bacterial evolution (Krimmer 
et al., 1999). 
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Figure 1.3 Summary of characteristics of (A) wild type S. aureus (B) S. aureus SCV.  
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1.8 Gene transfer in Staphylococcus aureus  
Genetic transfer is the mechanism by which DNA is transferred from a donor to a 
recipient. There are four transfer mechanisms for transfer of resistance genes between 
staphylococcus aureus. These are transformation, phage-mediated conjugation, 
conjugation and transduction. 
 
1.8.1 Transformation  
Transformation was first demonstrated in 1928 by British bacteriologist Frederick Griffith 
and the identification of the "transforming principle" as DNA (Avery et al., 1944). 
Transformation is a process by which naked DNA is taken up and integrated into the 
genome of a recipient cell and occurs with chromosomal or plasmid DNA under certain 
conditions (Lindberg et al. 1972). The transformation of S. aureus requires a high 
concentration of calcium ions or bacteriophage in either the prophage or vegetative state. 
In the absence of these conditions and the presence of nuclease, transformation is reduced 
(Lyon & Skurray, 1987).  
Transformation of staphylococci in vitro has been described but most cultures of S. aureus 
contain high levels of nucleases which probably prevent transformation in vivo (Sjostrom, 
et al., 1979).  The ability to absorb free DNA from the environment is relatively rare in 
species of Gram-positive bacteria. However S. aureus, under specific conditions, is able to 
take up (naked) DNA from the environment. The natural competence system of S. aureus 
in induced only in very early exponential growth (Novick, 1989). Chromosomal or 
plasmid DNA can be transformed into S. aureus, although competence requires high 
calcium concentration (Lacey, 1984). 
 
1.8.2 Phage-mediated conjugation  
Phage-mediated conjugation is the transfer mechanism most likely to occur between 
staphylococci in nature. MRSA have evolved from a single clone and are now 
heterogeneous in properties (Lacey, 1986). It is a mechanism which needs viable cell-to-
cell contact as well as the presence of lysogenic phage in either the donor or recipient cell 
(Lacey, 1980). This mechanism occurs in vivo between staphylococci at the high 
frequencies (≥ 10-1) when the recipient is a lysogen (Lacey, 1980; Lacey & Kruczenyk, 
1986). In this transfer high cell densities and calcium ions are both required for high rates 
of gene transfer (Witte, 1981). Gentamicin resistance is transferred at frequencies between 
10
-3
 and 10
-6 
by phage-mediated conjugation in vivo and vitro (Lacey & Lord, 1980; 
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Naidoo, 1984). High frequency of transfer suggests that transfer of small plasmids and 
chromosomal genes between staphylococci is likely to occur under natural conditions by 
this mechanism (Lacey, 1984). 
 
1.8.3 Conjugation  
The transfer mechanism is not affected by DNAase, chelating agents and human serum 
(McDonnell et al. 1983). Conjugative plasmid is able to mobilize non-conjugative 
plasmid between clinical isolates of S. aureus (Udo & Grubb, 1990).   
Bacterial conjugation is a highly specific process whereby DNA is transferred from donor 
to recipient bacteria by a specialized multi-protein complex, termed the conjugation 
apparatus (Figure 1.4; Lederberg and Tatum 1946). An important prerequisite for 
conjugative transfer is an intimate association between the cell surfaces of the interacting 
donor and recipient cells. In Gram-negative bacteria, this physical contact is established 
by complex extracellular filaments, designated sex pili. For the majority of Gram-positive 
bacteria, the means to achieve this intimate cell-to-cell contact have not yet been 
identified (Grohmann et al., 2003). 
Staphylococcal conjugation was first described in 1982 with the description of the transfer 
of plasmids carrying gentamicin resistant (Jaffe et al., 1982). These plasmids occur very 
commonly in S. epidermidis and may responsible for the spread of gentamicin resistance 
to S. aureus (Forbes & Schaberg1983). Conjugative staphylococcal plasmids isolated 
carried resistance to gentamicin and other aminoglycosides, ethidium bromide and 
quaternary ammonium compounds (Grohmann et al., 2003). These findings show that 
conjugation systems are probably of significant in the dissemination of antimicrobial 
resistance genes among the staphylococcus genus (Novick, 1989). 
 
1.8.4 Transduction  
Transduction is a mechanism by which chromosomal or plasmid DNA from the donor is 
carried by a bacteriophage to the recipient (Jawetz et al., 1987). Two types of transduction 
mechanisms, general and restricted, have been described (Jawetz et al., 1987). In 
generalized transduction the phage either carriers a phage genome or a segment of 
chromosome or plasmid from the donor, certain temperate phage strains can transfer only 
few genes of bacterial chromosome this is termed  restricted transduction (Jawetz et al., 
1987). Transduction in S. aureus was first carried out in vitro in 1958 (Ritz and Baldwin, 
1958) and frequencies of <10
-7
 per recipient were reported. Phage mediated transduction 
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has been postulated to be a mechanism by which β-lactamase genes have spread among 
staphylococci (Novick, 1989). The principles of transduction are shown in Figure 1.4.  
 
1.9 The susceptibility of S. aureus strains to bacteriophage 80α 
There are over 250 staphylococcal bacteriophages reported in the literature (Pantucek et 
al., 2004). Recognition of the importance of viral-mediated virulence gene transfer is 
growing (Rice, 2006).  While most strains of S. aureus contain at least one prophage, rare 
strains contain  15 phage types, suggesting a potential for a protective effect from lysis 
by phage integration (Lindsay & Holden, 2004). S. aureus bacteriophage 80α is a 
temperate phage that is capable of generalized transduction and also serves as a helper 
phage for the mobilization of several different SaPIs, including SaPI1, SaPI2, SaPIbov1, 
and SaPIbov2 (Novick et al., 2010 & Christie et al., 2010).  
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Figure 1.4 Transfer of DNA between bacteria cells. (a) Transformation  Involves 
acquisition of DNA from the extracellular environment, for example when DNA is 
released on lysis of an organism and subsequently picked up by another organism. The 
acquired gene can be integrated into the chromosome or into a plasmid of the recipient 
cell. (b) Transduction  Involves acquisition of foreign DNA by means of bacteriophages. 
(c) Conjugation  Occurs by direct contact between two bacteria and the formation of a 
mating bridge across the bacteria in which the DNA is exchanged (Furuya & Lowy, 
2006). 
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1.10 Aims 
 
The aims of this investigation were to: 
 
 Examine the ability of gentamicin and triclosan to select for S. aureus SCVs.  
 
 Compare the sensitivity and resistance to an antibiotic (gentamicin) and a biocide 
(triclosan) of MRSA strains. 
 
 Examine the effect of forward and reverse mutation cycles on S. aureus wildtype 
strains. 
 
 Make a physiological and genetical comparison of SCVs and wildtype strains. 
  
 Make a comparative analysis of staphylococcal genomes. 
 
 Examine the potential of SCVs to acquire and disseminate antimicrobial resistance 
by transduction.  
 
 Compare aerobic and anaerobic growth of S. aureus COL and SCV strains.  
 
 Compare the effects of inhibitors on the growth of S. aureus COL and SCV 
strains.  
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CHAPTER 2 : 
 MUTATION IN STAPHYLOCOCCUS AUREUS 
2.1   Introduction   
2.1.1 History of mutation 
A mutation is a change in the sequence of genomic DNA. Mutations come from errors 
made during the replication of DNA or from exposure to mutagens as radiation, 
viruses, transposons and mutagenic chemicals (Burrus, & Waldor, 2004; Denamur & 
Matic, 2006). Mutations include deletion (loss of DNA bases), duplication or insertion 
(gain of DNA bases), transposition and missense or nonsense (substitution of a DNA 
base). Such mistakes are rare (Alderson & Rowland, 1995), but occur consistently 
during the life of cells. Many mutations are recognized because the phenotype or 
resistant of the organism has changed (LeClerc et al., 1996). Bacteria undergo 
mutation at a rate of between about 10
-6
 to 10
-9
 per cell generation. This mutation rate 
can be increased by subjecting bacteria to certain chemicals or to irradiation. Many of 
these mutations physiologically impair the bacterium in some way and so for example 
gaining resistance to an inhibitor will often be at a cost (Saunders, 1984). Novel genes 
are produced by several processes, commonly through the duplication and mutation of 
an ancestral gene, or by recombining parts of different genes to form new 
combinations with new functions (Long et al., 2003). 
Most if not all bacteria transfer and receive genes and this process maybe mutagenic if 
recombination or transposition occurs. There are three transfer processes called 
transformation, transduction, and conjugation (Davison, 1999). Gene transfer has 
significance in antibiotic resistance as it allows the rapid transfer of ecologically 
relevant genes between different pathogens (Hastings et al, 2004). 
2.1.2  Causes of mutation 
2.1.2.1  Spontaneous mutation 
Spontaneous mutations arise from a variety of sources, including natural errors in 
DNA replication and spontaneous lesions. An error in DNA replication can occur 
when base is changed by the repositioning of a hydrogen atom, altering the hydrogen 
bonding pattern of that base resulting in incorrect base pairing during replication this 
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is called tautomerism (Griffiths et al., 2000). In addition to replication errors, 
spontaneous lesions, naturally occurring damage to the DNA, can generate mutations. 
Two of the most frequent spontaneous lesions result from depurination (loss of a 
purine base (A or G) to form an apurinic site) and deamination which is  hydrolysis of 
a base to an atypical base containing a keto group in place of the original amine group 
such as  C→U and A→HX (hypoxanthine), which can be corrected by DNA repair 
mechanisms; and 5MeC (5-methylcytosine) → T, which is less likely to be detected 
as a mutation because thymine is a normal DNA base (Montelone, 1998). The rates of 
such mutations have been determined for many species. E. coli has a spontaneous 
mutation rate of 10
-8 
(one error in every 10
8
 nucleotides replicated) (Khanna, 2008). 
2.1.2.2  Induced mutation 
Induced mutations are mutations that caused by agents in the environment. Induced 
mutations increase the mutation rate over the spontaneous rate (Burrus, & Waldor, 
2004). Mutations can be caused by interactions of the genome with chemical agents, 
radiation and transposon insertion (Khanna, 2009). 
2.1.2.2.1 Chemical mutagens 
The first report of mutagenic action of a chemical was in 1942 by Charlotte Auerbach, 
who showed that nitrogen mustard (component of poisonous mustard gas used in 
World Wars I and II) could cause mutations in cells. Since that time, many other 
mutagenic chemicals have been identified (Montelone, 1998).  Chemical mutagens 
may induce point mutations that occur when a single base pair of a gene is changed. 
These changes are classified as transitions or transversions. Transitions occur when a 
purine is converted to a purine (A↔G) or a pyrimidine is converted to a pyrimidine 
(T↔C) (Khanna, 2009). A transversion results when a purine is converted to a 
pyrimidine or a pyrimidine is converted to a purine. A transversion example is 
adenine (A) being converted to a cytosine (C). Two main classes of chemical 
mutagens are routinely used. These are alkylating agents and base analogs. Each has a 
specific effect on DNA. Alkylating agents (such as ethyl methane sulphonate (EMS), 
ethyl ethane sulphonate (EES) and mustard gas) can mutate both replicating and non-
replicating DNA (Tripathi, 2010). In contrast, a base analog (5-bromouracil and 2-
aminopurine) only mutate DNA when the analog is incorporated into replicating DNA 
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(Ogino et al., 2002). Each class of chemical mutagen has specific effects that can lead 
to transitions, transversions or deletions.  
2.1.2.2.2   Radiation 
Radiation is also capable of inducing mutations such as Ionizing radiation (X-ray, γ- 
ray), even non-Ionizing radiation (UV). Ionizing radiation has various effects on DNA 
depending on the type and energy of the radiation, can create free radicals that result 
in problems ranging from point mutations (changes in a single nucleotide) or deletions 
(loss of a chromosomal segment) (Larsen et al., 2006). Some types of ionizing 
radiation act directly on DNA, others act indirectly by stimulating the formation of 
reactive molecules such as peroxides in the cell (Brown, 1999). In addition to targeted 
effects of damage induced directly in cells by irradiation, a variety of untargeted 
effects may also make important short-term and long-term contributions to 
determining overall outcome after radiation exposures (Coates et al., 2004). Non-
ionizing radiation (UV radiation) induces dimerization of adjacent pyrimidine bases, 
especially if these are both thymines (Brash et al., 1991). UV light can induce 
adjacent pyrimidine bases in a DNA strand to become covalently joined as a 
pyrimidine dimer. UV radiation, particularly longer-wave UVA, can also cause 
oxidative damage to DNA (Kozmin et al., 2005). 
2.1.2.2.3   Transposon insertion 
Transposable elements are mobile pieces of DNA that can move from one location in 
a genome to another (Nagy & Chandler, 2004) and the presence of a transposable 
element in a wild type gene disrupts the normal function of that gene. The mechanism 
of transposition can be either (copy and paste) or (cut and paste).  
Transposons carry many genes, so for example some encode for antibiotic resistance 
and others for catabolic phenotypes (Reznikoff, 2003). Although transposon insertion 
in a gene usually causes complete loss of function, in a few rare exceptions, 
transposon insertions mutations are null alleles (Kleckner, & Botstein, 1977). 
2.1.3 Effects of mutation 
Mutations can affect individual cells in a variety of ways. Mutations can affect the 
organism’s phenotype, which effects how successfully the organism interacts with the 
environment. Thus some of these mutations are beneficial to the organism. However 
 31 
generally mutations have a negative impact and so cause biochemical variation.  So if 
a mutation occurs in a gene that encodes an enzyme involved in a metabolic pathway 
causing its’ inactivation, such as an enzyme involved in the biosynthesis of an amino 
acid (Snyder& Champress, 2007), the consequence is the cell dies. Such mutations are 
termed lethal as they lead to the death of the organism. Mutations change the genome 
sequence and can be diverse, ranging from single base pairs changes, inversions, 
transpositions and deletions.  All but the latter are revertable and these can be either 
true revertants, where the original sequence is recovered, or pseudorevertants where a 
second mutation suppresses the first (Ellis et al., 2001).   
Mutations can effect the cell’s phenotype, but in many cases there is no visible 
evidence of genomic change.  In this instance these are termed silent. 
2.1.4  Antibiotic and biocide selection for S. aureus SCVs 
2.1.4.1  Selection of S. aureus SCVs by gentamicin 
Gentamicin is member of the aminoglycoside family. Aminoglycosides are 
distinguished by a backbone of an aminocyclitol ring saturated with amine and 
hydroxyl substitutions (Shakil et al., 2008; Figure 2.1). Gentamicin is 2-
deoxystreptamine containing aminoglycosides (Magnet & Blanchard, 2004). 
Gentamicin display good synergetic activity with other antibiotic classes (such as β-
lactams) and are therefore used in the treatment of a range of bacterial infections 
including meningitis, pneumonia, tuberculosis and even plague (Nakamura et al., 
2000; Shakil et al., 2008). Aminoglycosides have a variety of effects within the 
bacterial cell but principally they inhibit protein synthesis by binding to the 30S 
ribosomal subunit to prevent the formation of an initiation complex with messenger 
RNA. They also cause misreading of the messenger RNA message, leading to the 
production of nonsense peptides. Another important function of the aminoglycosides 
is that they increase membrane leakage intracellular contents (White et al., 2005). 
Various classes of antimicrobial agents have been demonstrated to select 
Staphylococcus aureus SCVs most especially  
aminoglycosides and trimethoprim-sulfamethoxazole (SXT) (Gilligan et al., 1987). A 
number of different quinolones have also shown to select for S. aureus SCVs 
(Mitsuyama et al., 1997), and other antibiotic such as fusidic acid (Norstrom et al., 
2007) and biocides such as triclosan (Seaman et al., 2007) have all been shown to 
 32 
select for the SCV phenotype. Extracellular products produced by other bacteria have 
also been implicated in the formation of S. aureus SCVs. 4-hydroxy-2-
heptylquinoline-N-oxide (HQNO) and pyocyanin by P. aeruginosa both interfere with 
S. aureus electron transport chain (ETC) and have been demonstrated to select for 
SCVs in vitro (Biswas et al., 2009). The use of gentamicin beads provides a steady 
release of antimicrobial to the site of infection over the course of weeks or months if 
required (Evans & Nelson, 1993). It is hypothesised that the slow release of low levels 
of gentamicin into the infected area is an efficient way to select for SCVs (von Eiff et 
al., 1997a). Gentamicin selected SCVs maybe auxotrophic for haemin and menadione 
that confers defects in the ETC and consequently in ATP generation (Balwit et al., 
1994; von Eiff et al., 1997a).   
 
 
 
 
 
 
Figure 2.1 The chemical structure of gentamicin. (Klostermeier et al., 2004)  
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2.1.4.2  Selection S. aureus SCVs of by Triclosan 
Triclosan (2, 4, 4’-trichloro-2’-hydroxydiphenyl ether), (Irgasan DP300), (Irgacare 
MP) and (Irgacid LP10) (Figure 2.2) is a broad spectrum biocide that has been in use 
for more 35 years. It was developed in the 1960s by J.R. Geigy AG (Basel 
Switzerland) and is now manufactured predominantly by Ciba Specialty Chemicals 
GmbH (Grezach-Wyhlen, Germany) (Seaman, 2007). Usage was increasing, but has 
now stabilized, with about 350 tonnes of triclosan being used within countries of the 
European every year. Of this, the UK is estimated to use 60-90 tonnes (Fan, 2002). 
Recently, triclosan, a synthetic bisphenol antimicrobial agent that has a broad range of 
activity against Gram-positive and Gram-negative bacteria, has been shown to select 
for S. aureus SCVs (Seaman et al. 2007).  
Triclosan has been used in some skin care products for over 30 years and has been 
employed as surgical scrubs, hand washes and body washes to control MRSA 
(Russell, 2004). The wide use of triclosan in consumer products and in control of 
MRSA, coupled with its ability to select for SCVs of S. aureus has many implications 
in the healthcare setting (Bhargava & Leonard, 1996). In 1987 triclosan was 
successfully used to control an outbreak of MRSA and more recently it was used 
successfully to control MRSA outbreaks in a neonatal nursery (Tuffnell et al., 1987 & 
Zafar et al., 1995). Subsequently, in 1998 it was recommended for the control of 
nosocomial MRSA and 2% triclosan baths are now one of the recommended 
rationales for skin decolonisation of MRSA carriers (Ayliffe et al., 1998 & Coia et al., 
2006). Triclosan has been reported to achieve growth inhibitory activities by blocking 
fatty acid synthesis and more specifically by explicitly inhibiting an NADH-
dependent enoyl-acyl carrier protein (ACP) reductase, encoded by the fabI gene. 
(Payne et al., 2001 & Heath et al., 2000). Seaman et al. (2007) have found in vitro 
that triclosan can select for S. aureus colonies showing the characteristic SCV 
phenotype with low-level triclosan resistance and which coincidently have reduced 
susceptibility to penicillin and gentamicin. Additionally, triclosan-isolated SCVs were 
shown to have an increased tolerance to the lethal effects of triclosan. 
Despite all the research into SCV formation a description of the classes of SCVs 
remain obscure.  A description of prototroph and auxotroph is hardly sufficient as 
specific auxotrophic classes are found. Why are these classes unique? Additionally 
auxotrophs are found in clinically isolated SCVs, but to our knowledge have not been 
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found in laboratory isolations.  Thus the cycling experiment was designed to try and 
understand and determine what events took place in the formation and reversion of 
SCV mutants.  Critical to this investigation and understanding was the determination 
to sequence the final mutants and determine the locations of the mutations conferring 
the SCV phenotype.   Simply this will inform us to whether the mutations are site 
specific (forward - point mutations occurring and reverting at just one site) or of a 
more general nature.   Logic says the latter is the case. 
 
 
 
 
Figure 2.2 The chemical structure of triclosan (Heath et al., 1989) 
 
2.1.5 Identification characteristics mecA gene and nuc gene 
mecA gene is embedded in a large heterologous chromosomal cassette, the SCCmec 
genetic element and gene encodes the penicillin binding protein (PBP 2A) with 
reduced affinity for β-lactams ( Song et al., 1987; Ito et al., 1999). The characteristic 
methicillin resistance phenotype in S. aureus is due to the presence of mecA (Hartman 
& Tomasz, 1981; Ito & Hiramatsu, 1998). The mecA gene confers resistance to 
antibiotics such as methicillin because it prevents penicillin-like antibiotics inhibiting 
enzymes forming the cell wall of the bacterium (Abd El-Moez et al., 2011)  
The staphylococcal nuclease (nuc) gene from Staphylococcus aureus has been cloned 
and sequenced (Kovacevic et al., 1985). S. aureus strains produce an extracellular 
 35 
thermonuclease (Madison & Baselski, 1983). This maybe important because the 
enzyme produces thymidine from DNA possibly making it available to the pathogen 
during infection. Thus, success or failure with trimethoprim-sulfamethoxazole may 
well depend on the amount of tissue damage and organism burden, rather than 
acquisition of a resistance gene (Proctor, 2008). 
 
2.1.6 The experimental strategy and design of the cycling experiment  
The aim was to examine the evolutionally changes (mutations) occurring sequentially 
in successive cycling selections of SCV mutants and wildtype revertants. Two 
sequenced clinical MRSA strains MRSA COL (Dyke et al., 1966) and N315 (Kuroda 
et al., 2001) were chosen so changes in sequence in SCVs and revertants could be 
compared.  Selection for SCVs was made independently for triclosan and gentamicin 
resistance for both strains. Then WT revertants were obtained from these SCVs by 
growth on nutrient medium and selected by large wild type colony form.  Successive 
cycles of forward and reverse selection were made. From each selection cycle a 
representative SCV isolate and its WT revertant was stored. 
The experiment was to be terminated if the SCV or wild type was unable to revert or 
when the mutation rate between the two isolates became consistent. Due to time 
constraints we terminated the experiment after 15 cycles.  At this point DNA was 
obtained from the final SCV and wild type strains and sent for gnomic sequencing.  
This was examined to determine where mutational change had occurred.  The 
evolutionary history of the two strains selected on two antimicrobial stored as isolates 
from each stage in the 15 cycles.  Thus potentially all 60 strains could be examined to 
see when and what events have occurred. An analysis of the results should provide an 
idea of the mutational capacity and be suggestive of the evolutionary potential of the 
organism.  A comparison of the results between two antimicrobials and two genetic 
backgrounds will provide a sound basis for the analysis and interpretation.  So for 
example it may show what is a general phenomenon or a strain specific one. 
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2.1.7 Aims 
 
 To determine the forward (to SCV) and reversion (to WT) mutation rates of S. 
aureus isolates. 
 To compare the phenotypes exhibited by strains isolated in the successive cycles 
of selection   
 To analyse these strains which represent successive mutational steps in the 
selection cycle by a comparison of their genetic differences.  
 To determine if independent MRSA strains respond in a similar evolutionary 
manner to selection by antimicrobials. 
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2.2  Materials and Methods 
2.2.1 Bacterial strains and bacteriophage 
In this study two S. aureus strains that demonstrated susceptibility to a mutation of 
gentamicin and triclosan were included. Methicillin-resistant S. aureus (MRSA) COL 
(Dyke et al., 1966) and N315 (Kuroda et al., 2001) were the parental strains.  
Strain terminology was as follows.  The terms SCV01 and WT01 refer to the parental 
type (SCV or WT) and generation cycle (01, 02, 03, etc.). The terms COL-GEN, 
COL-TRI, N315-GEN and N315-TRI refer to strain (COL or N315) and the selection 
medium containing gentamicin (GEN) or triclosan (TRI). The original WT were thus 
termed COL WT00 and N315 WT00. Strains were maintained at -80°C in Mueller 
Hinton Broth (MH; CM0405: Oxoid Ltd, UK) supplemented with 8% 
dimethylsulphoxide (DMSO; 154938: Sigma Aldrich, UK) and re-grown on Mueller 
Hinton Agar (MH; CM0337: Oxoid Ltd, UK) plates when required. Bacteriophage Φ 
80α used to detect phage sensitivity (Novick, 1963).  
2.2.2 Preparation of gentamicin and triclosan stock solutions 
Gentamicin was obtained from Sigma Aldrich (UK G-3632) and triclosan (Irgasan 
DB300) was from Ciba Spezialitätenchemie Grenzach GmbH (Grenzach-Whlen, 
Germany) Manufactures potencies were used to determine amounts of each of 
gentamicin and triclosan powder required to produce a 10,000 mg/L solution. 
Gentamicin powder was dissolved in sterile deionised water, as for the triclosan 
powder was dissolved in sterile DMSO , dissolved thoroughly (through vortex 
mixing) and filter sterilised with a 0.2 µm filter (Minisart, UK). Reduced strength 
stock solutions were made where required in sterile deionised water. Stock solutions 
were maintained at 4°C. 
2.2.3 Determination of minimum inhibitory concentrations  
Minimum inhibitory concentrations (MICs) were determined according to Clinical 
Laboratory Standard Institute (CLSI) guidelines (CLSI, 2006). Cation adjusted 
Mueller Hinton (CAMHB) was used for MIC determination and stock solutions of 
CaCl2 and MgCl2 were prepared and added to MH broth to ensure each batch 
contained the correct concentrations of CaCl2 (20 mg/L) and MgCl2 (10 mg/L). 
Individual S. aureus colonies (3-4) were inoculated into CAMHB and incubated at 
37°C with shaking at 150 rpm. Cultures were grown to the end of logarithmic phase 
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and cell densities were adjusted to match the turbidity of a 0.5 McFarland standard at 
625 nm. The range of antimicrobial concentrations to be tested was decided and 
concentrations were made in CAMHB at double the required concentration to allow 
for dilution by the inoculum.  Microtitre well plates (Fisher, UK) were inoculated with 
100 µL of required antimicrobial concentrations and 100µL of inoculum to provide a 
test inoculum of 5 X 10
5
 CFU/mL. Microtitre plates were incubated at 37°C without 
shaking and the MIC was recorded as the lowest concentration that inhibited visible 
growth after 18 hours.  
2.2.4 Storage of wild type and SCV cultures 
The wild type and SCV strains were inoculated into 10 ml MH broth (plus 0.031 
mg/L triclosan or 0.25 mg/L gentamicin for the SCV strains).  Wild type strains were 
incubated at 37°C in an orbital shaker at 150 rpm for 24 hours and SCV strains for 48 
hours. The optical density at 700 nm (OD700) of each suspension was recorded and 1 
ml of each culture in 8% DMSO was prepared and stored at -80°C. 
2.2.5 Isolation of SCV mutants 
Appropriate serial dilutions from the wild type broth cultures of COL and N315 
strains (and labelled as appropriate e.g. COL WT00; COL WT01, etc) were made in 
sterile phosphate buffered saline (PBS; BR0014G: Oxoid, UK), and then plated out 
onto MH agar plus gentamicin or triclosan (concentrations in Table 2.1).  These plates 
were incubated at 37°C for 48 hours.  Colony counts were made at 48 hours yielding 
SCVs from strain-antimicrobial (e.g. COL SCV 01-TRI, N315 SCV01-GEN). 
One representative SCV colony was chosen per cycle (e.g. COL SCV01-GEN, etc.) 
from each of the four assays.  The strain was inoculated into MH broth plus selective 
agent (gentamicin or triclosan; Table 2.1).  These were incubated at 37°C for 48 h in 
an orbital shaker, their optical density recorded and stored as described previously 
(section 2.2.3). 
2.2.6 Isolation of wild type revertants 
Appropriate serial dilutions were made in PBS of an SCV (e.g. COL SCV01-GEN) 
culture was made and 100 µl spread-plated out onto MH agar. Plates were incubated 
at 37°C and colony counts of wild type and SCV were determined at 24/48 hours. 
Wild type revertants were represented by large colonies. A representative individual 
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colony was chosen and termed WT01 (e.g. COL-GEN, COL-TRI, N315-GEN and 
N315-TRI). It was inoculated onto MH broth and incubated overnight.  The OD700 
was recorded and a sample was stored at -80
o
C, as described above (section 2.2.4) and 
labelled appropriately, e.g. COL WT01-GEN. 
 
Table 2.1 The concentrations of gentamicin and triclosan used to isolate SCVs  
Strains Antimicrobial 
MIC 
(mg/L) 
Agar medium 
(mg/L) 
Broth medium 
(mg/L) 
COL 
gentamicin 0.25 1.00  0.25  
triclosan 0.125 0.5  0.03125  
N315 
gentamicin 0.25 2.00  0.30 
triclosan 0.125 0.50 0.03125  
Modal values were obtained from three independent replicates and three independent 
biological replicates. 
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Figure 2.3 A schematic of the steps for isolating SCV mutants and wild type 
revertants. There were 15 successive cycles of selection.   
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2.2.7 Characterisation of SCVs isolates  
S. aureus SCV strains were grown in MH broth, supplemented with 1 mg/L of either 
gentamicin or triclosan to prevent overgrowth by revertants with the parental 
phenotype. Cultures were prepared by inoculating individual colonies in 
supplemented MH broth followed by incubation at 37°C with shaking at 150 rpm for 
36-48 hours.  
2.2.7.1 Determination of auxotrophy 
SCVs may be auxotrophic for haemin, menadione or thymidine, hence the 
auxotrophic profiles of SCVs were examined. Stock solutions (1,000 mg/L) of 
haemin, menadione and thymidine (H9039; M5625; T1895; Sigma Aldrich, UK) were 
prepared by dissolving powders in DMSO (haemin) or sterile deionised water 
(menadione and thymidine). Stock solutions were stored at 4°C for maximum 14 
days. Lawns of SCVs were prepared by spreading 100 µL of a 48 h culture onto the 
surface of a MH agar plate. Sterile filter paper discs (151202; Whatman 42) plated in 
the centre of the plate and 10 µL of haemin, menadione or thymidine stock solutions 
added to filter discs and plate were incubated for 48 hours. SCVs were confirmed as 
auxotrophic if a zone of wildtype like growth (i.e. large colonies, restoration of 
pigment) was present surrounding the filter disc. 
2.2.7.2 Coagulase activity  
Coagulase production was determined by using Staphylase test kit (DR0595A; Oxoid 
Ltd, UK). Individual colonies were smeared into a test circle and a control circle on a 
reaction card. 1 drop of the Test Reagent was then added to the test circle and 1 drop 
of Control Reagent was added to the control circle. A colony was then mixed 
separately into the test reagent and into the control reagent. The presence of 
agglutination was recorded as coagulase positive and the absence of agglutination as 
coagulase negative.  
2.2.7.3 Haemolysis activity 
MH agar was supplemented with 5% defibrinated sheep blood (SB054; TCS 
Biosciences Ltd, UK) to examine haemolysis activity. Overnight cultures of S. aureus 
parent and SCV strains were adjusted to a density of 1 x 10
7
 CFU/mL and of this 
suspension 10 µL drops were spotted onto the surface of a blood agar plate. Following 
incubation for 24-48 hours at 37°C. Haemolysis activity was detected by the 
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production of zones of clearing surrounding bacterial growth. Heamolysis activity was 
quantified by measuring the zone of clearing observed and related to the wild type 
control (100%).  
2.2.7.4 Catalase activity  
Addition of 1% w/v hydrogen peroxide (H2O2; H1009: Sigma-Aldrich, Poole, UK) to 
S. aureus parent and SCV cultures was used to detect catalase production. Catalase 
activity was recorded using a 3 point scale. Immediate and rapid bubbling following 
addition of H2O2 was recorded as strong catalase production, bubbling observed after 
longer than 15 seconds was recorded as weak and lack of bubbling was recorded as 
absence of catalase production.  
2.2.7.5 DNase activity 
DNase agar was prepared by adding 39 g of dehydrate DNase culture media 
(CM0321: Oxoid, UK) to 1.0 L of deionised water. Overnight cultures of S. aureus 
parent and SCV strains were adjusted to a density of 1x10
7
 CFU/mL and of this 
suspension 10 µL drops were spotted onto the surface of a DNase agar plate. 
Following incubation for 24-48 hours at 37°C, plates were flooded with 0.5 M 
hydrochloric acid (HCl; 84415: Sigma Aldrich, UK) and left for 5 minutes at room 
temperature. The addition of HCl causes the hydrolysis of DNA resulting in the agar 
turning opaque. In the presence of DNase enzymes, DNA is digested and no DNA is 
available to be hydrolysed. Therefore clear zones indicated a presence of DNase 
enzymes. Excess hydrochloric acid was removed from the plate and zones of clearing 
were measured using callipers. DNAse activity was quantified by measuring the zone 
of clearing observed. The relative activity (R) was calculated relative to the wild type 
control (100%), so R= SCV diameter/WT diameter. 
2.2.7.6 Pigment production 
Pigment production was quantified using a methanol extraction protocol (Morikawa et 
al., 2001). Cells were pelleted by centrifuged at 10,000 rpm for 5 minutes and washed 
once with PBS. Cells were resuspended in 200 µL methanol (34860: Sigma Aldrich, 
UK) and heated at 55°C for 3 minutes. The supernatant was removed from the cell 
debris after spinning for 1 minute at 13,000 rpm and methanol added to yield a final 
volume of 1 mL. Absorption spectra of the methanol extracts were measured in a 
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quartz cuvette and the absorbance at 465 nm was recorded. Pigment production was 
quantified and absorbance reported relative to the wild type control (100%). 
2.2.7.7 Quantification of intracellular ATP  
Intracellular levels of ATP were determined by an enzyme based luciferase assay. The 
BacTiter-Glo™ Microbial Cell Viability Assay (G819A: Promega, UK) quantifies 
ATP using mono-oxygenation of luciferin to produce a light signal that can be 
detected using a luminometer. Cultures were adjusted to 1 X 10
7
 CFU/mL and 100 µL 
added to individual wells of 96 microtitre well plates.  BacTiter-Glo reagent (100 µL) 
was added to each well and gently shaken for 5 minutes at room temperature. Control 
wells contained no bacteria and were used to determine background luminescence. 
Luminescence was detected using relative light units (RLU) with a LUMIstar 
OPTIMA plate reader (BMG, UK). RLU/ATP was determined from a standard curve 
using dilutions of ATP standard (Promega, UK) and the concentration of ATP per mL 
was calculated. 
2.2.7.8 Phage sensitivity and phage yield  by Φ 80α  
Aliquots (~10
7
 CFU/ mL) of host culture were inoculated in 10 ml of Brain Heart 
Infusion Broth (BHI; CM1137: Oxoid Ltd, UK). Supplemented with 10 mM CaCl2 
and MgSO4 (containing 1 mg/L gentamicin for the SCVs cultures) with (~10
5
 PFU/ 
mL) of Ф80α. Incubated at 37°C for 24 (WT) or 48 (SCV) hours. Supernatants of 
samples were passed through a sterile nitrocellulose filter membrane (Millipore; pore 
size 0.2 µm). Then 500 µl (~5 x 10
8
 CFU/ mL) cells of a freshly grown overnight 
culture of host were mixed into an overlay of 3 ml BHI semi agar (BHI; CM1136: 
Oxoid Ltd, UK) supplemented with CaCl2 (10 mM) and MgSO4 (10 mM).  This was 
poured over the agar surface and let to dry for 10 min. Aliquots (10 µl) of serial 
dilutions of phage Ф80α lysate were applied and incubated at 37°C for 24 hours. The 
presence of plaques indicated phage sensitivity.  The phage titre/ml was determined 
by counting the plaques and multiplying by the dilution. 
2.2.7.9  Growth rate 
Growth dynamics were examined using a Bioscreen C analyser (ThermoFisher, UK) 
Overnight culture of S. aureus parent and SCVs strains were diluted to a density of 5 
x 10
5
 CFU/mL were inoculated with  100 µL of  MH broth into honeycomb bioscreen 
plates (Growth Curves Ltd, Finland). Plates were incubated for 48 hours at 37°C with 
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shaking for 5 seconds before every optical density measurement at intermediate. 
Optical density was read using the wideband filter (450 – 580 nm) every 10 minutes.  
2.2.7.10 DNA extraction  
DNA was extracted using the GenElute Bacterial genomic DNA Kit (NA2100: Sigma 
Aldrich, UK). Overnight cultures of S. aureus parent and SCV culture were pelleted 
by centrifuging at 10,000 rpm in microfuge tubes. 200 µL of lysis buffer (consisting 
of 200 U/mL lysostphin and 2 X 10
6 
U/mL lysozyme) was used to resuspend pellets, 
which were subsequently incubated for 30 minutes at 37°C. Proteinase K solution (20 
µL) was then added followed by 200 µL of manufactures specific lysis solution. 
Samples were vortexed thoroughly in order to create a homogenous mixture and 
incubated at 55°C for 10 minutes. DNA binding columns were optimised for binding 
using ethanol, followed by the addition of the previously prepared lysate. Samples 
were centrifuged at 8,000 rpm for 1 minute, followed by 2 additional washing steps 
before eluting bound DNA by the addition of 200 µL of manufacturer’s elution 
solution. Finally samples were centrifuged for 1 minute at 10,000 rpm and the 
remaining elute (regarded as pure genomic DNA) stored at 4°C until required. 
2.2.7.11 Species confirmation 
As S. aureus SCVs are frequently difficult to identify and so a modified version of the 
quadriplex PCR protocol developed by Zhang et al. (2004) was employed to confirm 
that SCV isolates were S. aureus. PCR target 16S rRNA (Staphylococcus genus 
specific), nuc (S. aureus species specific), and mecA (a determinant of methicillin 
resistance) primers were employed (Table 2.2). All PCR reagents were obtained from 
Qiagen (UK). PCR was carried out in 25 µL reactions with 2 µL template DNA 
(approximately 50 ng/µL) being added to a 23 µL PCR mixture consisting of; sterile 
deionised water, 1 X Coralload buffer, 1 X Q solution, 1.5 mM MgCl2, 0.12 µM each 
16S rRNA and mecA primers, 0.04 µM each nuc primer, 200 µM dNTPs, and 1 unit 
Taq DNA polymerase. PCR was 5 minutes at 94°C, followed by 10 cycles of 94°C for 
40 seconds, 68°C for 40 seconds, and 72°C for 1 minute, and 25 cycles of 94°C for 1 
minute, 58°C for 1 minute, and 72°C for 2 minutes, and a final hold at 72°C for 10 
minutes. PCR products (12 µL) were run on 2% w/v agarose (A4718: Sigma Aldrich, 
UK) gels and were visualised with ethidium bromide (E8751: Sigma Aldrich, UK) 
(0.5 µg/mL final concentration in TAE buffer; 40 mM Tris-acetate, 1 mM EDTA) for 
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30 minutes. Molecular standards were run on gels using Hyperladder I (33025: 
Bioline, UK).  
 
Table 2.2 Primers used in multiplex PCR for species confirmation of SCVs 
Primer Sequence (3’- 5’) 
Staph756F AACTCTGTTATTAGGGAAGAACA 
Staph750R CCACCTTCCTCCGGTTTGTCACC 
mecA1 GTAGAAATGACTGAACGTCCGATAA 
mecA2 CCAATTCCACATTGTTTGGGTCTA 
nuc1 GCGATTGATGGTGATACGGTT 
nuc2 AGCCAAGCCTTGACGAACTAAAGC 
Lyophilised primers were obtained from MWG Eurofins (Germany). 100 pmol stocks 
were obtained by the addition of nuclease free H2O. 
 
 
 
2.2.8 Statistical analysis  
An ANOVA analysis (IBM SPSS software 20) followed by LSD (Least Significant 
Difference) was used to investigate significant difference between parent and SCV 
isolates. 
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2.3  Results  
2.3.1 Wild type revertants  
Figure 2.4 shows the isolation frequency of wild type revertants from their respective 
SCV parental strains over 15 cycles. 
Statistical analysis shows that the selection of COL wild type revertants (gentamicin 
cycles; 2.08x10
9
 CFU/mL and triclosan cycles; 1.60x10
9
 CFU/mL) shows 
significantly reduced average frequency compared to N315 wildtype revertants 
(gentamicin cycles; 3.25x10
9
 CFU/mL and triclosan cycles,; 2.96x10
9
 CFU/mL; P = < 
0.05). Thus the average N315 reversion rate to wild type was 1.75-fold higher than 
COL (Table 2.3). 
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Figure 2.4 The number of wild type revertants, recorded at each cycle, from the 
SCV isolates of S. aureus COL and S. aureus N315. 
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Figure 2.5 compares the frequency of WT formation (ie reversion) of COL and N315 
from their respective SCVs and locates their cycle identifier.  The presence of the 
majority of the dots above the line signifies that the COL strain reverts at a lower 
frequency than N315 overall. 
 
 
 
 
 
 
 
Figure 2.5 Shows the distribution of reversion isolates with respect to triclosan 
isolated SCVs (a-p, red symbols) and gentamicin SCVs (1-15). The initial count is 
represented by @ 
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2.3.2 SCV formation 
Figure 2.6 compares the frequencies of formation of SCVs from COL and N315 after 
triclosan and gentamicin selection.  There is a downward trend (implying a reduction 
in mutation rate) to the data over the first 8 cycles, after which it appears to remain 
reasonably constant.  Thus both strains are behaving (evolving?) in a similar manner.  
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Figure 2.6 The number of SCV mutants, recorded at each cycle, from the 
wild type strains S. aureus COL and S. aureus N315. 
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Figure 2.7 shows the frequencies of SCV formation and locates the cycle number.  
Interestingly there is a clear distinction between triclosan and gentamicin shown by 
both strains. Triclosan shows a lower frequency of occurrence (1-2x10
9
) as the data 
clusters towards the axis. The implication is that SCV formation by gentamicin is a 
more common occurrence (4x10
9
). This could imply that there are more genes that 
could become mutated to provide the SCV phenotype.  There is a wide distribution of 
frequencies of SCV formation when selection is made by gentamicin. There is no 
correlation in the distribution with cycle number so the changes appear random. 
 
 
 
 
 
 
Figure 2.7 A comparison of the frequency of SCV formation by COL and N315 
at each cycle after selection by triclosan (a-m) and gentamicin (1-15). 
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2.3.3 Mutation frequency 
The SCV isolates occur at a frequency that averages at 1.17x10
9
 CFU/mL, for 
triclosan selection and 6.31x10
9
 CFU/mL for gentamicin selection (Table 2.3). This 
indicates that COL SCVs have adopted a lower mutation frequency than that of the 
wild type strain.  
 
 
 
Table 2.3 A summary of the average of forward and reverse mutation 
frequencies  
         Strain *GEN *TRI 
       SCVs (COL+N315) 6.31x10
9
  1.17x10
9
 
    WT reversion (COL+N315) 2.66x10
9
 2.28x10
9
 
*: CFU/mL 
 
 
 
 
2.3.4 The rates of reversion between wild type and SCV 
Figure 2.8 A-D compares the frequencies for the formation of triclosan and 
gentamicin SCVs plotted against their respective wild type reversion frequencies. It is 
clear that frequencies for SCV formation (COL: 5.44x10
9
 CFU/mL; N315: 7.18x10
9
 
CFU/mL) are higher than wildtype reversion for gentamicin treatments (COL: 
2.08x10
9
 CFU/mL; N315: 3.25x10
9
 CFU/mL). In contrast the SCV formation with 
triclosan selection (COL: 1.16x10
9
 CFU/mL; N315: 1.17x10
9
 CFU/mL) are lower 
than wildtype reversion (COL: 1.6x10
9
 CFU/mL; N315: 3.0x10
9
 CFU/mL). 
The degree of scatter on the graph is suggestive of a variation in spontaneous 
mutation rate, which is related to the type of drug/antimicrobial the organism is 
exposed to. Is this an example of a cell’s mutation rate being modified by the 
environment? 
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Figure 2.8 The frequency of reversion to wild type plotted against the mutation 
frequency to SCV. A) - S. aureus COL-Gentamicin; B) - S. aureus COL-Triclosan; 
C) - S. aureus N315-Gentamicin and D) - S. aureus N315-Triclosan.  
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Figure 2.9 A-D shows the relationship within the same strain to the two selective 
agents.  The reversion graphs (2.9A and C) forward  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9 The frequency of strains from triclosan agent plotted against the 
mutation frequency to strains from gentamicin. A) - S. aureus COL-wild type; B) - 
S. aureus COL-SCV; C) - S. aureus N315-wild type and D) - S. aureus N315-SCV. 
There is no significant difference between gentamicin and triclosan treatments. 
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2.3.5 Characterisation of gentamicin and triclosan selected SCV15 isolates 
All SCV15 isolates showed reduced or absented catalase, coagulase and haemolysis 
activity in comparison to their parental strains (Table 2.6). All SCV15s showed a 
complete absence of heamolysis activity, and all had a reduced catalase, coagulase, 
DNase activity.  Fig 2.17 illustrates the tests used. There were differences in DNase 
activity by isolates obtained by triclosan selection that showed less DNase activity in 
comparison to those isolated by gentamicin (Table 2.6). Auxotrophy was confirmed if 
SCVs appeared as large pigmented colonies around filter discs impregnated with 
haemin, menadione or thymidine. All SCV15 isolates were sensitive to phage 80. 
This also confirmed their identity as only S. aureus shows sensitivity to this phage 
(2.17 D). 
2.3.5.1 DNase activity  
DNase activity was determined by measurement of zones of extracellular DNA 
hydrolysis (Figure 2.10, Table 2.4). All SCV15 isolates showed significantly less 
DNase activity (reduced between 17-40 %) in comparison to parent strains (P = < 
0.05). This was also true of the revertant wild type isolates (WT15) and so illustrates 
the fact that some characteristics are attenuated in the isolates as they increase in cycle 
number. Both COL SCV isolates (from gentamicin and triclosan) showed 
significantly fewer DNase activity reduced between 7-18 % in comparison to both 
COL WT15 isolates (from gentamicin and triclosan; P = < 0.05). No significant 
different DNase activity between both N315 SCV isolates (from gentamicin and 
triclosan) and both N315 WT15 isolates (from gentamicin and triclosan; P = < 0.05). 
2.3.5.2 Pigment production  
All SCV15 isolates produced significantly lower amounts of pigment (52-79%) in 
comparison to wild type strains (P = < 0.05). Wild type revertants also produced 
significantly less (13-22% down) than the original strains (P = < 0.05). So pigment 
production is also attenuated in these mutants (Figure 2.11, Table 2.4).  
2.3.5.3 Intracellular ATP concentrations  
(Figure 2.12, Table 2.4 shows that all SCV15 isolates contained significantly lower 
intracellular ATP levels (39-47%) in comparison to parent strains (P = < 0.05).  ATP 
concentrations also significant different reduced in the wild type revertant strains (67-
73%; P = < 0.05).  
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2.3.5.4 Phage sensitivity and phage yield by Φ 80α 
All isolates were sensitive to phage 80α. The selection of N315 (WT00, WT15-GEN, 
WT15-TRI and SCV15-GEN; mean 3.7x10
8
 PFU/mL) gave significantly higher 
phage yields than COL (mean 1.84x10
8
 PFU/mL) generally.  However SCV 15-TRI 
and N315 (2.23x10
8
 PFU/mL) and COL (1.6x10
8
 PFU/mL) were not significant 
different (P = < 0.05). Also there was no significant difference between wild type 
original (COL and N315) and wild type revertants isolate from gentamicin (COL 
WT15-GEN and N315 WT15-GEN; P = < 0.05; Figure 2.13 and Table 2.4). 
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Figure 2.10 Extracellular DNase activity. A) by parental COL WT00, SCV15 and 
wildtype 15 strains; B) by parental N315 WT00, SCV15 and wildtype 15 strains. 
Results are the means of three independent replicates and three biological replicates. 
Error bars represent standard error. 
 
 
 
 
Figure 2.11 Pigment production. A) parental COL WT00, SCV15 and wildtype 15 
strains; B) parental N315 WT00, SCV15 and wildtype 15 strains. Results are the 
means of three independent replicates and three biological replicates. Error bars 
represent standard error. 
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Figure 2.12 Intracellular ATP concentration. A) parental COL WT00, SCV15 and 
wildtype 15 strains; B) parental N315 WT00, SCV15 and wildtype 15 strains. Results 
are the means of three independent replicates and three biological replicates. Error 
bars represent standard error 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13 The ratio phage yield from S. aureus strains. A)  phage yield by 
parental COL WT00, SCV15 and wildtype 15 strains; B) by parental N315 WT00, 
SCV15 and wildtype 15 strains. Results are the means of three independent replicates 
and three biological replicates. Error bars represent standard error. 
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2.3.5.5 Growth rate and maximum cell density 
Parental strains COL (WT00) and N315 (WT00) displayed typical S. aureus growth 
rates when grown in unmodified MH broth (Figure 2.14 A & B) and reached a final 
cell density at 24 hours of 1.35x10
9
 CFU/mL. The wild type revertant isolates 
obtained after 15 cycles (COL WT15 and N315 WT15) gave similar growth profiles 
to their WT00 original parental strains and there was no significant different between 
them (P = < 0.05).  However at 24 hours COL WT15 was slightly lower at 1.0 x10
9
 
CFU/mL compared to WT00 of 1.3x10
9
 CFU/mL.  
All SCVs had extended lag phases of between 4-6 hours in comparison to the 
wildtype (Figure 2.14). All the SCV isolates gave significantly reduced optical 
densities (0.77- 0.82 OD) at 24 hours (P = < 0.05); reduced to 58-63% of their 
respective parental strains (1.21-1.40 OD). 
Wild type revertants (COL 83% and N315 95%) were no significant to compared the 
original strains (P = < 0.05; Figure 2.14; Table 2.4).  
 
2.3.6 Identification of SCVs as S. aureus using multiplex PCR 
Amplification of 16S rRNA, mecA and nuc genes confirmed all SCVs were S. aureus. 
Figure 2.7 shows presence of 16S rRNA (756 bp), nuc (279 bp) and mecA (310 bp), 
which can also be observed in the parent strain (Figure 2.18) in wild type and SCV 
isolates. 
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Figure 2.14 Growth curves of COL and N315. A) COL strains; B) N315 strains. 
Results are the means of three independent replicates and three biological replicates. 
Error bars represent standard error. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.15 Maximum cell count of COL and N315. A) COL strains; B) N315 
strains. Results are the means of three independent replicates and three biological 
replicates. Error bars represent standard error. 
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Table 2.4 A comparison of physiological tests between SCVs and wild type strains 
        
Strain Catalase Coagulase Haemolysis Auxotrophy DNAse 
activity  
(% WT00) 
Phage Φ 80 
α yield a 
(%WT00) 
Pigment 
production 
 (% WT00) 
Intracellular 
ATP 
(concentration; 
RLU) (%WT00) 
growth 
(OD430-580 nm at 
24 h) 
(%WT00) 
Max cell 
yield 
 (% WT00) 
COL WT 00  *** *** *** NT 100 
 
100 100 100 100 100 
COL WT 15 -GEN 
 
*** *** ** NT 78 
 
72 87 73 86 83 
COL WT 15 -TRI *** *** ** NT 83 
 
59 78 68 80 78 
COL SCV 15 -GEN 
 
** ** - + 60  48 63 47 57 56 
COL SCV 15 -TRI ** ** - + 76  61  52 45 55 54 
N315 WT 00  
 
*** *** *** NT 100 
 
100 100 100 100 100 
N315 WT 15 -GEN 
 
*** *** ** NT 72 
 
83 86 67 95 78 
N315 WT 15 -TRI *** *** ** NT 68 
 
92 89 68 95 79 
N315 SCV 15 -GEN 
 
** ** - + 68 66 74 44 63 49 
N315 SCV 15 -TRI ** ** - + 63 
 
52 79 39 61 46 
 
***: Strong catalase/coagulase/haemolysis activity; **: Medium catalase/coagulase/ haemolysis activity; -: Absence of catalase/coagulase/ haemolysis activity; +: 
Auxotrophic; NT – not tested; RLU: Relative light units by using luminescence; GEN: gentamicin and TRI: triclosan.  
a Phage Φ 80 α titres on N315 were 6.5 x 109 and COL 3.2 x 109 pfu ml-1. 
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Figure 2.16 Summarises S. aureus COL and N315 wildtype test results with those of wildtype 15 and SCV 15. Error bars represent 
standard error.
 61 
 
 
 
B
B
C
 
WT
S C V
D
 
 
Figure 2.17 Characteristics associated with S. aureus SCVs A) Agglutination 
positive S. aureus (WT) and agglutination negative S. aureus SCVs (SCV); B) - 
Comparison of haemolytic activity of wildtype (right hand side of plate) and COL 
SCV; C) - Comparison of wildtype and SCVs of S. aureus on DNAse agar; D) - 
Plaques of bacteriophage 80α in a dilution series plated onto a soft agar overlay of S. 
aureus WT. 
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Figure 2.18 Multiplex PCR of SCV isolates from gentamicin and triclosan. L - 
Hyperladder 1; A1 – WT COL; A2 – WT N315; A3 – SCV15 COL-GEN; A4 - 
SCV15 COL-TRI; A5 - SCV15 N315-GEN; A6 – SCV15 N315-TRI. Amplification 
of the staphylococcal 16s rRNA (765 bp), nuc-genes (279 bp) and mecA-genes (310 
bp) are shown.   
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2.3 Discussion  
The fact that the cycling of the cultures was successful shows that no deletion SCV 
mutants occurred. So all the mutations to SCV were revertable point mutations.  
Figure 2.3 illustrated the steps in the cycle of repeated selection of SCV and WT 
strains. The cycling experiment resulted in the isolation of fifteen independent wild 
type and SCV strains, 60 in all. Multiplex PCR and sequencing of the staphylococcal 
16S rRNA, nuc-gene and mec-gene provides 100% clarity that isolates SCVs are 
indeed S. aureus. Phage sensitivity also confirms that the isolates are S. aureus. 
  
Figures 2.4 and 2.6 indicate that the rate of formation of wild type and SCV strains 
remains within an order of magnitude. Thus a mutational change to modify the 
spontaneous mutation rate has not been subject to selection.  
Figure 2.5 and 2.7 compare the mutational changes occurring between COL and N315 
strains and the data displayed indicates the cycle selection number.  If the strains were 
identical and all other parameters were equal then the points should all fall on the 45 
slope.  The fact they do not illustrates a basic difference in responses by and between 
the strains and possibly to the selective agents. Some antibiotics like ciprofloxacin 
induce the SOS system and thus promote spontaneous mutation rate (Drlica & Zhao, 
1997). Thus the potential is there for some antimicrobials to promote spontaneous 
mutation and thus raise the forward mutation rate to SCVs.  
 
Physiological tests (Table 2.4) were done on WT00 and cycling isolates WT15 and 
SCV15. The data is normalised to the WT strain values and shown in Figure 2.16.  
This figure shows that all the WT15 strains had reduced physiological activity 
compared the parental strain (WT00).  Thus although they acquired visually a normal 
morphology and physiological reactions, when measured most were clearly impaired.  
It is only the growth rates and phage yield by N315 WT15- TRI, that appear not to be 
statistically different for any WT15 isolates.   
All the assays for strain COL WT15 are significantly different from the SCV15 
results, except for phage yield and DNA’s by SCV15-TRI. 
Within these COL SCVs there is a lot of variation, but this is spread across the two 
strains. Both strains perform better in some assays and so neither strain is 
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physiologically equivalent.  Thus the regulation of phenotypes by energy shortage 
caused by the mutations to SCV is not having the same effect on physiology. This 
indicating that SCV formation is not a unique physiological state.   
The SCV strains all show reduced activities too.  In all case (except DNase activity) 
SCV15-TRI shows lower activity than SCV15-GEN. The one exception between 
these SCV15 and the WT15 strains is DNase activity. Statistically these are not 
different. 
Auxotrophy for haemin and menadione was regularly detected in SCVs isolated in 
this study (Table 2.4). Auxotrophy for haemin and menadione has been reported in S. 
aureus SCVs as well as SCVs isolated from several other bacterial species (Colwell, 
1946; Sasarman et al., 1970). The failure to produce menaquinone and haemin in the 
SCVs selected by gentamicin and triclosan results in a disrupted ETC resulting in 
reduced ATP levels.  Thus this provides evidence for a reduction in energy generation 
capacity seen as intracellular ATP changes (Table 2.4). The physiological 
consequences are clear. Pigment concentrations were reduced (Table 2.4) and S. 
aureus requires energy to drive carotenoid biosynthesis, as well as other essential 
cellular process, such as protein and cell wall synthesis (Proctor et al., 2006).  
These effects on SCVs have been noted previously (Proctor et al., 2006; Seaman et 
al., 2007), but no one has examined revertant physiology or activities before. The fact 
that N315 and COL wild type revertants reacquire some wild type characteristics and 
yet others do not requires further investigation.  
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2.4 Conclusions 
 
 There were no issues in the experimental design  
 
 Multiplex PCR and sequencing confirmed all isolates were S. aureus. 
 
 All mutations were revertable, therefore no deletion mutants occurred 
 
 The rate of formation of SCVs was about the same as the rate of reversion. 
 
 SCVs isolates had a reduction in a range of physiological parameters (intracellular 
ATP levels, pigment, catalase, coagulase, haemolytic, phage yield and DNase 
activity) that appear related to ATP generation capacity. 
 
 Wild type revertants were not true revertants. They showed a reduction in most 
physiological activities. 
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CHAPTER 3: 
 BACTERIOPHAGE 80α STUDIES 
3.1 Introduction 
3.1.1 Gene transfer in staphylococci 
Staphylococcus aureus is an effective opportunistic pathogen. This organism has acquired 
antimicrobial resistances through mutation and gene exchange. These antibiotic resistance 
determinants occur in both the chromosome and plasmid (Kayser et al., 1972; Townsend et 
al., 1985). It was recognised quickly that the organism acquires resistance soon after the 
introduction of new antibiotics (Lyon & Skurray, 1987). Antibiotic resistance phenotypes 
may be transferred by transformation, conjugation or transduction (Stiffler et al., 1974; 
Archer & Armstrong, 1983). The transfer and consequent spread of antibiotic resistance 
among strains of S. aureus presents a major concern in the treatment of staphylococcal 
infections. The outbreaks of nosocomial infections by gentamicin and other antibiotic 
resistant strains of S. aureus has increased in some countries (Gillespie & Skurray, 1986). 
 
3.1.2 Features of the rpoB, grlA and sarA genes 
The rpo gene:  
Rifampicin interacts specifically with the RNA polymerase beta-subunit encoded by the gene 
rpoB (Wichelhaus et al., 1995). Rifampicin resistance in S. aureus, as in other bacteria, is 
associated with mutations in particular regions (cluster I and II) of the gene rpoB (Aubry-
Damon et al., 1998 & Aboshkiwa et al., 1999).  
The grl gene:  
Quinolones are a group of compounds which target DNA topoisomerase IV (grl; Ferrero et 
al., 1995).  They have wide-ranging and potent antibacterial activity against Gram-negative 
and Gram-positive organisms, and are known under the names ciprofloxacin, ofloxacin, and 
norfloxacin (Shalit et al., 1989 & Kojima et al., 1990). Quinolone resistance genes of S. 
aureus reported thus far include norA (Yoshida et al., 1990), gyrA (Fasching et al., 1991 & 
Goswitz et al., 1992), gyrB (Ito et al., 1994), flqA (Trucksis et al., 1991), and grlA (Ferrero et 
al., 1994). The norA gene is normally present on the bacterial chromosome and encodes a 
membrane protein acting as a quinolone efflux pump (Kaatz et al., 1993). The mutated grlA 
genes responsible for quinolone resistance were dominant over the wild-type allele 
(Yamagishi et al., 1996). 
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The grlA and grlB genes encode the structural proteins of DNA topoisomerase IV, and 
mutations of the former gene are found in quinolone-resistant S. aureus strains, with or 
without gyrA mutations (Ferrero et al., 1995). 
The sar gene:  
SarA is a 14.5-kDa DNA binding protein that modulates the transcription of over 120 genes 
both directly and indirectly (Dunman et al., 2001) and its expression is carefully controlled 
during bacterial growth (Manna & Cheung, 2001). Recognizing that SarA can control over 
120 genes both directly and indirectly (Dunman et al., 2001). The sarA promoter region of S. 
aureus is complex, with three promoters (P2, P3, and P1) in an extensive region (~800 bp). 
The P1 promoter is most active and the sigB-dependent P3 promoter also contributes to sarA 
expression (Cheung et al., 1999 & Manna et al., 1998).  The distal P2 promoter is weak in 
vitro and in vivo and appears to play a relatively minor role in driving SarA expression 
(Cheung & Manna, 2005). 
 
3.1.3 Transduction in S. aureus  
There is a long history of antibiotic resistance transfer amongst staphylococci or from 
staphylococci to other bacteria by transduction (Ritz & Baldwind, 1958; Dowd et al., 1983). 
Transduction frequency (0.2-8.2x10
-6
) of methicillin resistance in S. aureus by bacteriophage 
80 was stimulated by a penicillinase plasmid (Stiffler et al., 1974), and other factors 
effecting gene exchange recognized include cell density temperature and media composition 
(Jarolmen et al., 1965; Tartera et al., 1988). All bacteriophages from S. aureus have either a 
relative or an absolute requirement for calcium ions (Rountree, 1951). Figure 3.1 shows a 
schematic of generalised transduction.  
 
3.1.4 Temperate bacteriophages of S. aureus  
Temperate (lysogenic) bacteriophages do not automatically enter the virulent cycle. 
Depending on a number of conditions, these bacteriophages may integrate their genome into 
that of the host cell where it remains until induced to become autonomous again and start 
replication and cell lysis (Brock & Madigan, 1988). The bacteriophage genome may also 
replicate autonomously in the cytoplasm of host cells without the production of new 
complete phage particles and lysis of the host cell (Hayes, 1968).  There are over 250 
staphylococcal bacteriophages reported in the literature (Pantucek et al., 2004). A large 
number of temperate double-stranded DNA bacteriophages that infects S. aureus have been 
characterized, while most strains of S. aureus strains contain at least one prophage and rare 
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strains contain 15 bacteriophage types, suggesting a widespread potential for a protective 
effect from lysis due to resident phage integration (Lindsay & Holden, 2004). Comparative 
analysis of genome sequences revealed that S. epidermidis vB_SepiS_phiIPLA5, 
vB_SepiS_phiIPLA7, phiPH15 and phiCNPH82 are closely related, while phi909 showed a 
high similarity to S. aureus phages, as similar size and overall genome organization  
 
 
 
 
 
 
 
 
 
Figure 3.1 A schematic of generalized transduction. DNA genome of a temperate 
bacteriophage (i.e. Φ80α) inserts into the chromosome as a prophage; it later replicates, lyses 
the cell, and infects a simple recipient cell in which the novel DNA recombines into the 
recipient host cell chromosome. Adapted (Griffiths et al, 2000). 
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(Gutierrez et al., 2012; Rosenstein et al., 2009), also detected close relationships between S. 
aureus and CoNS phages (Deghorain et al., 2012). Thus it is clear a bacteriophage 
population could play a significant role in the evolution of their host cells. S. aureus is a 
bacterial pathogen known to cause infections in epidemic waves and maybe transduction 
contributes in this. One such epidemic was caused by a clone known as phage-type 80/81, a 
penicillin-resistant strain that rose to world prominence in the late 1950s (DeLeo et al., 
2011).   
Phage 80α is a generalized transducing phage (Novick, 1963). Bacteriophage 80α belongs to 
a class of related staphylococcal Siphoviridae that are highly mosaic but retain a conserved 
organization of genes in functional modules (Kwan et al., 2005). Some staphylococcal 
Siphoviridae encode virulence factors, such as staphylokinase, exfoliative toxin A, 
enterotoxin A, Panton-Valentine leukocidin (Winkler et al., 1965; Yamaguchi et al., 2000; 
Betley & Mekalanos, 1985; van Wamel et al., 2006). The genome length of bacteriophage 
80α is 43,864 bp, encoding approximately 73 ORFs and is deposited in Genbank under 
accession number DQ517338 (Christie et al., 2010). 
 
3.1.5 Bacteriophage-host interaction 
The role of bacteriophages in genetic interactions with their hosts has been discussed by Fry 
& Day (1992), as is the use of phages in molecular biology (Freifelder, 1987). Transduction 
in natural environments may be a rare event, as generalised transduction has only been 
demonstrated once in freshwater ecosystems (Saye, 1987).  
Bacteriophage adsorption is the first step towards infection. This occurs at defined receptors 
thus giving phage:host relations a specificity. This particular step is sensitive to 
environmental conditions such as ionic composition, temperature and pH (Shao & Wang, 
2008). After adsorption the bacteriophage genome is introduced into the host cell. Once in 
the cytoplasm the most frequent outcome is expression on the phage genome. This leads to 
synthesis of phage proteins and replication of the phage genome. The phage genome is then 
packaged into capsids to produce infectious virions. The host cell then bursts releasing 
progeny phage (Freifelder, 1983). 
Certain bacteriophages delay the reproductive stage and these are termed temperate and 
remain as a prophage in association with the host.  The host is termed a lysogen. In this 
response the lytic functions are repressed by a phage encoded DNA binding protein (Ptashne, 
1967). There are benefits to the host as the prophage confers immunity to further infection 
and possibly encodes other phenotypic traits (see 3.1.4).  This is termed “lysogenic 
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conversion” (Rudin et al., 1974; Low & Porter, 1978). Lysogenic conversion in S. aureus 
strains can result in either loss or acquisition of phenotypic characters. The conversion of 
lipase-positive strains to lipase-negative strains has been reported by different authors 
(Rosendal & Bulow, 1965). After adsorption the bacteriophage genome is introduced into the 
host cell, lysogeny is favored when this occurs; similar host monitoring abilities have been 
reported in bacteriophage D3 of P. aeruginosa (Kokjohn & Miller, 1988) and P22 of S. 
typhimurium (Levine, 1957). Thus, phages clearly impact virulence by positive lysogenic 
conversion, since they provide novel functions and activities to the host, and virulent 
bacteriophages can only enter the lytic pathway, but a lysogenic-like stage has been recorded 
(Canchaya et al., 2003; Brussow et al., 2004; Malachowa  & DeLeo, 2010) This has been 
termed pseudolysogeny and bacteriophages were observed to exist in an arrested state of the 
lytic cycle due to host inactivity (Figure 3.2). As soon as host cell vegetative growth was 
restored, the bacteriophage lytic pathway ensued (Romig & Brodetsky, 1961). 
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Figure 3.2 A schematic of generalized bacteriophage replication. There are two cycles of 
replication temperate bacteriophage. Lytic cycle: bacteriophage enter cell, multiply and lyse 
cell. Lysogenic cycle: bacteriophage may integrate their genome into that of the infected 
host cell (Bauman, 2004). 
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3.1.6 Aims  
 
 To examine the ability to transduce rpoB, grlA and sarA genes between the wild type and 
SCV strains. 
 
 To determine whether transfer frequency was influenced by the recipient or donor lysate.  
 
 To determine relative susceptibilities of S. aureus wildtype and SCVs to bacteriophage 
80α. 
 
 Determine the relative frequency of phage 80resistance and lysogeny occurring 
between the strains. 
 
 Compare lysate yields from S. aureus wildtype, SCVs and their lysogens. 
 
 Analyse the effect of wild type and SCV their physiological status on phage interactions. 
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3.2  Materials and Methods 
 
3.2.1 Bacterial strains  
The bacterial strains and bacteriophage used in this study are listed in Table 3.1. These 
strains were selected to represent a broad range of methicillin-susceptible and methicillin-
resistant phenotypes. S. aureus MRSA COL; MRSA COL-SCV 1, 2 and 3 are sensitive to 
rifampicin and ciprofloxacin, Epidemic methicillin-resistant S. aureus (EMRSA) strain 16 is 
strain containing rpoB gene which encodes rifampicin resistance, MRSA N315 is strain 
containing grlA gene which encodes ciprofloxacin resistance, and gfpuvr with sarA P2 
promoter. Strains were maintained at -80°C in Mueller Hinton (MH) broth supplemented 
with 8 % dimethyl sulfoxide (DMSO) and re-isolated on MH agar plates when required. 
 
3.2.2 Transduction related protocols 
3.2.2.1 Preparation rifampicin and ciprofloxacin stock solutions 
Rifampicin (Rif: R3501) and ciprofloxacin (Cip: C17850) were obtained from Sigma 
Aldrich (UK). Antibiotic stocks (10,000 mg/L) were prepared by adding 100 mg of the 
required antibiotic to 10 mL of sterile DMSO for rifampicin and 10 mL of deionised water. 
Solutions were dissolved thoroughly by vortex mixing and solutions were filter sterilised by 
passing them through 0.2 µm filters (Minisart, UK), and diluted to reduced strength stock 
solutions in sterile deionised water. Stocks solutions were maintained at 4°C for a maximum 
of 14 days.  
3.2.2.2 Minimum inhibitory concentrations 
Minimum inhibitory concentrations (MICs) were determined as described previously 
(section 2.2.3). 
3.2.2.3 Bacteriophage propagation and titration  
Bacteriophage lysates were made with bacteriophage 80α (Novick, 1963). The phage was 
propagated on EMRSA 16, MRSA N315 and ALC 1473 (~ 10
7
 CFU/mL) and bacteriophage 
80α (~ 105 CFU/mL) were mixed with 10 mM CaCl2 and MgSO4 and poured onto the 
surface of MH agar and incubated at 37°C for 24 hours. The surface growth was harvested in 
4 mL PBS (supplemented with 10 mM CaCl2 and MgSO4) and cleared by centrifugation for 
10 minutes at 4000 rpm to remove cell debris. The supernatant was sterilised by passing 
through 0.2 µm filters (Minisart, UK) and titred on BHI.  Then an aliquot of cells (~5 x 10
8
 
CFU/ mL), from a freshly grown overnight culture of the host, were mixed into an overlay of 
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3 mL BHI semi agar (supplemented with 10 mM CaCl2 and MgSO4).  This was poured over 
the agar surface and let to dry for 10 minutes. Aliquots (10 µl) of serial dilutions of 
bacteriophage 80α lysate were applied and incubated at 37°C for 24 hours. The 
bacteriophage titre/mL was determined by counting the plaques and multiplying by the 
dilution. 
3.2.2.4 Viable bacterial cell count  
10 µL aliquots of a 10-fold serially diluted culture were deposited onto corresponding sectors 
of MH agar, incubated at 37°C for 48 hours, and then colonies were enumerated. 
3.2.2.5 Transduction procedure 
An overnight culture was grown in MH broth, harvested by centrifugation (5000 rpm for 5 
min), and the pellets resuspended in 1 ml fresh MH broth to ~10
9
 CFU/mL.  All media for 
bacteriophage work were supplemented with CaCl2 (10 mM) and MgSO4 (10 mM).  Then 
100 µL (~10
9
 CFU/mL) of the host strain was mixed with 100 µL of bacteriophage 80α, 
prepared on EMRSA 16, N315 or ALC1437.  The culture was incubated at 37°C for 30 
minutes. Aliquots (100 µL) were plated out onto selective media MH agar containing either 
50 mg/L rifampicin or 2 mg/L ciprofloxacin. Plates were incubated at 37°C for 48 hours, and 
transductants enumerated. Phage and cultures without bacteriophage were plated separately 
on selective media as controls. 
 
3.2.2.6 Preparation of lysogens  
 
Ninety six individual overnight (microtiter plate) cultures of COL-wildtype and COL-SCV1, 
2 and 3 were prepared by inoculating 10 ml of brain heart infusion (BHI; CMO135: Oxoid 
Ltd, UK) supplemented with 10 mM CaCl2 and MgSO4 (and 1 mg/L gentamicin for the 
SCVs cultures). Aliquots of host culture (~10
9
 CFU/ mL) and Ф80α-9789 (~108 CFU/ mL) 
were inoculated in 200  µL BHI supplemented with 10 mM CaCl2 and MgSO4 (containing 1 
mg/L triclosan for the SCV cultures) and  incubated at 37°C for 24 (WT) or 48 (SCV) hours.  
A sample of each well was streaked to single colonies on MH agar (for the SCVs this 
contained 1 mg/mL gentamicin) and these were incubated at 37°C for 48 hours. A single 
isolated colony from each plate was stabbed into an overlay (5 ml MH semi agar; 6 gm/L; 
plus 10 mM CaCl2 and 100 µL of an overnight grown culture of strain COL). The plates 
were incubated at 37°C for 24 hours. A zone of lysis indicated phage production and thus the 
presence of a lysogen. 
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Table 3.1 Bacterial strains and bacteriophage used in this study of transfer of antimicrobial resistance amongst staphylococci. 
 
Strain Description Resistance Source/Reference 
 
COL 
 
An MRSA strain originally isolated in 1961 Genome sequenced  
 
Tet, Oxa 
 
(Dyke et al., 1966 & Gill et al., 2005) 
COL
Rif-R
 derived from COL following rifampicin selection fiR This study 
COL SCV 1 derived from COL following triclosan  selection Tet (Day et al., 2012) 
COL SCV 2 derived from COL following triclosan  selection Tet  (Day et al., 2012) 
COL SCV 3 derived from COL following triclosan  selection Tet (Day et al., 2012) 
EMRSA 16 Epidemic methicillin-resistant S. aureus strain containing rpoB-
gene which encodes rifampicin resistance(isolated 1992) 
 
Cip, Ery, Neo, Kan (Murchan et al., 2004) 
 
MRSA N315 MRSA strain (isolated Japan 1982). grlA-gene (ciprofloxacin 
resistance).  Genome sequenced 
 
Cip, Ery, Neo, Oxa (Kuroda et al., 2001) 
ALC1437 RN6390 with pALC1421 (gfpuvr with sarA P2 promoter) – (Cheung et al., 1998) 
Mu50 MRSA strain (isolated Japan 1997).  Genome sequenced Van (Hiramatsu, et al., 1997) 
EMRSA 15 Epidemic MRSA type 15 (isolated UK 1991) Oxa (Richardson & Reith, 1993) 
ATCC 25923 Methicillin-sensitive  isolated  USA, Seattle 1945 – American Type Culture Collection 
ATCC 29213 Methicillin-sensitive isolated  USA, Wichita 1955  – American Type Culture Collection 
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Tet – Tetracycline; Oxa – Oxacillin; Cip – Ciprofloxacin; Ery – Erythromycin; Kan – Kanamycin; Neo – Neomycin; Van – Vancomycin; Mup – 
Mupirocin; Tec – Teicoplanin; Amp – Ampicillin; Nov – Novobiocin; Rif – Rifampicin;  – No information 
NCTC 9789 Methicillin susceptible S. aureus isolated UK  – The National Collection of  Type 
Cultures 
NCTC 6571 Oxford strain, isolated in 1940, methicillin-sensitive – The National Collection of Type 
Cultures 
IA48 MRSACOL hemB::ermB, SCV – Vaudaux et al., 2002 
DB24 8325-4 menD::ermC (8325-4: Prophage-cured derivative of wild-
type strain NCTC 8325, rsbU mutant ) 
– Bates et al., 2003 
OM1B Phenotype  SCV indistinguishable from OM1a – Lannergard et al., 2008 
Eagles Carries plasmid-borne, high-level mupirocin resistance Mup, Ery, Tec, Amp,  Thomas et al., 1999 
F89 Carries plasmid-borne, high-level
 
mupirocin-resistant strain Mup Thomas et al., 1999 
RN450 Plasmid-free recipient strain cured of  Φ11, Φ12 & Φ13 Nov, Rif Novick, 1967 
Bacteriophage 80α Mosaic genome related to Φ11 (transducing phage) –  Novick, 1963 
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3.2.2.7 Preparation of lysates from lysogens strains 
 
Overnight cultures of the lysogen (L-COL, L-SCV 1, L-SCV 2 and L-SCV 3) were 
prepared by inoculating 10 ml of BHI supplemented with 10 mM CaCl2 and MgSO4 
(and 1 mg/L triclosan for the SCVs cultures). An aliquot (~10
7
 CFU/ mL) of host 
culture were inoculated in 10 ml BHI supplemented with 10 mM CaCl2 and MgSO4 
(containing 1 mg/L triclosan for the SCV cultures) and ~10
5
 CFU/ mL of Ф80α-9789 
was added. The culture was incubated at 37°C for 24 (WT) or 48 (SCV) hours. 
Supernatants of samples were passed through a sterile nitrocellulose filter membrane 
(Millipore; pore size 0.2 µm). Then ~5 x 10
8
 CFU/ mL of a freshly grown overnight 
culture of host were mixed into an overlay of 3 ml BHI semi agar supplemented with 
CaCl2 (10 mM) and MgSO4 (10 mM).  This was poured over the agar surface and let 
to dry for 10 min. Aliquots (10 µl) of serial dilutions of bacteriophage Ф80α lysate 
were applied and incubated at 37°C for 24 hours. The bacteriophage titre/ml was 
determined by counting the plaques and multiplying by the dilution. 
 
3.2.2.8   Preparation of lysates from parental strains 
 
Overnight cultures of the parental strains (COL-wildtype, SCV 1, SCV 2 and SCV 3) 
were prepared by inoculating 10 ml of BHI supplemented with 10 mM CaCl2 and 
MgSO4 (and 1 mg/L triclosan for the SCVs cultures). Aliquots (~10
7
 CFU/ mL) of 
host culture were inoculated in 10 ml BHI supplemented with 10 mM of CaCl2 and 
MgSO4 (containing 1 mg/L triclosan for the SCVs cultures) and ~10
5
 CFU/ mL of 
Ф80α-9789. Incubated at 37°C for 24 (WT) or 48 (SCV) hours. The phage titre/ml 
was determined as described previously (section 3.2.3.7).  
 
3.2.2.9 Calculation of transduction frequency  
 
Transfer frequencies were calculated by dividing the total number of 
transductants/mL by total viable cell count per mL. 
 
3.2.3 Statistical analysis  
 
The mean of at least three independent experiments was used in all calculation. IBM 
SPSS software 20 was used for analysis of data. The ANOVA method was used to 
calculate the least significant difference (LSD), as described previously (section 
2.2.8).  
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3.3 Results  
3.3.1 Transduction experiments 
3.3.1.1 Transduction of ciprofloxacin resistance (cip-r; grlA gene)  
The transduction frequency of ciprofloxacin resistance into wildtype COL and SCVs 
by bacteriophage 80α-EMRSA 16 was determined. Table 3.2 shows that the 
transduction frequency of cip-r was significantly higher (P = < 0.01) at 1.8x 10
-7
 into 
the wild type COL host than into SCV 1. No transfer into SCV 2 and SCV 3 was 
observed.  The limit of detection was ≤1.0x10
-9
 cfu 
 
 
 
 
Table 3.2 Transduction of ciprofloxacin resistance into S. aureus COL and SCV 
strains by Φ 80α-EMRSA 16 
 
Donor 
EMRSA 
16 phage 
80α Cip-r 
Recipient 
cell 
count 
Number 
of 
phage 
Number of 
transductants 
Transductants 
/recipient 
 
Transduction 
frequency/phage 
 
 
% WT 
Transduction 
frequency 
COL-
wildtype 
2.3x10
9
 1.0x10
9
 1.8 x10
2
 7.8x 10
-8
 1.8x 10
-7 A
 100 
COL-  
SCV 1 
1.2x10
9
 1.0x10
9
 20 1.7x 10
-8
 2.0x 10
-8
  11 
COL-  
SCV 2 
1.3x10
9
 1.0x10
9
 0 ≤7.7x10-9 ≤1.0x10-9 ≤ 1 
COL-  
SCV 3 
1.1x10
9
 1.0x10
9
 0 ≤9.1x10-9 ≤1.0x10-9 ≤ 1 
Mean 
1.5x10
9
 1.0x10
9
 1.0x10
2
 4.7x10
-8
 1. 0x10
-7
 56 
 
A The transduction frequency was significantly higher than SCV1 (P = < 0.01). 
Transduction frequency values were obtained from three independent replicates and 
three independent biological replicates. The limit of detection was ≤1.0x10-9 cfu/mL             
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3.3.1.2 Transduction of rifampicin resistance (rpoB gene)  
A rifampicin resistant mutant of strain COL was made by selection on MH plates 
containing 50 mg/L rifampicin and this was used in the following experiment. Lysates 
were prepared on COL
Rif-r
 (Table 3.3). 
  
Table 3.3 and Figure 3.3 shows the transduction frequency was significantly higher 
into the wildtype COL (4.8x10
-7
) than SCV 3, SCV2 and SCV 1 which was the lowest 
(3.6x10
-7
). 
There was no significant difference in transduction frequency between SCV 1, SCV 2 
and 3 (P = < 0.05). 
 
 
Table 3.3 Transduction of rifampicin into S. aureus COL and SCVs by Φ 80α 
COL
Rif-r 
 
Donor 
COL 
phage 
80α Rif-r 
Recipient 
cell count 
Number 
of phage 
Number of 
transductants 
Transductants 
/recipient 
 
 
Transduction 
frequency/phage 
 
 
% WT 
Transduction 
frequency 
COL-
wildtyp
e 
2.5x10
10
 2.5x10
10
 1.2x10
4
 4.8x10
-7
 4.8x10
-7
 100 
COL-  
SCV 1 
4.9x10
9
 2.5x10
10
 9.0x10
3
 1.8x10
-6
 3.6x10
-7
 75 
COL-  
SCV 2 
2.9x10
9
 2.5x10
10
 9.5x10
3
 3.3x10
-6
 3.8x10
-7
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COL-  
SCV 3 
1.3x10
9
 2.5x10
10
 1.0x10
4
 7.7x10
-6
 4.0x10
-7
 84 
Mean  
8.5x10
9
 2.5x10
10
 1.0x10
4
 3.3x10
-6
 4.5x10
-7
 84.4 
 
Transduction frequency values were obtained from three independent replicates and 
three independent biological replicates. 
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Figure 3.3 A comparison of the transduction frequencies of rifampicin resistance 
into S. aureus COL wildtype and SCV 1, 2 and 3 by Φ 80α-COLRif-r.  
*The transduction frequency into strain COL was significantly higher than into the 
SCVs.  Error bars represent the standard error of the mean.  
 
 
3.3.1.3 Transduction of sarA P2 by Φ80α-ALC1437 
Table 3.4 shows an inability to transduce GFP into any strains.  The limit of detection 
was about 6x10
-9
 and for two strains it was 3x10
-11
. Thus it remains a possibility that 
if the recipient numbers were raised by another order of magnitude it may have 
resulted in transfer. 
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Table 3.4 S. aureus strains used in an attempt to transfer gfpuvr by Φ 80α-
ALC1437
 
 
Donor ALC1437 
phage 80α  
Recipient 
cell count 
Number 
of phage 
Number of 
transductants 
 
Transduction 
frequency/phage 
 
 
COL-wildtype 
 
2.1x10
9 
3.2x10
11*
 
6.4 x10
9 
3.4x10
11*
 
0 
0 
≤6.4x10-9 
≤3.4x1011* 
COL-SCV 1 
2.0x10
9 
 
6.4x10
9 
 
0 
 
≤6.4x10-9 
 
COL-SCV 2 
2.1x10
9 
 
6.4x10
9 
 
0 
 
≤6.4x10-9 
 
COL-SCV 3 
1.7x10
9 
 
6.4x10
9 
 
0 
 
≤6.4x10-9 
 
EMRSA15 1.2x10
9
 6.4x10
9 
0 
≤6.4x10-9 
 
EMRSA 16 1.6x10
9
 6.4x10
9
 0 ≤6.4x10-9 
MRSA N315 
4.7x10
9 
3.2x10
11*
 
6.4x10
9 
3.4x10
11*
 
0 
≤6.4x10-9 
≤3.4x1011* 
Mu50 1.7x10
9
 6.4x10
9
 0 ≤6.4x10-9 
ATCC 25923 2.3x10
9
 6.4x10
9
 0 ≤6.4x10-9 
ATCC 29213 3.5x10
9
 6.4x10
9
 0 ≤6.4x10-9 
NCTC 9789 3.5x10
9
 6.4x10
9
 0 ≤6.4x10-9 
NCTC 6571 4.1x10
9
 6.4x10
9
 0 ≤6.4x10-9 
IA48 4.4x10
9
 6.4x10
9
 0 ≤6.4x10-9 
DB24 1.7x10
9
 6.4x10
9
 0 ≤6.4x10-9 
OM1B 1.6x10
9
 6.4x10
9
 0 ≤6.4x10-9 
Eagles 2.1x10
9
 6.4x10
9
 0 ≤6.4x10-9 
F89 2.0x10
9
 6.4x10
9
 0 ≤6.4x10-9 
RN450 2.1x10
9 6.4x109 0 ≤6.4x10-9 
*Repeated with high number of cells and phage  
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3.3.2 Lysogeny of S. aureus COL 
3.3.2.1 Rates of resistance to and lysogen formation by bacteriophage 80α  
Figure 3.4 shows a clear zone of lysis of the indicator lawn due to phage reproduction 
in some spots.  The growth of lysogens causes the cloudy appearance which can be 
seen in some zones.  192 samples from (768 samples in all) each of four strains were 
tested for lysogeny or resistance (Figure 3.5). COL and SCV 3 were similar both gave 
a similar and greater proportion of lysogens (68.2 and 68.8% respectively) than either 
SCV 1 or SCV 2 (9.9 and 4.2 % respectively). These two groups were significantly 
different (P = < 0.01).   
Figure 3.6 shows the relative proportions of resistant and lysogens formed by each 
strain. Wildtype COL and SCV 3 were significantly different from SCV1 and 2 (P = < 
0.01). There is no obvious reason for the different response between these strains.  
The error bars represent the standard error of the mean. 
 
 
 
Clear zone
Cloudy zone
 
 
 
Figure 3.4 An illustration of bacteriophage 80α release by COL lysogens and 
lysis of the indicator lawn. Zones of clearing with cloudy centres were made by the 
release of bacteriophage from 80α COL lysogens.  
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Figure 3.5 A comparison of the frequency of formation of phage 80 α lysogens 
and resistant mutants of S. aureus COL and SCV strains 1, 2 and 3. Error bars 
represent the standard error of the mean.  
 
3.3.2.2 Viable cell counts of lysogens and parental strains 
 
The data in Table 3.5 (illustrated in Figure 3.6) compares the final viable cell counts 
after 48 hours incubation of parental strains and their respective lysogens.  As 
expected the wild type has about a 10-fold higher cell yield than the SCVs.  It is clear 
the final cell yields of lysogens are reduced compared to their parental strains, except 
for SCV3 (% CFU lysogen/parental strain column).  The effect is greatest in the wild 
type strain (53%) and least for SCV3 (98%). The cell yields of lysogens of COL, SCV 
1, 2 and 3 were reduced compared to the wildtype, by 47, 26, 38 and 2% respectively.  
Thus phage carriage clearly has a significant effect (P = < 0.01), but a decreasing one 
in the slower growing SCVs.  
 
The relative amount of phage produced by lysogens of SCV 1, 2 and 3 (compared to 
COL) was raised by 39, 16 and 84% respectively (Table 3.5). Thus although lysogeny 
reduces cell yield significantly it impacts phage production by about 10-fold at worst.  
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3.3.2.3 Phage 80α yield from lysogens  
Figure 3.7 compares the phage yields of lysogen and lysates.   Phage yields from 
lysogens are 5-10-fold higher than from lysates (Table 3.5) and were significantly 
greater in comparison to phage yield by lysates (P = < 0.05). 
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Table 3.5 A comparison of phage 80α yields from lysogens and parental strains of COL and SCVs 1, 2 and 3  
 
 
1
 Final viable cell counts; values were obtained from at least three independent replicates and three independent biological replicates. 
 
 
 
 
 
Strain CFU/mL 
(lysogen)
1
 
CFU/mL 
(parental 
strain)
1
 
PFU/mL 
lysogen  
PFU/mL 
lysate 
% PFU:CFU 
(phage yield: 
lysogen CFU) 
% PFU:CFU 
(phage yield  
:parental 
strain CFU) 
% CFU 
lysogen /  
CFU parental 
strain 
% WT   
phage yield 
% Ratio of 
phage yield 
lysate/lysogen 
lysate 
COL-
wildtype 
2.24x10
9
 4.20x10
9
 2.70x10
8 
5.90x10
7
 12.05 1.40 53 100 12 
COL- SCV 1 3.08x10
8
 4.16x10
8
 2.50x10
7
 6.50x10
6
 8.12 1.56 74  39 19 
COL- SCV 2 2.14x10
8
 3.46x10
8
 1.20x10
7
 1.60x10
6
 5.61 0.46 62 16 8 
COL- SCV 3 2.16x10
8
 2.20x10
8
 3.40x10
6
 7.00x10
5
 1.57 0.32 98 8 20 
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Figure 3.6 Comparison of the average viable counts of S. aureus COL and SCV 
strains and their lysogens. Lysogeny reduces cell yield when this is compared to that 
of their parental strains. Error bars represent the standard error of the mean. 
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Figure 3.7 A comparison of the phage yield from a lysate and lysogen strains of 
COL and SCV 1-3. The ratio between the phage yield of lysogens and lysates was 
highest for the wildtype. Error bars represent the standard error of the mean.  
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3.3.2.4 Lysate reproducibility 
 
Figure 3.8 A and B show the titres obtained for 14 individual lysates prepared from 
COL strains and their lysogens over a 3 month period. Table 3.6 shows the average 
lysate titre for the lysogens of COL wildtype was (3x10
8
 PFU mL
-1
) and SCV 1-3 
(30-3x10
6
 PFU mL
-1
).  
It is clear that the COL wildtype lysogen gave the highest average lysate titre. The 
SCV lysogens were 10-100 fold lower (Table 3.6).  
 
Table 3.6  The average phage titre from several lysates.  
    Strain Lysogen
1
 Lysate
1
 
COL- wildtype 3x10
8 $
 6x10
7 &
 
COL-SCV1  3x10
7 *
  7x10
6 &
 
COL-SCV2  1x10
7 *
 2x10
6 &
 
COL-SCV3  3x10
6 *
 7x10
5 &
 
1
n= 14; 
$
 significantly different from all SCV lysogens; 
*
 no significant difference; 
&
 no significant difference  
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Figure 3.8 Distribution of phage yields obtained from temporally separate A) 
lysogen and B) lysate cultures. Error bars represent the standard error of the mean. 
 
 
 
 
 
 
A 
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3.4 Discussion 
Transduction: 
Transduction of ciprofloxacin resistance (grlA from EMRSA 16) was observed into 
COL wildtype (mean 4.7x10
-8
, Table 3.2) and at a 5-10-fold higher frequency than 
into SCV1. Thus transduction of ciprofloxacin resistance was significantly decreased 
into SCV1 and not observed (≤1.10-9) into either SCV2 or 3. This experiment also 
examined transfer between genetically distinct MRSA strains (donor lysate prepared 
on EMRSA 16 and recipient was strain COL) and indicates a potential for interstrain 
antibiotic gene transfer.  This data also suggests that SCV strains are less efficient in 
gene exchange by transduction than wild type strains. Intra strain transductions (e.g. 
between SCVs and COL) experiments (Table 3.2) confirm this reduction into SCVs is 
real.  However transfer is only reduced by around 20%.  There is no explanation for 
the absence of ciprofloxacin resistance transfer into SCV2 and 3.  
Transduction of rifampicin resistance (Table 3.3) was observed into COL wildtype 
(4.8x10
-7
) and all SCVs at almost 10-fold reduced frequency (average 3.8x10
-6
).  
Transduction frequencies may be higher in wild type cells because that cell walls of 
SCVs are thicker than those in the wildtype, Thus phages could less effective in lysing 
the cell and hence yield a lower lysate phage population.  Others have suggested this 
may impact on transduction as it would not take place as efficiently (Bulger & Bulger, 
1967; Sendi & Proctor, 2009).  
Table 3.7 summarises the transfer data.  Transfer of ciprofloxacin resistance was 
significantly lower than rifampicin resistance. Transduction of ciprofloxacin 
resistance and rifampicin resistance were similar (Table 3.8), but about 10-fold lower 
at worst, to those reported by Stiffler et al., (1974). 
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Table 3.7 A summary of the transduction frequencies for ciprofloxacin and 
rifampicin resistance. 
Strain 
% WT rifampicin 
Transduction frequency 
% WT ciprofloxacin resistance 
Transduction frequency 
COL-wildtype 100 
(8.0x10
-7
)* 
100 
(1.8x10
-7
)* 
COL-SCV1 75 11 
COL-SCV 2 79 ≤1.0 
COL-SCV3 83 ≤1.0 
*The transduction frequency into COL wildtype is in parenthesis 
 
Transduction of gfpuvr with sarA P2 promoter was not seen in any S. aureus strains 
examined (Table 3.4).  However the P2 promoter is weak and so expression may not 
have occurred (Cheung & Manna 2005).  
 
 
Table 3.8 Comparison antibiotic resistance transduction frequencies between an 
earlier study and this investigation. 
Recipient strain 
Antibiotic   
resistance 
Transduction 
frequency 
Sources 
S. aureus RN450 
Chloramphenicol 2-30x10
-7
 
Stiffler et al., 1974 
     Tetracycline 26-82x10
-7
 
S. aureus COL 
    Ciprofloxacin 1.8x10
-7
 
This study 
    Rifampicin 4.8x10
-7
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Lysogen formation: 
The initial experiments examined the rate of formation of lysogens. The COL 
wildtype strain of S. aureus and SCV3 both yielded a high number of lysogens 
(~68%; Figure 3.4), the remaining being resistant mutants. SCV 1 and SCV 2 
provided a much lower proportion of lysogens (4-10%) as most were resistant to 
bacteriophage 80α.  In the summary Table 3.9 below these strains were shown to have 
different intracellular ATP levels. There is clearly not a relationship between cellular 
ATP levels and % lysogen formation. Therefore the frequency of lysogen formation 
(or that of resistance mutants) cannot be directly related to energy status.  It does not 
even relate to a predicted ATP yield ratio between wildtype and SCVs 1-3 
(32:20:10:2; Day et al., 2012). 
 
Table 3.9 A comparison of ATP levels and lysogen formation.  
Strain COL-wildtype COL-SCV 1 COL-SCV 2 COL-SCV 3 
ATP (RLU) 38663 12575 10968 10930 
% ATP 100 32 28.4 28.3 
predicted ATP 
yield 
32 20 10 2 
Lysogen* 131 19 8 132 
% Lysogen 
formation 
68.2 9.9 4.2 68.8 
* Represents number lysogens found from within 192 samples for each strain; RLU- 
Relative Light Units. 
 
Lysate reproducibility: 
Figure 3.8 shows that all strains produced phage with a distribution of between 2-3 
orders of magnitude. Thus it is not a consistent process, but one modified by 
parameters unknown at present.  So these lysate yield differences presumably reflect 
environmental impact, even under relatively controlled laboratory conditions.  It does 
appear that the amount of variation in yield is less in the lysates from lysogens than 
from growth through overlays. 
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3.5 Conclusions  
 
 Transduction is not consistent between the strains. Ciprofloxacin resistance only 
transferred between S. aureus strain COL and SCV1, and was not detected into 
SCV 2 or 3. GFP was not detected into any strain tested. 
 Rifampicin resistance was transferred into all strains.  
 The frequency of transduction was 1.8x10-7 to ciprofloxacin and 4.8x10-7 to 
rifampicin.  This is about equivalent to published data. 
 Phage 80α resistance was significantly different in some SCVs strains. 
 Phage carriage in the lysogen strains had a physiological cost and reduced cell 
yields by 53-98%. 
 Phage yields from lysates or lysogens were significantly reduced in SCV hosts 
compared to wildtype by 1-2 orders of magnitude. 
 Lysate reproducibility is lower by SCVs than the wild type. Environmental factors 
impact significantly resulting in 2-3 orders of magnitude in yields. 
 93 
CHAPTER 4:  
CHARACTERIZATION OF STAPHYLOCOCCUS AUREUS  
COL SCV 1, 2 AND 3 
4.1 Introduction  
4.1.1 Small colony variants of bacterial species  
Small colony variants (SCVs) were first described in 1910, in an aberrant form of 
Salmonella enterica serovar Typhi (Proctor et al. 2001), and have been since 
described in a number of different bacterial genera. SCVs have been isolated from a 
variety of other bacterial species have been isolated. These species include important 
Gram-negative pathogens such as Pseudomonas aeruginosa (Bryan & Kwan 1981), 
Gram-positive pathogens such as Enterococcus faecalis (Petersen et al., 2008) and 
Streptococcus pneumonia (Alleqrucci & Sauer 2007). SCVs have been isolated from 
methicillin resistant Staphylococcus aureus (MRSA) (Bulger 1967).  Although SCVs 
have been isolated from a number of different bacterial genera, SCVs of S. aureus 
have been most widely studied (Proctor et al. 2006). Since their discovery S. aureus 
SCVs have been associated with persistent, recurrent and antibiotic resistant 
infections (Seaman 2007).  
SCVs constitute a slow-growing subpopulation
 
of bacteria with distinctive phenotypic 
and pathogenic traits. Since their discovery S. aureus SCVs have been associated with 
persistent, recurrent and antibiotic resistant infections (Seaman 2007). SCVs have 
been described
 
in a wide range of bacterial
 
species, including Staphylococcus aureus, 
Staphylococcus epidermidis,
 
Escherichia coli, Salmonella enterica, Pseudomonas 
aeruginosa,
 
and Burkholderia cepacia (Proctor et al., 2006).  Generally, SCVs display 
a small
 
colony size, a slow growth rate, and atypical colony morphology. Since their 
discovery S. aureus SCVs have been associated with persistent, recurrent and 
antibiotic resistant infections (Proctor et al., 2006).  S. aureus is a member of the 
coagulase positive staphylococci (CoPS), which are differentiated from S. epidermidis 
by an ability to coagulate rabbit plasma (i.e. coagulase positive).   
S. aureus shares a core set of 1,681 open reading frames with S. epidermidis (Gill et 
al., 2005).  S. aureus SCVs, identification of CoPS SCVs is a challenge due to their 
abnormal colony phenotypes, slow growth rate and altered biochemical 
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characteristics.  Techniques such as amplification and sequence analysis of 16S rRNA 
are vital for accurate species identification (von Eiff et al., 1999). 
4.1.2 Molecular typing of MRSA 
The typing techniques are used in tracking sources, pathways of spreading infections 
and studying the population genetics. MRSA typing is essential for the establishment 
of national and international surveillance networks. In MRSA typing both phenotypic 
and genotypic methods are used (Weller, 2000).Various molecular epidemiological 
techniques have been employed to type and track isolates including; macrorestriction 
of chromosomal DNA via restriction enzyme digestion and profiling via pulse field 
gel electrophoresis (PFGE), nucleotide polymorphisms in the mecA gene and Tn554 
insertion patterns  (Oliveira et al., 2002). The need for more rapid methods has seen 
the development of several polymerase chain reaction (PCR) based methods including 
coagulase gene typing and random amplified polymorphic DNA (RAPD) (Weller, 
2000). 
4.1.2.1 Random amplified polymorphic DNA 
RAPD uses low stringency PCR of genomic DNA; it is performed with single short 
primers with arbitrary sequences to amplify portions followed by the separation of 
resulting fragments by electrophoresis (Williams et al., 1990). RAPD has been used 
to investigate a nosocomial outbreak of a non-type able MRSA strain (Tambic et al., 
1997) and the use of multiple primers has been demonstrated to improve 
discriminatory power (Cheeseman et al., 2007).   The advantage of RAPD over others 
is the relative speed and simplicity of the technique (Tambic et al., 1997). Although 
RAPD is considered simpler and less time consuming, comparison with PFGE reveals 
that RAPD is less discriminatory (Saulnier et al., 1993).  
4.1.2.2 DNA sequence analysis-based typing methods 
DNA sequence analysis is an objective genotyping method as the genetic code is 
highly portable, easily stored and can be analysed in a relational database. Two 
different strategies have been used to type the isolates by analysing their DNA 
sequences: Multilocus sequence typing (MLST) and Single-locus sequence typing 
(SLST) (Mehndiratta & Bhalla, 2012). MLST was first applied to Neisseria 
meningitidis in order to overcome the problems associated with traditional and 
molecular typing methods (Maiden et al., 1998). MLST differs from PFGE as it is a 
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sequence-based technique and exploits the differences in the nucleotide sequence of 
several house keeping genes. Fragments (~ 450 bp) of these house keeping genes are 
sequenced and a single polymorphism results in the assignment of a new allele 
number. The combination of the seven alleles generates an allelic profile, which 
translates into a single sequence type (ST; (Enright & Spratt, 1999). The 
discriminatory power of MLST was validated through comparison with PFGE profiles 
and the power of MLST as an epidemiological monitoring tool has been facilitated by 
an easily accessible online database which is expanded as novel STs are identified 
(Urwin & Maiden, 2003). MLST has proved instrumental in analysing and tracing the 
origins and evolutionary history of MRSA (Enright et al., 2002; Oliveira et al., 2002).  
 
4.1.3 Aims  
 
 Compare physiological and genetic differences between SCVs 1, 2 & 3 and S. 
aureus COL wildtype. 
 
 Study the relationship between the effects on phenotype, growth curve and other 
factors. 
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4.2 Materials and methods 
4.2.1 Bacterial strains and growth medium   
S. aureus COL, COL-SCV 1, COL-SCV 2 and COL-SCV 3 were all maintained on 
Mueller Hinton (MH) agar and grown in MH broth at 37°C with shaking (150 rpm) 
unless otherwise stated. All growth media were obtained from Oxoid (UK), with the 
exception of components required for certain agar assays, which were obtained from 
Sigma (UK).  
4.2.2 Preparation of antimicrobial agents  
Gentamicin was obtained from Sigma Aldrich (UK) and triclosan from Ciba 
Speciality Chemicals (Germany). Gentamicin powders were dissolved in sterile 
deionised water, and triclosan was dissolved in dimethyl sulfoxide. Reduced strength 
stocks were made where required in deionised water and all stock solutions were 
stored at 4°C for a maximum of 4 days.  
4.2.3 Determination of minimum inhibitory concentrations  
MICs were determined using Clinical Laboratory and Standards Institute (CLSI) 
guidelines as described previously (section 2.2.3).  
4.2.4 Characterisation of S. aureus COL SCV 1, 2 & 3 
4.2.4.1 Determination of auxotrophy 
Auxotrophy was determined using haemin, menadione or thymidine, as described 
previously (section 2.2.7.1). 
4.2.4.2 Coagulase production  
Coagulase production was determined by using Staphylase test kit (DR0595; Oxoid 
Ltd, UK) as described previously (section 2.2.7.2). 
4.2.4.3 Haemolysis activity 
Haemolysis activity was determined by MH agar was supplemented with 5% 
defibrinated sheep blood (SB053; TCS Biosciences) as described previously (section 
2.2.7.3).    
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4.2.4.4 Catalase production  
Catalase production was determined by 1% w/v hydrogen peroxide (H2O2) (H-1009; 
Sigma-Aldrich, Poole, UK) to S. aureus parent and SCVs as described previously 
(section 2.2.7.4). 
4.2.4.5 DNase production 
DNAse activity was quantified by measuring the zone of clearing observed and 
related to the wild type control (100%), by DNase culture media (CM0321; Oxoid, 
UK) as described previously (section 2.2.7.5). 
4.2.4.6 Pigment production 
Pigment production was quantified using a methanol extraction protocol (Morikawa et 
al., 2001) as described previously (section 2.2.7.6). 
4.2.4.7 Quantification of intracellular ATP  
Intracellular levels of ATP were determined by an enzyme based luciferase assay. The 
BacTiter-Glo™ Microbial Cell Viability Assay (G819A; Promega, UK), as described 
previously (section 2.2.7.7). 
4.2.4.8 Phage sensitivity 
Phage sensitivity by Φ 80α was studied by  overlays of 3 ml 50% w/v agar Brain 
Heart Infusion agar (BHI; CM1136, Oxoid) (6 gm/L), plus 10 mM CaCl2, 10 mM 
MgCl2 and 500 µL of culture, as described previously (section 2.2.7.8). 
4.2.4.9 Growth curve  
Growth rate were examined using a Bioscreen C analyser (ThermoFisher, UK) as 
described previously (section 2.2.7.9). 
4.2.4.10 DNA extraction  
DNA was extracted using the GenEute Bacterial genomic DNA Kit (NA2100, Sigma 
Aldrich, UK) as described previously (section 2.2.7.10). 
4.2.4.11 Aerobic and anaerobic growth 
S. aureus COL and their SCVs strains were inoculated into 10 ml MH broth (plus 1 
mg/L of gentamicin for the SCV strains). Aerobic cultures were incubated at 37°C in 
an orbital shaker at 150 rpm for 24 hours and SCV strains for 48 hours. For the 
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anaerobic cultures 2 ml paraffin oil (76235; Fluka Analytical) was added to 10 ml MH 
broth and this was sterilised by autoclaving for 15 minutes at 121°C. These were 
inoculated and incubated at 37°C without shaking. Their optical density recorded after 
24 or 48 hours. 
 
4.2.4.12  Species confirmation  
4.2.4.12.1  Random amplified polymorphic DNA PCR (RAPD-PCR) 
RAPD-PCR was carried out as described previously by (Mahenthiralingam et al., 
1996). All PCR reagents were supplied by Qiagen (UK). Primers 208 (5′-
ACGGCCGACC-3′) 268 (5′-AGGCCGCTTA-3′) 272 (5′-AGCGGGCCAA-3′) 
(MWG Biotech, UK). RAPD-PCR was carried out in 25 µL reactions consisting of 2 
µL template DNA (approximately 50 ng/µL) being added to a 23 µL PCR mixture 
consisting of; sterile polished deionised water, 1 X Coralload buffer, 1 X Q solution, 3 
mM MgCl2, 1.6 µM each RAPD primer, 200 µM dNTPs, and 1 unit Taq DNA 
polymerase. PCR was conducted in a Flexigene Thermal Cycler (Techne Ltd., UK) 
with the following cycle; 5 min at 94°C, followed by 4 cycles of 36°C for 5 min, 
72°C for 5 min and 94°C for 5 min and a further 30 cycles of 94°C for 1 min, 36°C 
for 1 min and 72°C for 5 min and a final hold at 72°C for 5 minutes. PCR products 
(12 µL) were run on 1.5 % w/v agarose (Sigma Aldrich, UK) gels and were visualised 
with ethidium bromide (0.5 µg/mL final concentration in TAE buffer; 40 mM Tris-
acetate, 1mM EDTA) for 45 minutes. Molecular standards were run on all gels using 
molecular weight maker Hyperladder I (Invitrogen, UK).  
4.2.4.12.2  Multiplex PCR 
As S. aureus SCVs are frequently to identify a modified version of the quadriplex 
PCR protocol developed by Zhang et al. (2004) was employed to confirm that SCV 
isolates were S. aureus. PCR target 16S rRNA (Staphylococcus genus specific), nuc 
(S. aureus species specific), and mecA (a determinant of methicillin resistance) as 
described previously (section 2.2.7.11). 
 
 
 99 
4.3 Results  
4.3.1 Minimum Inhibitory Concentrations 
The susceptibility profiles to gentamicin and triclosan of S. aureus COL-SCVs were 
significantly raised (P = < 0.05). The MIC of COL-SCVs for gentamicin was 
increased by 0.5 fold and MICs for triclosan increased between 0.5-0.8 fold (Table 
4.1). 
4.3.2 Characterisation of COL and SCV 1, 2 & 3 
4.3.2.1 Catalase, haemolysis and auxotrophy 
SCV1, 2 and 3 isolates showed reduced or absented catalase, coagulase and 
haemolysis activity in comparison to their wild type strain (Table 4.2). Certain SCVs 
showed a complete absence of heamolysis activity, and all had a reduced catalase and  
coagulase activities. Auxotrophy was confirmed for all three SCVs.  Growth of fast 
growing pigmented colonies around filter discs impregnated with haemin, menadione 
or thymidine. All isolates were sensitive to phage 80. 
4.3.2.2 DNase activity  
DNase activity was obtained by measurement of zones of DNA hydrolysis.  DNase 
activity in COL-SCV 1 was about 65% of the wildtype strain and this was 
significantly reduced (P = < 0.05).  The SCV 2 and 3 displayed an absence of 
DNAase activity (Figure 4.1; Table 4.2). 
4.3.2.3 Pigment production  
S. aureus COL and SCV strains 1, 2 and 3 produced lower amounts of pigment (61; 
43; 21%) respectively in comparison to wild type strains (Figure 4.2).  Figure 4.10 
and 4.11 show images of the colony morphologies at two magnifications to illustrate 
the lack of visual pigment. Despite this the SCVs strains retained 40-80 % of the 
pigment produced by the COL-wildtype (Table 4.2). 
4.3.2.4 Intracellular ATP concentrations  
All SCVs strains had reduced intracellular ATP levels (around 30%) compared to 
COL-wildtype (Figure 4.3; Table 4.2). 
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Table 4.1 MIC (mg/L) for S. aureus COL wildtype and SCVs  
 
GEN - Gentamicin; TRI - Triclosan. Modal values were obtained from three 
independent replicates and three independent biological replicates. These are 
significantly different. 
 
 
 
 
 
 
Figure 4.1 Extracellular DNAase activity of COL wildtype and SCV strains; 
Results are the means of three independent replicates and three biological replicates. 
Error bars represent standard error. 
 
 
Strain GEN TRI 
COL-wildtype 0.25 0.125 
COL-SCV 1 1 2 
COL-SCV 2 2 4 
COL-SCV 3 4 5 
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Figure 4.2 Pigment production by COL wildtype and SCV strains. Results are the 
means of three independent replicates and three biological replicates. Error bars 
represent standard error, showing all are significantly different. 
 
 
              
 
             
Figure 4.3 Intracellular ATP concentrations of COL wildtype and SCV strains. 
Results are the means of three independent replicates and three biological replicates. 
Error bars represent standard error. 
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4.3.2.5 Growth rate and maximum cell count 
The growth profile of S. aureus COL-wildtype is typical (Figure 4.4).  It shows a 
short lag phase and then increases in cell density during exponential phase, with the 
culture reaching high cell densities upon entering the stationery phase.   
The SCVs strains are atypical; their lag phase clearly extended. The duration of lag 
phase in wildtype strain was approximately 1.5 hours in comparison to an average of 
8-12 hours for the SCVs (Figure 4.4). Furthermore SCVs also reached lower 
maximum cell densities reflected by the lower optical density values (Figure 4.5). 
Viable counts revealed that SCV1, 2 and 3 reached a maximum cell density of 3x10
8
, 
1.3x10
8
 and 7x10
7
 CFU/mL respectively.  In comparison the wildtype strain reached a 
higher average cell density of 2.7x10
9
 CFU/mL (Figure 4.4).  
  
4.3.3 Aerobic and anaerobic growth  
Figure 4.6 shows the effect of aerobic growth on stationary phase cell densities.   Cell 
densities of COL-SCV 1, 2 and 3 were decreased between 0.35-0.84-fold compared to 
COL-wildtype.   
Surprisingly perhaps the stationary phase densities after anaerobic growth were 
similar between 0.36-0.49 (Figure 4.6).   
 
 
4.3.4 Species confirmation - RAPD 
RAPD fingerprints for SCVs isolated were identical to wildtype fingerprints 
generated from three primer sets (Figure 4.7). Thus confirming the identity of the 
strains.  
 
4.3.5 Species confirmation - multiplex PCR  
Amplification of 16S rRNA, mecA and nuc genes confirmed all SCVs were S. aureus. 
Figure 4.8 shows presence of 16S rRNA (756 bp), nuc (279 bp) and mecA (310 bp), 
which can also be observed in the parent strain (Figure 4.8). Again confirming the 
identity of the strains.  
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Figure 4.4 Growth curves of COL wildtype and SCV strains. 
SCVs exhibited significantly extended lag in comparison to wildtype strains. Results 
are the means of three independent replicates and three biological replicates. Error 
bars represent standard error.  
 
 
 
 
 
Figure 4.5 Maximum cell count of COL wildtype and SCV strains.  
The wildtype was significantly different from the SCV strains. Results are the means 
of three independent replicates and three biological replicates. Error bars represent 
standard error. 
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Figure 4.6 Comparison of aerobic (∆) and anaerobic () growth yield of COL 
wild type and SCV strains. Results are the means of three independent replicates and 
three biological replicates.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 RAPD profiles of COL wild type and SCV strains. 
L – Hyperladder; lane; COL wildtype; lane 1 –SCV 1; lane2 –SCV 2; lane 3 –SCV 3.   
All strains displayed identical profiles with three different primer sets.  
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Figure 4.8 Multiplex PCR of S. aureus.  
L – Hyperladder, lane 1; –COL-wildtype; lane 2 –-SCV 1; lane 3 –SCV 2; lane 4 - 
SCV 3. Amplification of the staphylococcal 16s rRNA (765 bp), nuc-genes (279 bp) 
and mecA-genes (310 bp) are shown.   
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Table 4.2 Summary of the characteristics of S. aureus COL wildtype and SCV strains  
 
Strain Catalase Coagulase Haemolysis Phage 
80α 
sensitivity 
Auxotrophy Triclosan 
MIC 
(mg/L) 
Gentamicin 
MIC 
(mg/L) 
DNAse  
(% wild 
type) 
Pigment 
production 
(% wild 
type) 
Intracellular 
ATP 
concentration 
(%wild type) 
Growth 
rate  
(OD530; 
%wild 
type) 
Max cell 
count 
(CFU/mL; 
%wild 
type) 
Lag 
phase 
(hours) 
 
wildtype 
 
*** *** *** 
 
+ NT 0.125 0.25 100 100 100 100 100 100              
(1-2) 
SCV 1 
 
 
** * * 
 
+ 
 
+ 2 1 65 61 32 40.5 11 433             
(6-7) 
SCV 2 
 
 
** - -  + 
 
+ 4 2 - 34 28.4 24.5 5 633             
(9-10) 
SCV 3 * - -  +  + 5 4 - 21 28.3 11.2 3 733           
(10-12) 
 
***: Strong catalase/coagulase/haemolysis activity; **: Medium catalase/coagulase/ haemolysis activity *: Weak catalase/coagulase/ haemolysis activity; -: Absence 
of catalase/coagulase/ haemolysis activity; +: Positive; NT: not tested. 
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Figure 4.9 A comparison of S. aureus COL wildtype test results with SCV strains. Error 
bars represent standard error. 
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Figure 4.10 Morphological differences between S. aureus wildtype and SCVs strains 
 A) COL-wildtype; B) SCV 1; C) SCV 2; D) SCV 3.  
SCVs colonies were approximately one tenth the size of wild type colonies.  
 
          
 
Figure 4.11 Magnified morphological differences between S. aureus wildtype and SCVs 
colonies A) COL-wildtype; B) SCV 1; C) SCV 2; D) SCV 3.  
Note of the lack of pigmentation of SCVs.  
A B 
C D 
  
  
10 mm 10 mm 
10 mm 10 mm 
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Figure 4.12 A schematic of differentially expressed phenotypes common to S. aureus 
and SCVs strains.  
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4.4 Discussion  
Phenotype and expression: 
The small colony phenotype and the lack of pigmentation of COL SCVs selected on triclosan 
medium are typical. This contrasts with the wild type colony size. These SCVs displayed 
morphological characteristics (Figure 4.10 and 4.11) that correlate well with other studies 
(e.g. Seaman et al., 2007, Proctor et al 2006). The presence of pigment in S. aureus protects 
them from oxidative stress (Clauditz et al., 2006), so the absence in SCVs is interesting.  
Thus presumably the limit in energy generation means it is utilised first for essential cellular 
process such as cell wall biosynthesis at the cost of pigment production.  Although the 
colonies look to have lost pigment, analysis shows that it is still present.  This indicates that 
the pigment could still be essential for survival. 
Table 4.1 is important to an understanding the SCV phenotype. Firstly the SCVs were 
isolated as triclosan resistant. They are clearly gentamicin resistant to SCVs. Also there is a 
crossover in resistance in SCVs with other antimicrobials. Also Table 4.1 shows a 
progressive lack of sensitivity by the SCVs compared to the wild type strain. When compared 
to the growth rates of the strains (Table 4.2) it shows the slowest growing strain, SCV3, has 
the highest MIC. 
Table 4.2 showed each SCV shows a reduction in intracellular ATP levels, catalase, 
coagulase, DNase activity and maximum cell yield, compared to the wild type strain. The 
absence of haemolytic activity in SCVs has been noted previously (Proctor et al., 2006; 
Seaman et al., 2007). Presumably the loss of these functions (catalase, haemolysis, coagulase 
and DNase) are related to the pathogenicity success of these organisms.   
Aminoglycoside (gentamicin) insensitivities increased and growth rate, together with 
gentamicin resistance, were found to be inversely and linearly related (Day et al., 2012; 
Figure 4.12). 
SCVs commonly display reduced susceptibility to a variety of antimicrobial compounds as a 
direct result of the SCV phenotype. The SCVs isolated in this study showed reduced 
susceptibility to gentamicin (Table 4.1) even though they were selected on triclosan. It is well 
documented that SCVs are less susceptible to aminoglycosides antibiotics such as gentamicin 
(Proctor et al., 1998). This is because the presence of an electrochemical gradient across the 
bacterial membrane is essential for the uptake of positively charged molecules such as 
aminoglycosides (Balwit et al., 1994). As SCVs have a reduced electrochemical gradient, 
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fewer uptakes of these positively charged molecules occurs, resulting in reduced 
susceptibility.  Interestingly the reduced susceptibility to ß-lactam antibiotics has been related 
to the slow growth rate of SCVs reducing the effectiveness of these cell wall active 
antibiotics (Schnitzer et al., 1943; Youmans et al., 1945).  
 
Growth and lag:  
These SCVs were selected on triclosan and produced growth profiles substantially different 
from the wildtype strain. The extension of the lag phase in comparison to the wildtype was 
between 6-12 hours (Table 4.2). In addition their growth rates (Figure 4.5), with a gradual 
increase in cell density during exponential phase and with the culture reaching maximum cell 
densities upon entering the stationary phase of growth.  COL wildtype was 1.412 and SCVs 
were 0.84 - 0.435 (Figure 4.4). 
 
Compared with S. aureus COL wildtype the SCV isolates were less efficient in aerobic 
respiration thus had reduced growth.  Anaerobic cell yield was almost equal (Figure 4.6).  
Presumably SCVs obtain less energy per glucose molecule aerobically than the wild type.  
However when these are grown anaerobically when both SCVs and wild type utilise the same 
pathway to generate ATP. In common with other facultative aerobes, S. aureus can grow in 
the absence of oxygen either by fermentation or by using an alternative terminal electron 
acceptor, such as nitrate (Clements & Foster, 1999). These terminal electron acceptors have 
smaller reduction potentials than O2, meaning that less energy is released per oxidized 
molecule (Yarwood & Schlievert, 2000). Presumably these are the pathways being utilised by 
SCVs to generate ATP. 
 
Identity of SCV strains: 
The identity of the culture in these experiments is critical. This is why the strains were tested 
critically to ensure their identity. RAPD-PCR has been applied to study and track the 
epidemiology of S. aureus in both clinical and environmental settings (Lee, 2003; 
VandenBergh et al., 1999) and so was an appropriate test.  The SCV isolates were confirmed 
as S. aureus by both RAPD-PCR (Figure 4.7), and Multiplex PCR (Figure 4.8). We also used 
phage sensitivity to confirm these isolates were S. aureus.   
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4.5 Conclusions 
 
 Multiplex PCR and sequencing successfully confirmed all isolates were S. aureus.  
 SCVs and COL produced identical RAPD profiles indicating clonality. 
 There is a physiological diversity between SCV strains 1-3. 
 S. aureus SCVs show reduced activity of several enzymes. 
 The lag phase is extended in SCVs  
 The growth rate of the SCVs is by 60-89% reduced 
 Final cell densities (stationary phase) are reduced in SCVs compared to the wild type 
 Growth rate is related to final cell densities 
 Anaerobic growth of the S. aureus wildtype and SCVs was identical, suggesting they 
were using the same energy generating pathway. 
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CHAPTER 5:  
SUSCEPTIBILITY AND RESISTANCE OF 
STAPHYLOCOCCUS AUREUS COL AND THEIR SMALL 
COLONY VARIANTS TO INHIBITORY AGENTS 
5.1 Introduction  
5.1.1 Brief history of resistance in Staphylococcus aureus 
Staphylococcus aureus strains comprise one of the significant human pathogens.  
They are major cause of hospital-acquired infection and frequently cause severe 
infection and the persistent increase in the number of methicillin resistant S. aureus 
(MRSA) and methicillin susceptible S. aureus (MSSA) (Wadworth et al., 1992; 
Office for National Statistics, 2006). The rise and spread of microorganisms with 
reduced susceptibility to antimicrobials occurs around the world (Lu et al., 2005). 
Staphylococci are no different with MRSA strains acquiring resistance to newly 
introduced antibiotics.  They thus pose a clinical problem as they spread rapidly and 
are difficult to treat even with newer antibiotics (Pechere et al., 1992). Multi-
resistance S. aureus strains are potential hazard in the hospital environment (Russell, 
1991; Udo & Grubb, 1993). MRSA can encode resistance to >20 antibiotics, and to 
antiseptics such as quaternary ammonium compounds (Lyon & Skurry, 1987). 
Plasmid encoded resistance occurs also to various other agents (e.g. ethidium bromide 
and acriflavine; Emslie et al., 1985).  Many metals (e.g. AgNO3, CuSO4, HgCl2, and 
ZnSO4) have antimicrobial properties and are used in disinfectant and antiseptic 
formulations. For example AgNO3 was used to prevent gonococcal eye infections, 
mercurochrome and merthiolate (mercury salts) are applied to skin after minor 
wounds, and zinc is used in antifungal antiseptics, while CuSO4 is used as an algicide 
(Ronald, 1995). 
The relationship between the use of antibiotic and development of antibiotic 
resistance has been discussed at length (Livermore, 2003). More recently the 
increased use of biocides as disinfectant, antiseptics and preservatives has also created 
discussion about their role in the development of resistance (Russell, 1997). To 
compound the problem of insensitivity there are various challenges to antibacterial 
drug discovery have kept the output of new classes of antibacterial agents extremely 
low. These difficulties have further exacerbated the current crisis of increasing 
 114 
antibiotic resistance in clinically-relevant bacteria (Norville, 2011). One of the key 
issues to the discovery of novel antibacterial agents is that the majority of targets that 
allow selective toxicity have already been exploited (Moellering, 2011).  
 
5.1.1.1 The susceptibility of S. aureus strains to antimycin, oligomycin and 
carbonyl cyanide m-chlorophenylhydrazone (CCCP) 
The absence of oxidative phosphorylation in cells is the consequence of the absence 
of components of both the electron transport chain and the ATP synthase complex 
(Epstein et al., 2001). This occurs normally when cells are grown in anaerobic 
conditions.   Aerobic growth eukaryotic cells when exposed to different inhibitors of 
oxidative phosphorylation antimycin, CCCP, and oligomycin have their mitochondrial 
functions affected by inhibition of oxidative phosphorylation (Epstein et al., 2001).  
Antimycin, was first isolated from Streptomyces sp. in 1949 (Neft & Farley, 1972), 
and targets the Qi site of cytochrome c reductase, thereby inhibiting the oxidation of 
ubiquinol (Figure 5.1). The inhibition of this reaction disrupts the formation of the 
proton gradient across the inner membrane. The production of ATP is subsequently 
inhibited, as protons are unable to flow through the ATP synthase complex in the 
absence of a proton gradient (Dairaku et al., 2004). Antimycin demonstrated 
significant activity as a growth inhibitor of B. subtilis and S. aureus (Arsianti et al., 
2010). 
CCCP uncouples the proton gradient established from the normal activity of electron 
carriers in the electron transport chain (Park et al., 1997). Tynecka et al (1999) 
showed S. aureus 17810R was inhibited by CCCP as it prevented ATP synthesis via 
oxidative phosphorylation. 
 Oligomycin is isolated from Streptomyces diastatochromogenes and inhibits 
mitochondrial H
+
-ATP synthase by blocking its proton channel (F0 subunit) (Kagawa 
& Racker, 1966), responsible for oxidative phosphorylation of ADP to ATP. A 
characteristic feature of the structure in oligomycin probably plays a role in the 
interaction with F1 and F0 moieties of the of E. coli ATPase complex (Ovchinnikov et 
al., 1984). Figure 5.1 shows chemical structure to antimycin, oligomycin and CCCP.  
Figure 5.2 shows a summary of the various metabolic pathways predicted or 
confirmed to be affected in respiratory-deficient staphylococci by Proctor et al. 2006. 
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Antimycin A 
 
 
 
Oligomycin A 
 
 
 
 
Carbonyl cyanide m-chlorophenylhydrazone (CCCP,) 
 
 
 
Figure 5.1 Chemical structure of antimycin A, oligomycin A and CCCP 
(Ulanovskaya, et al., 2008). 
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Figure 5.2 Metabolic pathways affected in respiratory-deficient cells as inferred 
from transcript profiling. Solid coloured bars indicate sites of inhibition by 
antimycin, oligomycin and CCCP, have their mitochondrial functions affected by 
inhibition of oxidative phosphorylation (adapted Proctor et al. 2006).  
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5.1.1.2 Susceptibility to heavy metals  
Metal ions are directly and indirectly important to microbial metabolism. Although 
ions (e.g. Al, Ag, Cd, Sn, Cu, Cr, Hg and Pb) have essential biological roles, many are 
frequently inhibitory at higher concentrations (Gadd, 1988). Staphylococci are often 
resistant to heavy metal ions, especially cadmium and mercury, and arsenic (Dyke et 
al., 1970) and this is thought to be related to their exposure in clinical environments.    
In some instances resistance is plasmid encoded, so for example the penicillinase 
plasmids in Staphylococcus aureus also carry genes determining resistance to several 
heavy metal ions (Novick & Roth, 1968). Resistance to penicillin G in S. aureus 
depends mainly upon the production of a penicillinase enzyme (Rosdahl & Rosendal, 
1983). Richmond et al. in 1964 investigated 181 selected strains and found that the 
active production of penicillinase closely correlated with multiple antibiotic resistance 
and resistance to mercury salts. Rosdahl and Rosendal (l980) found that changes in 
staphylococcal flora in Denmark were associated with changes in resistance to heavy 
metals. Resistance to mercury was most often found in multi-antibiotic resistant 
strains but rarely in strains resistant only to penicillin. 
Thus metals may play a role in maintaining retention of antibiotic resistance once 
resistance is achieved. Many antibiotic resistance genes are plasmid-borne and in 
clinical isolates tend to be present on the same plasmids as resistance factors for 
metals such as mercury (Christon et al., 1997).  
Resistance to cadmium (Cd
2+
) is widespread in Staphylococcus aureus. There are two 
separate Cd
2+
resistance determinants, cadA and cadB, located on plasmids (Witte et 
al., 1986; Novick et al., 1979). The resistance function coded by the cadA determinant 
results from decreased intracellular accumulation of Cd
2+
 (Weiss et al., 1978). The 
cadB gene product may protect the cell by binding Cd
2+
 (Perry & Silver, 1982). 
Resistance to mercury has been found in a number of Staphylococcus aureus strains, 
especially in those connected with outbreaks of infections in hospitals (Hall, 1970; 
Witte et al., 1980), mercury resistance has been plasmid encoded on plasmid p1258 
the merA gene codes for the mercuric reductase enzyme, and the merB gene codes for 
an organomercurial lyase enzyme (Weiss et al., 1977). Free copper ions can be toxic 
to cellular systems, as these can create harmful oxygen species by reacting with 
hydrogen peroxide (Gaetke & Chow, 2003). Copper ions may also disrupt 
proteins/enzymes by binding to free protein thiol groups or by competing with other 
metals for cofactor binding sites (Teitzel et al., 2006).  
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5.1.2 Aims 
 
 Study the relative sensitivity of S. aureus parent and SCVs strains to various 
antibiotics and chloride salts of heavy metals using a disc diffusion method 
 
 Determine if any agents selected for SCVs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 119 
5.2    Materials and methods 
5.2.1 Bacterial strains     
Methicillin-resistant S. aureus (MRSA) strain COL and the small colony variants 1, 2 
and 3.  Strains were stored at -80°C in Mueller Hinton (MH) broth supplemented with 
8% dimethyl sulfoxide (DMSO) and re-isolated on MH agar plates when required. 
5.2.2 Preparation of antibiotics stock solutions 
Antimycin A (A8674), oligomycin A (O4876) and CCCP (C2759) were obtained 
from Sigma Aldrich (UK). Antibiotic stocks (10,000 mg/L) were prepared. 100 mg of 
the antimycin and CCCP were dissolved in 10 mL of ethanol. 100 mg oligomycin was 
dissolved in 10 mL of DMSO. Solutions were mixed thoroughly by vortex mixing and 
then filter sterilised by passing them through 0.2 µm filters (Minisart, UK). Stocks 
solutions were maintained at 4°C.  
5.2.3 Preparation of chloride salts of heavy metals stock solutions 
Cadmium chloride (10064: BDH chemicals; fw:183.32), chromium chloride (022887: 
Aldrich Chemical Company; fw: 158.136), copper chloride (10088: BDH chemicals; 
fw:170.48) and mercury chloride (3450; Fisons Scientific; fw:271.50). Stock solutions 
(5 M) were prepared by adding formula weight of the required chloride salts to 10 mL 
of sterile deionised water and filter sterilised by passing them through 0.2 µm filters 
(Minisart, UK). Reduced strength stock solutions were prepared in sterile deionised 
water and held at 4°C. 
5.2.4 Disc diffusion  
The standardised disc susceptibility testing method (Andrews, 2009) was carried out 
following guidelines from the British Society of Antimicrobial Chemotherapy 
(BSAC). Briefly individual S. aureus colonies (3-4) were inoculated into cation 
adjusted Mueller Hinton broth (CAMHB) and incubated at 37°C with shaking at 150 
rpm.  Cultures were grown to the end of logarithmic phase and cell densities were 
adjusted to match the turbidity of a 0.5 McFarland standard at 625 nm. SCV strains 
failed to reach the densities required by the McFarland standard, in which case 
densities of parent strains were adjusted to ensure similar inoculum concentrations. A 
sterile cotton swab was dipped into the suspension and spread evenly over the surface 
of MH agar plate. Sterile filter discs (150 mm; Whatman) were applied to the centre 
of the agar onto which 5 µL of antibiotics stock solutions (1,000 mg/L) and 5 µL 
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chlorides salts heavy metals stock solutions (5 M) were dispensed, as shows Table 5.1 
and 5.2. Plates were allowed to dry for 10 minutes before being incubated for either 
24 hours (wildtype) or 48 hours (SCVs) at 37°C and then zones of inhibition were 
measured.  
 
 
 
 
 
 
 
Table 5.1 The concentrations of antibiotics used  
 
Antibiotics Drop (µL) Stock (mg/L) Final concentration (mg) 
Antimycin 5 1000 5  
Oligomycin 5 1000 5 
       CCCP 5 1000 5 
 
 
 
 
 
 
 
 
 
Table 5.2 The concentrations of chloride salts of heavy metals used  
 
Biocides Drop (µL) Stock (M) Final concentrations (mM) 
Cadmium chloride 5 5 25 
Chromium chloride 5 5 25 
  Copper chloride 5 5 25 
  Mercury chloride 5 5 25 
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5.3    Results  
5.3.1 Disc diffusion  
5.3.1.1 The activity of antimycin, oligomycin and carbonyl cyanide m-
chlorophenylhydrazone (CCCP)  
The antimicrobial action of antimycin, oligomycin and CCCP against S. aureus SCVs 
and their parent strains was assessed using a simple disc diffusion method. All 
antimicrobials produced inhibition zones in all SCVs (1, 2 and 3) and their respective 
parent strains (Figure 5.3).  
Table 5.3 show the inhibition zone size of COL wild type was 1.8-2 folds less 
susceptible to CCCP than SCV 1-3 and mean 1.3-2.2 folds less were each of 
antimycin and oligomycin. All were almost equally sensitive to antimycin and 
oligomycin. CCCP produced the largest inhibition zones in SCV and parent strains 
(mean 21 mm), followed by antimycin (4 mm) and oligomycin (3 mm).  
Statistical analysis shows that the SCV strains from the three antimicrobial produced 
significantly more sensitive (the diameter of inhibition zones were larger) in 
comparison to wildtype strain (P = < 0.05).  There was no significant difference in 
sensitivity to oligomycinin by SCV 1-3 (P = > 0.05). Wildtype and SCV1 show the 
same sensitivity to antimycin and oligomycin and both are significantly more resistant 
than SCV 2 and 3.   
Three small colony variants arose in the CCCP zone of inhibition of the wildtype 
strain COL.  One of these (SCV-CCCP) was stored and later sequenced. 
 
 
Table 5.3 Relative sensitivities of S. aureus wildtype strain and their SCVs to 
CCCP, antimycin and oligomycin.  
 
Antimicrobial 
Concentration 
(mg) 
COL-
wildtype
a
  
COL-
SCV 1
a
  
COL-
SCV 2
 a
 
COL-
SCV 3 
a
  
Antimycin  5 4 5 7 9 
Oligomycin  5 3 4 5 6.5 
CCCP  5 21 38 41 43.5 
a 
Inhibition zone diameter (mm) 
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Figure 5.3 The relative % differences in sensitivity to antimycin, oligomycin and 
CCCP of S. aureus strain COL and SCV 1-3. Inhibition zones are the results of 
three independent replicates and three independent biological replicates. Error bars 
represent standard error. 100% is the wild type arbitrary resistance level. 
 
5.3.1.2 The activity of chloride salts of cadmium, chromium, copper and mercury 
The wildtype COL strain was significantly less sensitive to the chloride salts of four 
heavy metals than the SCVs strains (P = < 0.05). The average diameter of inhibition 
zone in wildtype strains was 7.4 mm where as the SCV average was 1.6 times greater 
at 12.3 mm (Figure 5.4). 
With copper, cadmium and mercury salts the relative sensitivity increased, such that 
SCV3 was the most sensitive and the least was SCV strain 1. 
Sensitivity to the SCVs to the chromium salt was significantly higher compared to the 
wild type, but there was no difference between them. 
There is little difference between the SCV strains in sensitivity to cadmium chloride 
(Table 5.4).  
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SCV 2 is significantly more susceptible to copper chloride than the other two SCV 
strains (P = < 0.05). 
SCV 3 is significantly more susceptible to both cadmium and mercury chloride than 
the other two SCV strains 
SCVs were significantly more sensitive to cadmium chloride than the wildtype strain 
(P = < 0.05). 
Small colony variants were not obtained from any of the chloride salts. 
 
 
Table 5.4 Relative sensitivities of S. aureus wildtype strain and their SCVs to 
heavy metal chloride salts 
  
Heavy metal 
chloride salts 
Concentration 
(mM) 
COL-
wildtype
a
  
COL-
SCV 1
a
  
COL-
SCV 2
 a
 
COL-
SCV 3 
a
  
  Chromium chloride 25 9 13 13.5 17.5 
  Copper chloride 25 3.5 7 8.5 8 
  Cadmium chloride 25 6.5 10 11 12.5 
  Mercury chloride 25 10.5 12.5 14 19.5 
a 
Inhibition zone diameter (mm) 
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Figure 5.4 The relative % differences in sensitivity to cadmium, chromium and 
copper salts of S. aureus parent strain and their SCVs. Wildtype produced 
significantly smaller inhibition zone compared to the SCV strains (P = < 0.05). The 
results of three independent replicates and three independent biological replicates. 
Error bars represent standard error.  
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5.4 Discussion   
Disc diffusion was applied to assess the antimicrobial susceptibility to various 
antibiotics and salts heavy metals.    
All strains of S. aureus tested were sensitive to antimycin, oligomycin and CCCP 
(Figure 5.3). These different inhibitors of oxidative phosphorylation, namely 
antimycin, CCCP, and oligomycin, each inhibit oxidative phosphorylation (Epstein et 
al., 2001). 
The data (Table 5.3 and Figure 5.3) shows that the SCV strains were significantly 
more sensitive to antimycin (the diameter of inhibition zones were larger) in 
comparison to the wild type.  Also SCVs 1 and 2 and 3 showed significantly increased 
sensitivities between themselves (P = < 0.05). This is probably because antimycin 
affects the Qi site of cytochrome and this then disrupts the formation of the proton 
gradient across the inner membrane (Dairaku et al., 2004; Arsianti et al., 2010). 
There was no significant difference in sensitivity to oligomycinin between SCVs 1, 2 
or 3 but they were significantly more sensitive than the wild type (P = < 0.05).   
Oligomycin targets the interaction with F1 and F0 moieties of the of ATPase complex 
(Ovchinnikov et al., 1984). Why the SCVs were more sensitive remains 
undetermined, but maybe it was due to interference of the proton gradient. 
SCVs 1, 2 and 3 were significantly more sensitive to CCCP than the wild type. Also 
they were significantly different themselves. CCCP is a protonophores and, disrupts 
Proton Motive Force (PMF) (Eva et al., 1994) and so inhibits efflux (molecular 
traffic) across the cell membrane. Thus CCCP inhibits growth by affecting the cell’s 
PMF. The NADH dehydrogenase complex, functioning as the first energy coupling 
site in the respiratory chain, the activity of this hypothetical coupling device in S. 
aureus, which seems to be required for tight coupling between respiration and 
phosphorylation, was observed only in whole cells but not in broken ones. Thus it 
appears that all three SCVs have a common functional pathway up to this point in 
oxidative ATP generation. Hence that in the L-lactate oxidizing system operating at 
the second energy coupling site in the respiratory chain of S. aureus, such a 
controlling device may be absent (Tynecka et al., 1999). Thus the effect on SCVs 
cannot be explained. 
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Small colony variants arose in the CCCP zone of inhibition of the wildtype strain 
COL. These were not studied further. None was seen for the other inhibitors. 
The SCV strains were more sensitive to three heavy metals than the wildtype strain 
(Figure 5.3). SCVs strains exposed to cadmium, copper chromium and mercury 
showed significantly higher sensitivity (the diameter of inhibition zones were larger) 
in comparison with wild type.  
The clinical use of and hence exposure to heavy metals results in the selection of 
bacterial strain also able to resist antibiotics. This occurs for genes encoding heavy 
metals are located together with antibiotic resistance genes. So for example the 
penicillin binding protein A2 (PBP A2) in Staphylococcus aureus also carries genes 
determining resistance to several heavy metal ions (Novick & Roth 1968) as well as 
those to erythromycin and other antibiotics (Mitsuhashi 1963). Many staphylococci 
are resistant to heavy metal ions, especially cadmium and mercury, and arsenic (Dyke 
et al., 1970). 
No small colony variants were observed with any of the heavy metal chloride salts.  
This is strange as Hirsch (1954) reported SCVs from E. coli strain B after exposure to 
copper sulphate.  However another important fact not commented upon is that he did 
some isolations anerobically and found no SCV were isolated.  This correlates with 
the phenotypes of the SCVs we have isolated. To our knowledge this is the only paper 
to report an attempt to isolate SCVs anaerobically.  
Perron and colleagues (2004) studied resistance to carbepenem and heavy metals in 
Pseudomonas aeruginosa. Part of the reason for their high levels of 
tolerance/resistance is the presence of multiple efflux pumps. They found a RND 
proton driven pump conferring resistance to cadmium/cobalt/zinc that also conferred 
resistance to carbapenem.  This cross resistance as the result of a single mutation, thus 
there is the possibility that in SCVs an analogous mutation may lead to either raised or 
lowered sensitivities to antimicrobials. 
 
To have raised or lowered sensitivities to these inhibitors suggests that the mutations 
conferring the SCV phenotype co-incidentally impacts on their tolerance or sensitivity 
to these inhibitors. Therefore to explain this change in sensitivity it is important to 
consider the potential physiological impact of reduced ATP generation capacity.  
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The ability of S. aureus to switch to an alternative phenotype in the presence of 
antimicrobial agents is clearly favourable if it permits survival. SCVs have many 
characteristics that are associated with survival in unfavourable conditions. Various 
reports of phenotypic switching have been published (Mitchell et al., 2010a).   
Formation of the SCV phenotype in S. aureus was hypothesised as a potential 
phenotypic switching system that could be influenced by the alternative sigma factor, 
σB (Mitchell et al., 2010a). This was a hypothesis discussed early in the work, 
however the sequencing data on the cycling mutants discussed later (chapter 6) 
suggests strongly that this is not involved. 
 
It had been hoped that there may have been some differences in sensitivities between 
the SCVs and then this could have been used to try and understand and explain their 
physiological changes. 
 
 
 
 
 
5.5   Conclusions  
 
 CCCP can select SCV at higher concentration. Antimycin and oligomycin were 
not observed to select for SCV from S. aureus COL.  
 
 No SCV were select heavy metal chloride salts. 
 
 SCV1, 2 and 3, wild type strains show significant differences in sensitivity for 
reasons that remain unknown.  
 
 128 
CHAPTER 6: 
SEQUENCING OF THE S. AUREUS GENOME 
6.1 Introduction 
6.1.1 Structure of the S. aureus genome  
Whole genome sequences of several different S. aureus strains have been determined.  
The first two S. aureus strains to be sequenced were N315 and Mu50 (Kuroda et al., 
2001), which were followed by nine, including strain COL, additional strains (Baba et 
al., 2002; Diep et al., 2006 & Gill et al., 2005). The sequenced genomes are between 
2.7-3 million base pairs (bp) in size and have a low G+C content (~32%). Their  
genomes contain a single circular chromosomes which encodes approximately 2700 
coding sequences as well as structural and regulatory RNAs (Holden & Lindsay, 
2008).  
Bacterial genomes are commonly viewed as having a core genome, comprising of 
genes essential for growth and functionality, coupled with an auxiliary set of genes 
(Frost et al., 2005). It has been proposed that the auxiliary genes confer traits which 
may be beneficial under certain circumstances (Dobrindt et al., 2004). In the S. aureus 
genome ~75% of genes  are highly conserved between isolates and make up the core 
genome (Lindsay & Holden, 2004). The auxiliary gene set is composed of genes 
associated with virulence and drug resistance, which are frequently carried on mobile 
genetic elements (MGEs) (Holden & Lindsay, 2008). S. aureus contains many types 
of MGEs, including plasmids, transposons, bacteriophages, genomic islands, plasmids 
and staphylococcal cassette chromosomes all of which can move around bacterial 
genomes via the process of horizontal gene transfer (Malachowa & DeLeo, 2010). 
Analysis of closely related orthologues (genes in different species that originated by 
vertical descent from a single gene of the last common ancestor) indicates that the 
genetic background of S. aureus has been vertically transmitted from a common 
ancestor that subsequently diverged into Bacillus and Staphylococcus species (Ito et 
al., 2003).  
 
There are several possible mutations that could occur in these genomic sequences.  
These could be point mutation (substitutions) which are termed a transition when a 
purine replaces a purine (adenine, guanine or a pyrimidine replaces a pyrimidine 
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(thymine, cytosine and uridine); or a transversion when a purine replaces a pyrimidine 
or vice versa. Other sequence changes are defined as duplications, deletions and 
transpositions. These potentially involve the change or movement of several to 
hundreds of bases.  
 
6.1.2 Relevant biochemical features in staphylococci. 
6.1.2.1 dnaC gene  
dnaC gene encoded DNA helicases which cut the hydrogen bonds between bases in 
double stranded DNA, which serve as a single strand  DNA template for DNA 
polymerases (Arai et al., 1981). A protein encoded by the S. aureus dnaC gene has 
44% homology with E. coli dnaB and 58% homology with B. subtilis dnaC 
replicative DNA helicases (Kaito et al., 2002).  Kaito and colleagues suggested that 
the dnaC is involved in DNA repair and that S. aureus dnaC helicase is a promising 
target for antibiotics providing bactericidal effects. 
6.1.2.2 mecA gene (penicillin binding protein A2) 
The mecA gene allows staphylococci to be resistant to antibiotics such as methicillin 
and other penicillin-like antibiotics. mecA gene is spread on the SCCmec genetic 
element (Ito & Hiramatsu, 1998). The gene encodes the penicillin binding protein 
(PBP), called PBP 2A, has a low affinity for β-lactam antibiotics. This enables 
transpeptidase activity in the presence of β-lactams, preventing them from inhibiting 
cell wall synthesis (Hartman & Tomasz, 1984; Ubukata et al., 1989). In addition to 
mecA, more than 30 kb of flanking sequences is also acquired, and the entire region is 
called mec locus (Beck et al., 1986). Both mecA and mec locus DNAs hybridize 
among all species of staphylococci that display the methicillin-resistant phenotype, 
suggesting the horizontal transfer of mec DNA (Archer & Pennell, 1990). Kipp and 
colleagues study evaluate the influence of SCV phenotype on the detection of 
methicillin resistance (mecA) and detect mecA gene in SCVs in comparison with (wild 
type) normal-phenotype (Kipp et al., 2004). 
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6.1.2.3 fusA gene (Elongation factor-G "EF-G") 
Fusidic acid inhibits bacterial protein synthesis by preventing release of EF-G from 
the ribosome (Bodley et al., 1969).  Resistance to fusidic acid in Staphylococcus 
aureus may result from transfer of the fusB determinant or from spontaneous 
mutations in the fusA gene that encodes the drug target, the elongation factor G (EF-
G; O'Neill et al., 2007). Mutations in the EF-G gene (fusA) which prevent binding by 
fusidic acid protect the staphylococcal translation apparatus from inhibition (O'Neill 
et al., 2004). S. aureus as SCV phenotype on the basis of resistance to 
aminoglycosides belong to either the fusA-SCV or fusE resistance class (Norstrom et 
al., 2007). 
6.1.2.4  ccpA (catabolite control protein A)  
ccpA is global transcriptional regulator of carbon catabolite repression and carbon 
catabolite activation, which ensures optimal energy usage under diverse conditions 
(Gill et al., 2005). The catabolite control protein A is a member of the LacI/GalR 
family of transcription factor that binds to specific cis-acting DNA sequences 
designated the catabolite responsive element (CRE; Henkin, 1996; Stulke & Hillen, 
1999).  In S. aureus, ccpA appears to function as a global regulator, affecting not only 
carbon metabolism but also the production of virulence determinants, antibiotic 
resistance, biofilm formation, and nitrogen metabolism (Seidl et al., 2008; Seidl et al., 
2006). Recent transcriptome and proteome analysis confirmed the broad effects of 
ccpA on gene expression in S. aureus (Seidl et al., 2009).  
6.1.2.5  fabI (enoyl acyl carrier protein reductase) 
Fatty acid biosynthesis in staphylococci is typically catalyzed by the type II fatty acid 
synthase system, utilises several discrete enzymes effecting fatty acid chain 
elongation and subsequent membrane synthesis (Heath et al., 2000). The enoyl-acyl 
carrier protein (ACP) reductase, which catalyzes the last step of each cycle of fatty 
acid elongation, is a promising target because it plays a key role in the regulation of 
the pathway (Heath & Rock, 1995; Heath et al., 2001). The fabI enzymes are 
receiving increased attention not only because of their regulatory significance, but 
also because of the recent discovery that inhibitors of this step in the pathway are 
effective antibacterials. The diazoborines inactivate fabI through the formation of a 
covalent bond with NADH in the active site of the enzyme (Baldock et al, 1996; 
Baldock et al, 1998). Triclosan, widely used as a disinfectant agent with broad-
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spectrum antibacterial activity, was found to inhibit fabI, the enoyl-ACP reductase of 
S. aureus (Heath et al., 2000). fabI gene reduced susceptibility within the SCVs 
phenotype. This implies that fabI is not the sole target for triclosan (Seaman et al., 
2007). 
6.1.2.6 mnh gene (Na+/H+ antiporter) 
The Na
+
/H
+
 antiporter has several roles in bacterial cells. Firstly it is to establish an 
electrochemical potential across the cytoplasmic membrane (Chen et al., 1958; 
Jackowski & Alix, 1900). Secondly to extrude Na
+
 and Li
+
, ions which are toxic if 
accumulated at high concentrations (Inaba et al., 1994; Nozaki et al., 1996). Thirdly it 
is to regulate intracellular pH under alkaline conditions and cell volume (Krulwich, 
1983; Padan & Schuldiner, 1994).  
Antiporters are composed of multiple subunits, were shown in Staphylococcus aureus 
to be part of an operon encoding seven genes mnhA-G. (Hiramatsu et al., 1998). The 
mnh cluster in S. aureus is required to confer significant resistance to sodium ions and 
alkaline pH (Hiramatsu et al., 1998).  
6.1.2.7 menD gene (Menaquinone biosynthesis) 
Menaquinone is one of the bacterial forms of vitamin K and is an important 
component of the electron transport system (Lin & Kuritzkes, 2003; Taber, 1980). 
Menaquinoneis is derived from the shikimate pathway via isochorismate (Weische & 
Leistner, 1985). The menD gene of S. aureus codes for the first enzyme of 
menaquinone biosynthesis, 2-succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-
carboxylate (SEPHCHC) synthase (Gill et al., 2005). The menD mutation provides 
the S. aureus SCVs with a survival advantage during antimicrobial therapy, compared 
with its parent strain (Bates et al., 2003). However, selected or constructed mutations 
in menD produce the electron transport deficiency-associated phenotypes of SCVs 
(Bates et al., 2003). Mutations in menB were shown to be a possible genetic basis for 
such a switch in a set of SCV menadione auxotrophic mutants and their revertants 
recovered from patients (Lannergard et al., 2008). 
 
6.1.2.8 atl or nag gene (Autolysin gene)  
The S. aureus autolysin gene, atl, encodes a unique 138-kDa protein with amidase and 
glucosaminidase domains. The atl protein is proposed to undergo proteolytic 
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processing to generate two extracellular peptidoglycan hydrolases, endo-β-N-
acetylglucosaminidase and N-acetylmuramyl-L-alanine amidase (Komatsuzawa et al., 
1997).  S. aureus contains several types of peptidoglycan hydrolases that can break 
covalent bonds in their own cell walls (Oshida et al., 1995; Perkins, 1980). The 
activity of some of these hydrolases is clearly involved in bacterial autolysis (induced 
by antibiotics or adverse physiological conditions), cell wall turnover, and cell 
separation (Perkins, 1980; Handwerger & Tomasz, 1985).  
 
6.1.2.9  folD gene (coenzyme transport and metabolism) 
The S. aureus folD gene, bifunctional protein, protein contains two distinct enzymatic 
activities. Methylenetetrahydrofolate dehydrogenase and methenyltetrahydrofolate 
cyclohydrolase, the latter is a hydrolase and general process is coenzyme transport 
and metabolism (Gill et al., 2005). 
6.1.2.10 isdA or stbA gene (iron-regulated surface determinant protein A) 
isdA gene has broad-spectrum ligand-binding activity, including fibrinogen and 
fibronectin (Clarke et al., 2004). It’s only expressed in iron-limited conditions under 
the control of iron-regulated surface determinant protein A (Clarke et al., 2008). The 
isdA gene has two domains with distinct functions. The N-terminal NEAT domain of 
isdA binds a broad spectrum of human extracellular matrix and serum proteins, 
including transferring (Taylor & Heinrichs, 2002; Vermeiren, et al., 2006). The C-
terminal domain of isdA has recently been shown to decrease the cellular 
hydrophobicity of S. aureus and confer resistance to hydrophobic fatty acids and host 
antimicrobial peptides and thus aid survival on live human skin (Clarke et al., 2007).  
Thus in SCVs it is expected to be up regulated.   
 
6.1.2.11 trmFO or gid gene (methylenetetrahydrofolate--tRNA-(uracil-5-)-
methyltransferase) 
trmFO encodes for the folate/ FAD-dependent tRNA methyltransferase, has been 
identified in most Gram-positive and some Gram-negative bacteria, including 
(Urbonavicius et al., 2005; Urbonavicius et al., 2007). 
 133 
6.1.2.12 spl gene (serine protease) 
The S. aureus spl gene has been considered as virulence gene as they encode secreted 
six serine protease-like proteins (Reed et al. 2001). The spl proteins appear to be 
synthesized without propeptides. Because of their sequence similarities to serine 
proteases, the genes encoding these proteins were designated splA, splB, splC, splD, 
splE, and splF for serine protease like (Reed et al. 2001).  
6.1.2.13 fmtA gene (autolysis and methicillin resistance related protein) 
fmtA gene specifically interacts with β-lactams antibiotics forming covalently bound 
complexes. fmtA has a low binding affinity for β-lactams, and it experiences a slow 
acylation rate, signifying that this protein is intrinsically resistant to β-lactam 
inactivation (Fan, 2007). It has been suggested that fmtA affects the cell wall structure 
(Komatsuzawa et al., 1997). The putative fmt protein showed a hydropathy pattern 
similar to that of S. aureus penicillin-binding proteins and contained two of the three 
conserved motifs shared by penicillin-binding proteins and β-lactamases 
(Komatsuzawa et al., 1997).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 134 
6.1.3 Aims  
 
 
 Annotate the S. aureus COL and S. aureus N315 SCV genomes.  
 
 Determine the novel mutations that produce the SCV phenotype and 
discriminate these from the historic mutations unrelated to SCV formation.  
 
 Comment on and analyse their diversity 
 
 Determine if the forward and reversion mutations that determine the SCV state 
are random or not. 
 
 Describe the classes of mutations involved 
 
 Determine if the SCV formation cycle is a random or dedicated mutational 
event. 
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6.2   Materials and methods 
6.2.1 Bacterial strains  
The bacterial strains used are listed in Table 6.1.  Briefly these were each obtained 
after 15 cycles of forward (to an SCV form) and reversion (back to a wild type form).  
For further details refer to Chapter 2.  
 
Table 6.1 Bacterial strains used in this study  
 
 
 
 
 
 
 
 
 
 
 
 
 
6.2.2 Genome sequence analysis 
6.2.2.1 Selection of strains for sequencing 
Because of time and financial constraints only four of the cycled strains (COL SCV 
15-GEN, COL SCV 15-TRI, N315 SCV 15-GEN, N315 SCV 15-TRI) were analysed 
(Table 6.1).  Briefly these four isolates were the result of 15 cycles of selection for 
SCV by triclosan, combined with 15 cycles of selection for WT by fast growth in non-
selective conditions (see chapter 2 for a full explanation). It was hoped that an 
examination of the genome sequences would provide a clear historical record or 
evolutionary fingerprint of the mutations that had occurred in the two strains.  
Although the best strategy would have been to sequence all 60 strains, this was not 
economically feasible. Thus the final SCV strains isolated (COL-SCV15 and N315-
SCV15) were sequenced and compared between themselves and with the published 
genome sequence of their parental strains. It was recognized that there would be 
Strain Description Source/Reference 
COL SCV 15-TRI derived from COL following 
triclosan  selection 
(This study chapter 2; 
section 2.2.1) 
N315 SCV 15-TRI derived from N315 following 
triclosan  selection 
(This study chapter 2; 
section 2.2.1) 
COL SCV 15-GEN derived from COL following 
gentamicin  selection 
(This study chapter 2; 
section 2.2.1) 
N315 SCV 15-GEN derived from N315 following  
gentamicin  selection 
(This study chapter 2; 
section 2.2.1) 
 136 
sequence differences in the genomes of our COL and N315 strain parental strains and 
the published sequences.  We thus termed the common mutations arising in the strains 
after different selection antimicrobials as an indication thus describe these as historic. 
The novel mutations are therefore ones not occurring in the same strain undergoing 
the alternative selection cycles.    
6.2.2.2 Rationale of the sequencing strategy 
  
The logic behind the experiment was that the genome would show evidence of the all 
the mutational changes occurring after 15-cycles. The most mutations expected would 
be 60 and this would be the case if all forward changes (to SCV) were at different 
sites and suppressed by reversion at different sites. The least changes would be zero 
and this would suggest a site specific mutation process. This would deliver a WT 
revertant with no evidence for mutation.   
6.2.2.3 The genome comparison  
Sequence comparisons used BLAST. The BLAST software was obtained from the 
NCBI site. The resulting list of matching tandem repeats was then imported in the 
database, where it was queried.  
6.2.2.4 Electronic genome structure 
The original genome map of S. aureus was based on the strain 8325, created by Pattee 
and colleagues, and then by 2000 the whole genome of strain 8325 had been 
sequenced and annotated. Since then, at least six other S. aureus strains have been 
completed (COL, N315, Mu50, MW2, MRSA252, MSSA476) (Patel et al., 1989; 
Diep et al., 2006). The S. aureus strain N315 and COL has been completed circular 
genome map shows ~2.8-Mb open reading frames.  The two strains have 79 and 72 
RNA genes, 2614 and 2615 protein coding genes, and 5 complete ribosomal RNA 
operons in their genome. These strains have ~33% G+C content, utilise ~84% as 
coding sequence.  There is a single plasmid ~25,000 base pairs in length with a G+C 
content of 28.7% (Kuroda et al., 2001; Gill et al. 2005). 
 
 
 
 
 
 137 
6.3  Results  
This experiment was designed to determine whether there were a multitude of sites at 
which the SCV phenotype was conferred. The alternative was that the phenotype was 
produced from a single site mutational event that was freely revertable, resulting from 
a site specific mutational change. Thus the genomic sequence of the final revertants in 
the cycling experiment would provide the evidence for either hypothesis.  Numerous 
changes at various sites would confirm the more random process, whilst no evidence 
of significant genomic change would suggest the site specific mechanism. 
Examining the sequence data in Tables 6.2 and 6.3 show there are numerous changes 
to the sequence of the cycled strains of COL and N315 when compared to the parental 
sequenced strains. However the changes highlighted in grey (8 N315and 25 COL) are 
common to each strain with different repeated selection process. These strains have 
been cultured in our laboratory for over 10 years and must statistically have acquired 
spontaneous mutations in their genomes.  Thus the mutations highlighted in grey are 
probably not related to the cycling and selection steps in the experiment, but are 
historic.  If this premise is accepted then there are 5 (N315-TRI), 4 (N315-GEN), 10 
(COL-TRI) and 21 (COL-GEN) novel mutations in the four strains (Table 6.4).   
It would be predicted that over the 15 forward and 15 reverse selection cycles that a 
maximum of 30 independent mutations would be seen. That is if the mutations 
occurred in different sites. These sites could be in the same gene or in different genes.  
However there is the possibility that some mutations revert to wild type and so there 
would be no footprint (sequence change) of their occurrence. Thus logic dictates no 
more than 30 changes would be seen. So this sequence analysis relies on mutations to 
wild type that are suppressed and do not occur by true reversion. Thus changes in the 
number of mutations less than 30 are predicted.   
If the mutational event SCV – WT – SCV were a site specific one then there should 
be no evidence of change other than in genes unrelated to SCV formation. It would 
also be expected that there would be no sequence change and so the final wildtype 
would have the same sequence as the initial parental strain. The sequencing data thus 
suggests that the site specific mutational mechanism is not operating.  The finding that 
there are not about 30 mutational changes in any of the genomes of final revertants 
implies in many cases the cycled mutant selected was a true revertant.  Thus there is 
no evidence for suppressed mutants.  
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N315-TRI and N315-GEN share 8 mutations and COL-TRI and COL-GEN share 25 
mutations (grey shading in Table 6.2). These indicate historic changes unrelated to the 
cycling experiment. This suggests the rate of spontaneous mutation maybe 3-4-fold 
higher in COL than in N315. Although this assumes their growth histories are 
equivalent. 
There are just 5 novel mutations in N315-TRI and 4 in N315-GEN instead of the 
predicted 30. There are more in COL-TRI (10) and most in COL-GEN (21).  Thus this 
suggests the mutation rate in COL is higher. 
Examining N315 first.  Table 6.2 shows some mutations to be greyed out.  These are 
common between the selection cycles and so are predicted to be unrelated to the 
selection agent and are thus predicted to be historical.  Importantly they do not have 
any obvious sequence (gene function/phenotype) importance, thus inferring this is a 
reasonable conclusion. Interestingly there are no mutations in common between N315 
SCVs selected on triclosan or gentamicin. This implies there are many sites at which 
SCV formation can occur. Interestingly fabI is one gene consistently recognised to be 
effected when selection is made for triclosan resistance and this was found in both 
strains (COL and N315) when selection was made on triclosan (Tables 6.2 and 6.3).   
An examination of COL (Table 6.3) shows 24 common mutations (greyed out) that 
are presumed to be historical. Only two could potentially be significant, an 
osmoprotectant transporter (ACOL0781) and an antiporter (SACOL1014) and it is 
possible that these offer a common phenotypic response to gentamicin and triclosan 
selection pressure. This remains to be determined and by examining these gene 
sequences in our parental COL strain by PCR analysis we could determine if they are 
historic or novel.  Although triclosan selects for a mutation in fabI, but this is only one 
of eight mutations seen in this cycled strain.  Thus in this strain there are several 
putative sites which confer the SCV phenotype.   
 
There are numerous mutations to examine to determine their significance.  Without 
further analysis these can only be examined theoretically to hypothesise their 
relevance to SCV formation (Tables 6.2 and 6.3).  These are examined individually  
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6.3.1 Genes effected in the S. aureus N315 strain 
The S. aureus N315 SCV-GEN dnaC gene has a transition mutation (C→T). The gene 
encodes a DNA helicase that serves as a single strand DNA template for DNA 
polymerases (section 6.1.2.1). 
S. aureus N315 SCV-GEN (SA0857) mecA gene has a transversion mutation (G→C). 
The gene encodes a penicillin binding protein PBP2A. The mecA gene prevents 
methicillin and other penicillin-like antibiotic binding to the enzymes that help 
forming the cell wall of the bacterium, and hence the bacteria can replicate normally 
(section 6.1.2.2). 
S. aureus N315 SCV-TRI (SA0323) mepA gene has a transition mutation (C→T). 
This is possibly acted as a multidrug resistance protein and secondary transporter of 
unknown function. So its impairment affects metabolism resulting in the SCV 
phenotype.  
S. aureus N315-TRI (SA0376) guaA gene has a transition mutation (A→G). The 
enzyme catalyzes the synthesis of GMP (guanine monphosphate synthetase) which 
converts XMP (xanthosine monophosphate) to guanosine monophosphate (5'-
guanidylic acid; Gene bank; NCBI).  So its impairment possibly affects energy related 
metabolism resulting in the SCV phenotype.  
S. aureus N315 SCV-GEN (SA0505) fusA gene has a transition mutation (A→G). 
The fusA gene encodes the elongation factor G (EF-G; O'Neill et al., 2007). Mutations 
in the EF-G gene (fusA) which prevent binding by fusidic acid protect the 
staphylococcal translation apparatus from inhibition (O'Neill et al., 2004). S. aureus 
SCV phenotype belongs, on the basis of resistance to aminoglycosides, to either the 
fusA-SCV or fusE resistance classes (Norstrom et al., 2007). 
 
S. aureus N315 SCV-TRI (SA1882) kdpD gene has a transversion mutation (T→A). 
KdpD together with KdpE constitutes a two-component signal transduction system, 
which was first characterized in E. coli (Altendorf et al., 1992). In S. aureus the 
proteins KdpD and KdpE regulate the production of Kdp-ATPase, which is an 
inducible high-affinity K
+
 transporter that is synthesized under conditions of severe 
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K
+
 limitation or osmotic upshift (Laimins et al., 1981). So its impairment potentially 
affects membrane transport/proton transport resulting in the SCV phenotype.  
S. aureus N315 SCV-TRI (SA2109) gene has a transversion mutation (A→C). It 
encodes an amino acid permease (Kuroda et al., 2001). How its impairment affects 
metabolism resulting in the SCV phenotype remains unknown. 
 
6.3.2 Genes effected in S. aureus COL strain  
The S. aureus COL SCV-TRI (SACOL0129) gene for a hypothetical ABC transporter 
has a transition mutation (G→A). There are a enormous number of putative ABC 
transporters in staphylococci, most of which have not yet been characterized. Some 
have been detected in a signature-tag transposons-mutagenesis approach aiming at 
finding possible novel drug targets (Coulter et al., 1998). In addition an ABC 
transporter has been identified as the immunodominant protein during S. aureus 
infections (Burnie et al., 2000), both findings demonstrate than ABC transporters will 
play important role as target molecules in the search for novel antistaphylococcal 
therapies (Otto & Gotz, 2001).  Thus their removal in SCVs would make them less 
sensitive to antibody recognition. 
The menD gene in COL SCV-TRI strain (SACOL1052) had multi-point mutation in 
different positions gene (substituted A→G, T→C) and one small deletion mutation. 
Mutations in menD are recognised to produce the electron transport deficiency-
associated phenotypes of SCVs (Bates et al., 2003). Menaquinone (vitamin K2) has an 
important role in transport of electrons in respiratory chain.  Mutations which block 
menadione biosynthesis result in the SCV phenotype (Sendi & Proctor, 2009). 
S. aureus COL SCV-GEN (SACOL1058) gene encodes a class 1 aminotransferase.  It 
has a transversion mutation (C→A). How it selects for the SCV phenotype is 
unknown. 
The atl gene in COL SCV-TRI strain (SACOL1062) had two different substitution 
mutations (G→T, G→A) and at one position, a deletion of cytosine. The atl gene 
cluster has several types of peptidoglycan hydrolases that can break covalent bonds in 
the cell’s own cell walls (section 6.1.2.8). How it selects for the SCV phenotype is 
unknown. 
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The folD gene in COL SCV-TRI (SACOL1072) has a transition mutation (C→T). 
This gene encodes a protein that possesses two distinct enzymatic activities, 
dehydrogenase and cyclohydrolase (Gill et al., 2005).  How it selects for the SCV 
phenotype is unknown.  It is possible that the dehydrogenase is involved in energy 
metabolism and maybe thus has some impact in this way.  
The isdA gene (iron-regulated surface determinant protein A) in COL SCV-TRI strain 
(SACOL1140) had two deletions in different positions within the gene. isdA gene 
product decreases the cellular hydrophobicity of S. aureus and confer resistance to 
hydrophobic fatty acids and host antimicrobial peptides and thus aid survival on 
human skin (Clarke et al., 2007).  Thus in SCVs it is expected to be up regulated 
(section 6.1.2.10) and so have a mutation in its regulation, but what impact on its 
function these internal mutations have to result in the SCV phenotype is unknown.  
The trmFO gene in COL SCV-GEN (SACOL1428) gene has a transition mutation 
(G→A). The gene encodes for the folate/ FAD-dependent tRNA methyltransferase. 
How it selects for the SCV phenotype is unknown. 
The S. aureus COLSCV-TRI (SACOL2042) ilvD gene has a transition mutation 
(G→A). The ilvD gene regulates valine, leucine and isoleucine biosynthesis. How it 
selects for the SCV phenotype is unknown. 
 
6.3.3 A mutation occurring in both S. aureus COL and N315  
 
Both of COL-TRI (SACOL1016; fabI) and N315-TRI (SA0869; fabI) had mutations 
in fabI.  These were C→T and G→T substitutions respectively (Table 6.1 and 6.2). 
The fabI encodes a protein (enoyl acyl carrier protein reductase) involved in lipid 
transport.  The fabI mutation reduced the susceptibility of the SCV, compared to the 
wild type strain, thus selecting for the SCV phenotype (Seaman et al., 2007). This 
mutation was only observed in SCVs isolated on triclosan. 
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Table 6.2 Characteristics of the genes associated with SCV formation in N315   
GEN: N315 SCV 15 gentamicin; TRI: N315 SCV 15 triclosan; UN unknown; 
Del
: deletion mutant; -: no mutation; GA or AG = guanine substituted by an adenine or 
vice versa; TA or AT = thymine substituted by an adenine or vice versa; TG or GT = thymine substituted by a guanine or vice versa; CA or AC = cytosine 
substituted by an adenine or vice versa; GC or CG = guanine substituted by a cytosine or vice versa;  TC or CT = thymine substituted by a cytosine or vice versa;  
bp = base pair. 
Locus 
Sequence 
number 
Gene 
name 
Product or putative 
function 
Process 
Mutation  
N315-TRI 
Mutation  
N315-GEN 
References and 
sources 
 20766 dnaC Helicase DNA helicase activity - CT NBCI Gene bank 
 36135 UN   AGAAADel GAAADel  
 37605 UN   CT CT  
 37631 UN   GA GA  
 41690 UN   CT CT  
SA0857 64975 mecA 
Penicillin-binding protein 
2a 
Cell wall and membrane biogenesis GC - 
(Kuroda et al., 2001; McAleese et 
al., 2006) 
 81245 UN   
T 
Del  
+ 
GACA
Del
 
T 
Del  
+ 
GACA
Del
 
 
SA0323 380993 mepA 
Multidrug resistance 
protein 
Transport and binding proteins (P-A 165 
Multidrug efflux) 
CT - 
McAleese et al., 2005;  NBCI 
(Gene bank NCBI) 
SA0376 435235 guaA   GMP synthase Nucleotide transport and metabolism AG - 
(Kuroda et al., 2001; Scherl et al., 
2005) 
SA0505 589974 fusA Elongation factor G Translation elongation factor G - AG 
(Vaezzadeh et al., 2005; O'Neill et 
al., 2004 
SA0869 984367 fabI 
Enoyl-[acyl-carrier-protein] 
reductase 
Lipid transport and metabolism; (fabI G-C 
113) 
GT - Heath et al., 2000 
SA1882 2131592 kdpD 
Sensor histidine kinase 
KdpD 
Signal transduction by phosphorylation TA - Kuroda et al., 2001 
 2309464 UN   - GA  
SA2109 2372458 UN Amino acid permease Amino acid transport and metabolism - AC Kuroda et al., 2001 
 2561821 UN   CT CT  
 2753061 UN   TA Del T Del  
Number of novel mutations 5 4  
Differences from reported sequence (historic mutations) 8 
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Table 6.3   Characteristics of the genes associated with SCV formation in COL   
Locus 
Sequence 
number 
Gene 
name 
Product or putative function Process 
Mutation  
COL-TRI 
Mutation  
COL-GEN 
References  
SACOL0085 91185 UN Peptidase, M20/M25/M40 family General function prediction only 30bp Del 30bp Del 
Kuroda et al., 
2001; 
SACOL0129 145010 UN Transport ABC V-I 268 putative Hypothetical GA - Gill et al., 2005 
SACOL0132  148085/8 UN Pseudo Posttranslational modification TA, AC TA, AC NBCI Gene bank 
SACOL0338 363030 UN Topoisomerase putative Replication, recombination and repair GA - 
Kuroda et al., 
2001 
SACOL0367 375225 UN 
Prophage L54a, terminase, large 
subunit, putative 
Miscellaneous-Phage, (M-I) GA - 
Gill et al., 2005 
 
 465935 UN   TA TA  
SACOL0511 511017 UN Hypothetical protein Hypothetical TM Yib E/F family - CA Gill et al., 2005 
 623565 UN   GA GA  
SACOL0781 805360 UN Osmoprotectant ABC transporter Amino acid transport and metabolism G Del G Del Gill et al., 2005 
SACOL1014  1022865 UN 
Na+/H+ antiporter, putative, 
authentic point mutation 
Antiport; hydrogen ion transport; ion 
transport and sodium transport 
T 
Del
 T 
Del
 Gill et al., 2005 
SACOL1016 1023925 fabI 
Enoyl-[acyl-carrier-protein] 
reductase 
Lipid transport and metabolism, (fabI 
A-V 95) 
CT  
Gill et al., 2005;  
Heath et al., 2000 
 1045162 UN   A 
Del
, T 
Del
 A 
Del
, T 
Del
  
SACOL1052 1058605 menD 
2-succinyl-6-hydroxy-2,4-
cyclohexadiene-1-carboxylic acid 
synthase/2-oxoglutarate 
Coenzyme transport and metabolism, 
(Menaquinone biosynthetic process) 
- AG 
Gill et al., 2005;  
Bates et al., 2003 
"         "         " 1058651 "      " "         "         " "         "         " - TC "          " 
"         "         " 1058745 "      " "         "         " "         "         " - A Del "          " 
"         "         " 1058775 "      " "         "         " "         "         " - AG "          " 
"         "         " 1059135 "      " "         "         " "         "         " - TC "          " 
 1063050    GT GT  
SACOL1058 1064925 UN Aminotransferase, class I Amino acid transport and metabolism - CA Gill et al., 2005 
SACOL1062 1068304 atl (nag) Bifunctional autolysin Cell wall and membrane biogenesis - GT 
Gill et al., 2005; 
Komatsuzawa et 
al., 1997 
"         "         " 1068311 "      " "         "         " "          "         " - C Del "          " 
"         "         " 1070773 "      " "         "         " "          "         " - GA "          " 
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 1081800 UN   - CT  
SACOL1072 1082805 folD 
methylenetetrahydrofolate 
dehydrogenase/methenyltetrahydrof
olate cyclohydrolase 
Coenzyme transport and metabolism - CT Gill et al., 2005 
SACOL1140 1148845 isdA (stbA) 
Cell wall surface anchor protein; 
Iron-regulated surface determinant 
protein A 
Cell wall and membrane biogenesis A
 Del
 - 
Gill et al., 2005;  
Taylor & 
Heinrichs, 2002 
"         "         " 1148920 "          " "         "         " "          "         " G 
Del
 GC "          " 
SACOL1188 1192900 UN 
Hydrolase, haloacid dehalogenase-
like family 
General function prediction only  CT - Gill et al., 2005 
 1227842 UN   A Del A Del  
 1227906 UN   AG AG  
SACOL1268 1279941 
gid 
(trmFO) 
Methylenetetrahydrofolate--tRNA-
(uracil-5-)-methyltransferase trmFO 
Translation - GA 
Gill et al., 2005;  
Urbonavicius et 
al., 2007 
SACOL1359 1365405 UN Hypothetical protein Hypothetical - CT Gill et al., 2005 
SACOL1428 1440658 lysC Aspartokinase Amino acid transport and metabolism T 
Del
 T 
Del
 Gill et al., 2005 
SACOL1454  1468807 UN   2 bp 
Del
 -  
SACOL1472 1482135 ebh Extracellular matrix-binding protein pathogenesis - GA Gill et al., 2005 
SACOL1662 1691715 UN 
Acetyl carboxylase biotin carrier 
protein 
Lipid transport and metabolism A 
Del
 C-A 
Del
 Gill et al., 2005 
SACOL1747 1785033 accA 
acetyl-CoA carboxylase, carboxyl 
transferase, alpha subunit 
Lipid transport and metabolism - GA Gill et al., 2005 
 1830469 UN   CG CG  
SACOL1866 1918837 splD Serine protease 
Posttranslational modification, protein 
turnover, chaperone 
TT 
Del
 TT 
Del
 
Gill et al., 2005;  
Reed et al. 2001 
 2004705 UN   C 
Del
 AC 
Del
  
SACOL2042 2102282 ilvD Dihydroxy-acid dehydratase 
Valine, leucine and isoleucine 
biosynthesis, 
related molecules (ilvD R-K 405) 
GA - Gill et al., 2005 
 2123390 UN   - GA  
 2241656 UN   AG AG  
 2286720 UN   AT AT  
 2286770 UN   AT AT  
SACOL2345 2404465 UN Esterase putative Lipid transport and metabolism - GA Gill et al., 2005 
SACOL2346 2405685 UN Hypothetical protein Hypothetical - GA Gill et al., 2005 
 2428185 UN   GC GC  
 2470605 UN   G Del G Del  
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GEN: COL SCV 15 gentamicin; TRI: COL SCV 15 triclosan; UN: Unknown; 
Del
: deletion mutant; -: no mutation; GA or AG = guanine substituted by an adenine or vice 
versa; TA or AT = thymine substituted by an adenine or vice versa; TG or GT = thymine substituted by a guanine or vice versa; CA or AC = cytosine substituted by an 
adenine or vice versa; GC or CG = guanine substituted by a cytosine or vice versa; TC or CT = thymine substituted by a cytosine or vice versa; bp = base pair. 
 
 
 
 
 
 2482180 UN   TG TG  
 2492156 UN   TA TA  
SACOL1066 2504495 fmtA 
FmtA, autolysis and methicillin 
resistance related 
protein 
Pathogenic factors (toxins and 
colonization factors) 
TA 
Del
 TA 
Del
 
Komatsuzawa et 
al., 1997;  
Komatsuzawa et 
al., 1999; 
 2595460 UN   CA CA  
SACOL2696 2770880 hisI (hisIE) 
Phosphoribosyl-ATP 
pyrophosphatase/phosphoribosyl-
AMP cyclohydrolase 
Amino acid transport and metabolism 
A-AG-T 
Del
 
AG 
Del
 Gill et al., 2005 
Number of novel mutations 10 21 
 
Differences from reported sequence (historic mutations) 25 
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Table 6.4 Total the mutation types and proportion in both strains  
Strain 
Deletion 
mutations 
Point 
mutations 
Novel 
mutations  
Historic 
mutations 
Agent 
Novel 
deletions 
mutations 
Novel 
point 
mutations 
Historic 
deletions 
mutations 
Historic 
point 
mutations 
S. aureus 
N315 
4 13 9 8 
TRI 0 5 
4 4 
GEN 0 4 
S. aureus 
COL 
19 37 31 25 
TRI 4 6 
12 13 
GEN 3 18 
Total per 
mutation 
23 50 40 33 
    
Total to 
all 
mutation 
73 
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6.4  Discussion 
General Mutations (novel and historical): 
Analysis of the sequences illustrate there are numerous changes to COL and N315 
genomes when compared to the parental sequenced strains. However some changes 
are historic.  Thus the mutations highlighted in grey are probably not related to the 
cycling and selections steps in the experiment, but are historic.  That is they are 
present in the strain prior to the experiment. Thus 8 mutations in COL and 25 
mutations in N315 have arisen since the strain we obtained was originally sequenced. 
It would be predicted that over the 15 forward and 15 reverse selection cycles that a 
maximum of 30 independent mutations would be seen. That is if the mutations 
occurred in different sites. These sites could be in the same gene or in different genes.   
Novel mutation were arose 9 mutations in N315 SCV (5:N315-TRI), (4:N315-GEN) 
and 31 mutations in COL (10: COL-TRI) and (19: COL-GEN) novel mutations in the 
four strains (Table 6.4).  
 Exposure of S. aureus N315 and COL to triclosan and gentamicin work by inducing 
point mutations which occurs when a single base pair of a gene is changed, and 
deletion (loss of DNA bases). N315 and COL strains found point mutations by 
(13:37) mutations and deletion mutations by (4:19) mutations, while mutations the 
same in the two strains were presented in fabI (Table 6.4). 
The genomes of N315 and COL encode 2593 and 2615 protein genes (Kuroda et al., 
2001 and Gill et al., 2005). The sequencing data (Table 6.4) shows there are a total of 
38 different genes in the two strains which give an SCV phenotype significantly only 
one is in common (fabI) and thus it is probable that there are even more than this.  
Since there is little difference in the two staphylococci genomes we can add the SCV 
mutants together and so estimate (33/2615) that 1.3% of the genome (or about 40 Kb 
if each gene is about 1 kb in size) is concerned with the SCV phenotype. One 
unexplained aspect of the historic mutations column in Table 6.4 is that N315 has 
more historic mutations than COL, but an apparent lower mutation rate, as is evident 
from the lower number of novel mutations.  The fact that the rates of SCV formation 
are not impacted by the selective agent also suggests that they are both generalist. By 
this it is meant they are not directly selecting for on or a reduced SCV phenotype 
array.  Table 6.5 indicates the known array of genes and phenotypes affected. The 
importance of the remaining unidentified sequences (genes?) and their potential 
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phenotypes is unknown.  This however suggests there are many other ways to become 
an SCV.  This clearly has implications to understanding the infection success and 
treatment potential for the organism. 
The data in Table 6.5 shows that about a quarter of the mutations occurred in known 
genes.  These are responsible for amino acid metabolism (9 genes), lipid metabolism 
(5 genes), DNA metabolism (4), pathogenicity (4 genes), transport (3) and cell wall 
and membranes (2).  The remaining mutations were in sequences for which no actual 
or putative function has been assigned. 
 
N315: 
The S. aureus N315-GEN dnaC gene has a transition mutation (C→T).   Kaito and 
colleagues as identified five mutant strains whose temperature-sensitive colony 
formation phenotypes were complemented by the dnaC gene. DNA replication in 
these mutants has a fast-stop phenotype (Kaito et al., 2002).  How this relates to SCV 
formation is unknown. 
 
COL: 
SACOL1058 in S. aureus COLSCV- GEN encodes an aminotransferase and had a 
point mutation (C-A) conferring gentamicin resistance. There are three types of 
aminoglycoside modifying enzymes and this type, SACOL1058 N-Acetyltransferases 
(AAC), catalyzes acetyl CoA-dependent acetylation of an amino group, a class 1 
aminotransferase. Enzymatic modification is the most common type of 
aminoglycoside (gentamicin) resistance (Davies & Wright, 1997).  It is hypothesized 
that the enzyme is derived from organisms that make the aminoglycoside or from the 
mutation of genes that encode the enzymes involved in cellular respiration (Gilbert, 
2000). Gentamicin is member of aminoglycoside family; they inhibit protein synthesis 
by binding to the 30S ribosomal subunit to prevent the formation of an initiation 
complex with messenger RNA. They also cause misreading of the messenger RNA 
message. Another important function of the aminoglycosides is that they increase 
membrane leakage intracellular contents (White et al., 2005). How it selects for the 
SCV phenotype is unknown. 
 
The menD gene in COL SCV-TRI strain (SACOL1052) had multi-point mutation in 
different positions within the gene and one deletion mutation. Mutations in menD are 
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recognised to produce the electron transport deficiency-associated phenotypes of 
SCVs (Bates et al., 2003). Menaquinone (vitamin K2) has an important role in 
transport of electrons in respiratory chain. Mutations that block menadione 
biosynthesis, reduce ATP yield and thus result in the SCV phenotype (Sendi & 
Proctor, 2009). 
 
N315&COL: 
Both mutants COL-TRI (SACOL1016; fabI) and N315-TRI (SA0869; fabI) arose 
from a substitution of 2 base pairs (Table 6.2).  Seaman et al., (2007) found 5 base 
pairs substitution mutation in the fabI gene of S. aureus after exposure to triclosan. 
The fabI gene is one of the key enzymes in the bacterial fatty acid biosynthetic cycle 
(Bergler et al., 1996; Slater-Radosti et al., 2001). The fabI mutation reduced the 
susceptibility of the SCV, compared to the wild type strain, thus selecting for the SCV 
phenotype (Seaman et al., 2007). 
Thus examining the historic mutations we can say they occurred in regions which 
have no apparent impact on staphylococcal activity. Until we sequence the entire 
collection we can only assume at present that we have labelled these historic 
mutations correctly.  
The novel mutations are more diverse than others have suggested or even considered.  
It goes to illustrate that there are many individual ways to produce an SCV.  
Presumable when these are really understood metabolically and phenotypically an 
understanding of the individuality of the phenotypes resulting from mutations, their 
classes and types will become apparent.  
 
Table 6.5 summarises the mutations assigned/associated with SCV formation.  Some 
are hypothetical and others real.  Many would not be predicted and have no apparent 
physiological/biochemical link or prior association with generating the SCV 
phenotype.  So although the basis for SCV formation in the literature seems simple, it 
is clearly not.  The Table also indicates that we have identified a further 77 
independent and novel mutations which produce an SCV on unknown basis.   Thus 
with a large number of potential gene target to produce an SCV it is predictable that a 
microbial cell can acquire the SCV phenotype at a 10-100-fold higher frequency than 
a normal mutation rate.  That is assuming that all SCVs are equal and we know they 
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are not. However they may be better than the wild type at surviving and that is all they 
have to do. 
Table 6.5  27 genes associated with SCV formation and their metabolic roles 
Amino acid 
metabolism 
Lipid metabolism DNA 
metabolism 
Pathogenicity Transport Cell 
wall/membrane  
SA2109 fabI (SA0869) dnaC fusA KdpD mecA 
SACOL0085 
fabI 
(SACOL1016) 
guaA ebh SACOL0129
#
 isdA 
SACOL0781 accA  SACOL0338
#
 splD SACOL1014
#
  
SACOL1062 SACOL1662 gid (trmF0) SACOL0367
#
   
menD SACOL2345
#
     
folD      
lysC      
ilvD    
 
 
hisI    
 
 
9 5 4 4 3 2 
#
 Hypothetical function; 77 others had unknown activities 
 
 
One of the aims asked if SCV formation cycle was a random or dedicated mutational 
event. It seems clear from Table 6.4 that finding 6 - 19 mutations in the final wild type 
sequences is indicative of point mutations as a response to SCV formation and 
reversion. However finding just 3 novel mutations in N315-TRI after 15 cycles 
suggests this strain (and the other 29 cycle intermediates) ought to be examined in 
more detail. At the very least the finding of low numbers of mutations after 15 cycles 
is suggestive of true reversion and not intragenic suppression.  It maybe of course that 
some of the unknown mutations are suppressing intergenically, the original SCV 
causing mutation.  
 
 
 
 
 151 
6.5      Conclusions 
 
 
 Numerous mutations have occurred in the genomic sequence of COL and 
N315 when compared to the parental sequenced strains (over 70 mutations; 
Table 6.4). 
 
 There were 25 historical mutations in COL and 8 in N315. 
 
 S. aureus COL and S. aureus N315 genomes have acquired spontaneous 
mutations in their genomes since they have been in our laboratory.  
 
 
 Novel mutations conferring the SCV phenotype occur in each strain (5: N315-
TRI), (4: N315-GEN), (10: COL-TRI) and (21: COL-GEN). 
 
 These novel mutations are not part of a gene a cluster, but effect different 
components of the cell’s metabolic pathways.  Thus there is not just one SCV 
mutation, but a diverse population of them. 
 
 Only one mutational site was found to be common between COL and N315 
and this was in the fabI gene. 
 
 At least 1.3% of the genome (≥40 Kb) is concerned with the SCV phenotype, 
but it might well be significantly higher. 
 
 The two strains have shown many different metabolic routes to becoming and 
SCV. 
 
 Thus SCVs appear to be generated by spontaneous mutations occurring in a 
range of very different genes. 
 
 The two strains appear to have different rates of mutation. 
 
 There was no evidence for a site specific mechanism. 
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CHAPTER 7:  
DISCUSSION, CONCLUSIONS AND FUTURE WORK  
7.1 General discussion  
Staphylococcus aureus is recognized as one of the most common organisms causing 
nosocomial and community-acquired infections in every region of the world. The 
increasing prevalence of methicillin resistance among staphylococci is an increasing 
problem (Yilmaz et al., 2007). However under certain conditions S. aureus behaves as 
an opportunistic pathogen and is frequently the causative agent of various human 
diseases. As such it is of the most intensively studied bacterial species (Plata et al., 
2009), and is associated with prolonged hospital stay, increased morbidity and 
mortality, as well as increased healthcare costs (Que & Moreillon, 2010). Thus the 
research discussed here should be viewed in this context. 
The work in thesis supports and confirms that S. aureus SCVs possess many 
characteristics that are abnormal for wildtype strains, they pose difficulties in 
identification and isolation in the laboratory ((Proctor et al. 1994). Atypical growth 
rates are clearly shown to be key to their metabolic performance and can lead to their 
presence being missed on agar plates and their atypical phenotypic and enzymatic 
characteristics can also lead to misidentification. In this study multiplex PCR was 
successfully employed for the identification of S. aureus SCVs.  
These data shows the rate of formation of wild type and SCV strains are within an 
order of magnitude. Thus the spontaneous mutation rate has not been subject to 
selection and the remains equal to the original WT strains.  
 
7.1.1 Selection and identification of SCVs  
Physiological tests on isolates from the cycling experiment showed all SCV isolates 
and the wild type revertants (WT15) had a reduction in intracellular ATP levels.  
They also had a reduction or absence in pigment, catalase, coagulase, haemolytic and 
DNase activities. The maximum cell yield was also reduced in the COL wild type 
revertants, but not those from N315. These effects on SCVs have been noted 
previously (Proctor et al., 2006; Seaman et al., 2007), but no one has examined 
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revertant physiology or activities before. The fact that N315 wild type revertants 
reacquire the wild type growth yield and yet the COL revertants do not requires 
further investigation.  It also shows again that not all SCVs are the same and also that 
not all wild types are either, this metabolic diversity is a key feature of the SCV story. 
A comparison of growth rate, pigment and phage yield and maximum cell count 
showed a relationship for strain COL, while DNAs activity was less well associated, 
although it was reduced in all SCVs.  
Auxotrophy for haemin and menadione has been reported in S. aureus SCVs as well 
as SCVs isolated from several other bacterial species (Sasarman et al., 1970). The 
failure to produce menaquinone and haemin in the SCVs selected by gentamicin and 
triclosan results in a disrupted ETC resulting in reduced ATP levels. The reduction in 
cellular ATP levels results in the characteristic non-pigmented microcolonies 
observed, thus the ATP concentration was determined in isolates.  It was clear that the 
levels were reduced in all SCV isolates. Thus the evidence suggests that the 
phenotype changes in SCVs are driven by basic energy insufficiency.  This has been 
suggested by others (Proctor et al., 2006), but none performed an ATP assay to 
confirm their supposition.  
All the SCV isolates were confirmed as S. aureus by both RAPD-PCR and Multiplex 
PCR and were also checked for phage sensitivity. 
 
7.1.2 Transduction and lysogen formation in S. aureus and SCVs 
Transduction of ciprofloxacin resistance (grlA) was observed into COL wildtype at a 
5-10-fold higher frequency than into SCV1 and about the same as previously reported 
(Stiffler et al. 1974). Transduction of rifampicin resistance (rpoB) into SCVs was 
reduced almost 10-fold. As transduction was significantly decreased into SCVs 
maybe this process is influenced by reduced ATP levels too. The data suggests that 
SCV strains will be less efficient in gene exchange by transduction in vivo.  
Transduction of GFP (sarA P2) by Φ80α-ALC1437 was not observed.  
The rate of formation of lysogens was examined. The COL wildtype strain of S. 
aureus and SCV3 both yielded a high number of lysogens (~68%) the remaining 
being resistant mutants. SCV 1 and SCV 2 provided a much lower proportion of 
lysogens (4-10%).  Although these strains were shown to have different intracellular 
ATP levels, there was no obvious relationship between cellular ATP levels and 
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lysogen formation. Consequently the frequency of lysogen formation (or that of 
resistance mutants) cannot be related to energy status.   
7.1.3 Physiological variety in small colony variants 
S. aureus has developed various strategies to enable its persistence within the host, 
particularly when under antimicrobial challenge, and one of those strategies is to 
generate subpopulations of small colony variants (SCVs) that are auxotrophic 
metabolic mutants (Proctor et al., 2006). Three SCV strains (SCV1, SCV2 and SCV3) 
were isolated from the MRSA strain, S. aureus COL on triclosan (Norville, 2010). 
These SCVs showed a reduction of intracellular ATP levels, pigment, catalase, 
coagulase and DNase activities. Their growth rate and maximum cell yield were also 
reduced. When examined all showed differences between themselves and the wild 
type.  
Such effects on SCVs have been noted previously (Proctor et al., 2006; Seaman et al., 
2007). If the electron transport chain is SCVs is not fully operational, an upregulation 
of glycolytic and fermentative pathways is required in order to generate ATP (Kohler 
et al., 2003). However in order to utilise other carbohydrates, a fully functional 
tricarboxylic acid cycle (TCA cycle) is required (von Eiff et al., 2006).  So if this is 
the case it would explain the differences in carbohydrate utilisation observed in these 
SCVs.  
The original hypothesis was that the SCV 1-3 had mutations in dissimilar loci. We 
assume these differentially effect cell yield and growth patterns. This we think reflects 
a difference in ATP metabolism and that this coincidently contributes to the 
physiological differences between the SCV isolates 1-3 (Day et al., 2012).  
A comparison of aerobic growth of the wildtype with the SCV isolates showed these 
had reduced growth. Interestingly anaerobic growth yields were almost the same. 
Thus all SCVs appear to be respiring as an anaerobic wild type and this explains why 
they obtain less energy per glucose molecule.  
7.1.4 Phenotypic switching 
The ability of S. aureus to switch to an alternative phenotype in the presence of 
antimicrobial agents is clearly favourable if it permits survival. SCVs have many 
characteristics that are associated with survival in unfavourable conditions. Various 
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reports of phenotypic switching have been reported in the literature, in the presence of 
antibiotics (Mitchell et al., 2010a). 
Formation of the SCV phenotype in S. aureus could be viewed as a phenotypic 
switching system which appears to be strongly influenced by the alternative sigma 
factor, σB (Mitchell et al., 2010a). This was one hypothesis we discussed early in the 
work, however the sequencing data on the cycling mutants discussed later suggests 
strongly that this is not involved 
7.1.5  Antibiotic susceptibility 
To have raised or lowered sensitivities to these inhibitors suggests that the mutations 
conferring the SCV phenotype co-incidently impacts on their tolerance or sensitivity 
to these inhibitors. Therefore to explain this change in sensitivity it is important to 
consider the potential physiological impact of reduced ATP generation capacity. The 
process of energy generation is closely tied to the proton pump operation.    
One inhibitor antimycin effects the Qi site of cytochrome and disrupts the the proton 
gradient across the inner membrane (Dairaku et al., 2004). The results show that the 
SCV strains are significantly more sensitive to antimycin for example. Thus it seems 
the relative lack of energy generation impairs their proton relationships and so makes 
them more sensitive. 
7.1.6 The cycling experiment   
This was planned to determine whether there was a single site-specific or multiple 
sites at which the SCV phenotype arose. Thus the genomic sequence of the final 
revertants (WT15) in the cycling experiment would provide the evidence for either 
hypothesis. Numerous changes at various sites would confirm the more random 
process, whilst no evidence of significant genomic change would suggest the site 
specific mechanism. 
Analysis of the sequences illustrate there are numerous changes to COL and N315 
genomes when compared to the parental sequenced strains. However some changes 
are historic.  That is they are present in the strain prior to the experiment. Thus 25 
mutations in COL and 8 mutations in N315 have arisen since the strain we obtained 
was originally sequenced. These strains have been cultured in our laboratory for over 
10 years and must logically have acquired spontaneous mutations in their genomes. 
Thus the mutations are probably not related to the cycling and selection steps in the 
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experiment, and are therefore historic. If this premise is accepted then those others are 
novel.  There are 5 (N315-TRI), 4 (N315-GEN), 10 (COL-TRI) and 21 (COL-GEN) 
novel mutations in the four strains.  
The sequencing data thus suggests that the site specific mutational mechanism is not 
operating.  The finding that there are not about 30 mutational changes in any of the 
final revertants genomes implies in many cases the cycled mutant selected was a true 
revertant.  Thus not many suppressed mutations were found.  
Methicillin resistance was confirmed for both N315 and COL by sequence genome of 
the mecA gene. Just one mutational site was found to be common between COL and 
N315. The mutation is in the fabI gene. It’s in the same gene but not at the same site 
and only occurred when selection was made on triclosan.  
 
7.1.7 How many SCV genes are there?   
The genomes of N315 and COL encode 2593 and 2615 protein genes. Since the 
genomes are much alike in gene content and sequence it was decided they could be 
seen as just one strain in this analysis, thus we combined the data.  The sequencing 
shows there are a total of 38 different genes in the two strains which give the SCV 
phenotype. Significantly only one is in common (fabI) and thus it is statistically 
improbable that there are no more.   
We determined 33 of the 2615 genes are concerned with SCV formation.  This is 
1.3% of the genome, a minimum of 40 Kb, is concerned with the SCV phenotype. 
Figure 7.1 shows the distribution of the mutations (genes) around the composite 
chromosome of COL and N315.  Figure 7.2 shows the locations of the historic 
mutations and most are located around 91185-2770880.  Why they are focus in this 
region is entirely unclear? One would expect these mutations to be randomly scattered 
throughout the chromosome and clearly without such a focus. 
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Figure 7.1 A composite of the chromosomes of COL and N315 showing the 
locations of the mutations conferring the SCV phenotype.  
 
 
 
Figure 7.2 Composite chromosomes of COL and N315 showing the locations of 
the historic mutations. 
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7.2 Conclusions 
 
 SCVs from S. aureus COL and N315 share characteristics with other S. aureus 
SCVs including altered growth and biochemical profiles.  
 S. aureus SCVs acquire and disseminate antimicrobial resistance by transduction 
with a normal frequency was 1-4 x10
-7
. 
 The frequency of phage 80α resistance was significantly different between SCV 
strains. 
 Lysate reproducibility was significantly lower with lysates from SCVs than from 
SCV lysogens.  
 Anaerobic growth was not significant different when S. aureus wildtype and 
SCVs were compared.   
 CCCP can select for SCVs in S. aureus COL. No SCVs were obtained from 
antimycin, oligomycin or heavy metal chloride salts.  
 The rate of ATP formation is important in SCV phenotype expression.  
 There is no evidence for phenotypic switching 
 Numerous and diverse mutations occurred in COL and N315 SCVs from the 
cycling strains (over 100 mutations). 
 There were 25 historical mutations in COL and 8 in N315. 
 Only one mutational site was found to be common between COL and N315 and 
this was in the fabI gene. 
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7.3  Future work  
 
 It is clear that the genetic mechanisms for forward to SCV and reversion to 
wildtype need to be defined by future investigations. The sequencing data shows 
there is a need to focus on metabolic pathways which are different to those 
involved with the thymidine biosynthesis.  How these deliver the SCV phenotype 
is a major question.   
 The sequencing data demands further analysis of the strains as there are still 
uncertainties in some of the mutations and how they operate to produce an SCV.  
 It is clear that SCVs have electron transport deficiencies.  So are these novel and 
unknown in SCV types that are clinically relevant?  There is a requirement to 
examine clinical strains now and make this determination. Since SCVs are not all 
the same metabolically there needs to be further study into their biochemistry and 
genetics. 
 What determines the differences in growth rate and physiology of S. aureus COL 
SCVs 1-3 strains has still to be explained fully. 
 This approach seems to provide the basis for the development of novel drugs for 
therapeutic treatment.  This is a clinical imperative, since the current drugs are 
becoming unusable through the development of microbial resistance.   
 4% of the genome (~ 40 Kb) is concerned with the SCV phenotype.  
 When I return home I intend to gain funding to further analyse the genomes of 
these SCV mutants.  These organisms have clinical relevance in Saudi Arabia as 
well as Europe and the ideas developed here may well help their treatment in my 
country. 
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Appendix 
 
Chapter 2 statistical analysis data - Multiple Comparisons 
 
1- Dependent Variable: Cycling  LSD 
 
(I) Strain (J) Strain Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
1 
2 -1039555555.4933* 354976756.3767 .004 
-
1742896495.51
4 
-336214615.473 
11 -118666666.6733 354976756.3767 .739 
-
822007606.694 
584674273.347 
22 -555111111.0933 354976756.3767 .121 
-
1258452051.11
4 
148229828.927 
111 112222222.2867 354976756.3767 .752 
-
591118717.734 
815563162.307 
222 -2208463644.6067* 354976756.3767 .000 
-
2911804584.62
7 
-1505122704.586 
1111 -132666666.6067 354976756.3767 .709 
-
836007606.627 
570674273.414 
2222 -1919555555.5400* 354976756.3767 .000 
-
2622896495.56
1 
-1216214615.519 
2 
1 1039555555.4933* 354976756.3767 .004 336214615.473 1742896495.514 
11 920888888.8200* 354976756.3767 .011 217547948.799 1624229828.841 
22 484444444.4000 354976756.3767 .175 
-
218896495.621 
1187785384.421 
111 1151777777.7800* 354976756.3767 .002 448436837.759 1855118717.801 
222 -1168908089.1133* 354976756.3767 .001 
-
1872249029.13
4 
-465567149.093 
1111 906888888.8867* 354976756.3767 .012 203547948.866 1610229828.907 
2222 -880000000.0467* 354976756.3767 .015 
-
1583340940.06
7 
-176659060.026 
11 
1 118666666.6733 354976756.3767 .739 
-
584674273.347 
822007606.694 
2 -920888888.8200* 354976756.3767 .011 
-
1624229828.84
1 
-217547948.799 
22 -436444444.4200 354976756.3767 .221 
-
1139785384.44
1 
266896495.601 
111 230888888.9600 354976756.3767 .517 
-
472452051.061 
934229828.981 
222 -2089796977.9333* 354976756.3767 .000 
-
2793137917.95
4 
-1386456037.913 
1111 -13999999.9333 354976756.3767 .969 
-
717340939.954 
689340940.087 
2222 -1800888888.8667* 354976756.3767 .000 
-
2504229828.88
7 
-1097547948.846 
22 
1 555111111.0933 354976756.3767 .121 
-
148229828.927 
1258452051.114 
2 -484444444.4000 354976756.3767 .175 
-
1187785384.42
1 
218896495.621 
11 436444444.4200 354976756.3767 .221 
-
266896495.601 
1139785384.441 
111 667333333.3800 354976756.3767 .063 -36007606.641 1370674273.401 
222 -1653352533.5133* 354976756.3767 .000 
-
2356693473.53
4 
-950011593.493 
1111 422444444.4867 354976756.3767 .237 
-
280896495.534 
1125785384.507 
2222 -1364444444.4467* 354976756.3767 .000 
-
2067785384.46
7 
-661103504.426 
111 1 -112222222.2867 354976756.3767 .752 
-
815563162.307 
591118717.734 
198 
 
2 -1151777777.7800* 354976756.3767 .002 
-
1855118717.80
1 
-448436837.759 
11 -230888888.9600 354976756.3767 .517 
-
934229828.981 
472452051.061 
22 -667333333.3800 354976756.3767 .063 
-
1370674273.40
1 
36007606.641 
222 -2320685866.8933* 354976756.3767 .000 
-
3024026806.91
4 
-1617344926.873 
1111 -244888888.8933 354976756.3767 .492 
-
948229828.914 
458452051.127 
2222 -2031777777.8267* 354976756.3767 .000 
-
2735118717.84
7 
-1328436837.806 
222 
1 2208463644.6067* 354976756.3767 .000 
1505122704.58
6 
2911804584.627 
2 1168908089.1133* 354976756.3767 .001 465567149.093 1872249029.134 
11 2089796977.9333* 354976756.3767 .000 
1386456037.91
3 
2793137917.954 
22 1653352533.5133* 354976756.3767 .000 950011593.493 2356693473.534 
111 2320685866.8933* 354976756.3767 .000 
1617344926.87
3 
3024026806.914 
1111 2075796978.0000* 354976756.3767 .000 
1372456037.97
9 
2779137918.021 
2222 288908089.0667 354976756.3767 .417 
-
414432850.954 
992249029.087 
1111 
1 132666666.6067 354976756.3767 .709 
-
570674273.414 
836007606.627 
2 -906888888.8867* 354976756.3767 .012 
-
1610229828.90
7 
-203547948.866 
11 13999999.9333 354976756.3767 .969 
-
689340940.087 
717340939.954 
22 -422444444.4867 354976756.3767 .237 
-
1125785384.50
7 
280896495.534 
111 244888888.8933 354976756.3767 .492 
-
458452051.127 
948229828.914 
222 -2075796978.0000* 354976756.3767 .000 
-
2779137918.02
1 
-1372456037.979 
2222 -1786888888.9333* 354976756.3767 .000 
-
2490229828.95
4 
-1083547948.913 
2222 
1 1919555555.5400* 354976756.3767 .000 
1216214615.51
9 
2622896495.561 
2 880000000.0467* 354976756.3767 .015 176659060.026 1583340940.067 
11 1800888888.8667* 354976756.3767 .000 
1097547948.84
6 
2504229828.887 
22 1364444444.4467* 354976756.3767 .000 661103504.426 2067785384.467 
111 2031777777.8267* 354976756.3767 .000 
1328436837.80
6 
2735118717.847 
222 -288908089.0667 354976756.3767 .417 
-
992249029.087 
414432850.954 
1111 1786888888.9333* 354976756.3767 .000 
1083547948.91
3 
2490229828.954 
 
 
*. The mean difference is significant at the 0.05 level. 
 
2- Dependent Variable: ATP  LSD 
(I) Strain (J) Strain Mean Difference (I-
J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
1 
2 -1620.333 939.988 .100 -3581.11 340.45 
11 10498.000* 939.988 .000 8537.22 12458.78 
22 12014.000* 939.988 .000 10053.22 13974.78 
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111 12751.000* 939.988 .000 10790.22 14711.78 
222 11691.667* 939.988 .000 9730.89 13652.45 
1111 20395.333* 939.988 .000 18434.55 22356.11 
2222 20966.333* 939.988 .000 19005.55 22927.11 
11111 21206.000* 939.988 .000 19245.22 23166.78 
22222 22815.333* 939.988 .000 20854.55 24776.11 
2 
1 1620.333 939.988 .100 -340.45 3581.11 
11 12118.333* 939.988 .000 10157.55 14079.11 
22 13634.333* 939.988 .000 11673.55 15595.11 
111 14371.333* 939.988 .000 12410.55 16332.11 
222 13312.000* 939.988 .000 11351.22 15272.78 
1111 22015.667* 939.988 .000 20054.89 23976.45 
2222 22586.667* 939.988 .000 20625.89 24547.45 
11111 22826.333* 939.988 .000 20865.55 24787.11 
22222 24435.667* 939.988 .000 22474.89 26396.45 
11 
1 -10498.000* 939.988 .000 -12458.78 -8537.22 
2 -12118.333* 939.988 .000 -14079.11 -10157.55 
22 1516.000 939.988 .122 -444.78 3476.78 
111 2253.000* 939.988 .026 292.22 4213.78 
222 1193.667 939.988 .219 -767.11 3154.45 
1111 9897.333* 939.988 .000 7936.55 11858.11 
2222 10468.333* 939.988 .000 8507.55 12429.11 
11111 10708.000* 939.988 .000 8747.22 12668.78 
22222 12317.333* 939.988 .000 10356.55 14278.11 
22 
1 -12014.000* 939.988 .000 -13974.78 -10053.22 
2 -13634.333* 939.988 .000 -15595.11 -11673.55 
11 -1516.000 939.988 .122 -3476.78 444.78 
111 737.000 939.988 .442 -1223.78 2697.78 
222 -322.333 939.988 .735 -2283.11 1638.45 
1111 8381.333* 939.988 .000 6420.55 10342.11 
2222 8952.333* 939.988 .000 6991.55 10913.11 
11111 9192.000* 939.988 .000 7231.22 11152.78 
22222 10801.333* 939.988 .000 8840.55 12762.11 
111 
1 -12751.000* 939.988 .000 -14711.78 -10790.22 
2 -14371.333* 939.988 .000 -16332.11 -12410.55 
11 -2253.000* 939.988 .026 -4213.78 -292.22 
22 -737.000 939.988 .442 -2697.78 1223.78 
222 -1059.333 939.988 .273 -3020.11 901.45 
1111 7644.333* 939.988 .000 5683.55 9605.11 
2222 8215.333* 939.988 .000 6254.55 10176.11 
11111 8455.000* 939.988 .000 6494.22 10415.78 
22222 10064.333* 939.988 .000 8103.55 12025.11 
222 
1 -11691.667* 939.988 .000 -13652.45 -9730.89 
2 -13312.000* 939.988 .000 -15272.78 -11351.22 
11 -1193.667 939.988 .219 -3154.45 767.11 
22 322.333 939.988 .735 -1638.45 2283.11 
111 1059.333 939.988 .273 -901.45 3020.11 
1111 8703.667* 939.988 .000 6742.89 10664.45 
2222 9274.667* 939.988 .000 7313.89 11235.45 
11111 9514.333* 939.988 .000 7553.55 11475.11 
22222 11123.667* 939.988 .000 9162.89 13084.45 
1111 
1 -20395.333* 939.988 .000 -22356.11 -18434.55 
2 -22015.667* 939.988 .000 -23976.45 -20054.89 
11 -9897.333* 939.988 .000 -11858.11 -7936.55 
22 -8381.333* 939.988 .000 -10342.11 -6420.55 
111 -7644.333* 939.988 .000 -9605.11 -5683.55 
222 -8703.667* 939.988 .000 -10664.45 -6742.89 
2222 571.000 939.988 .550 -1389.78 2531.78 
11111 810.667 939.988 .399 -1150.11 2771.45 
22222 2420.000* 939.988 .018 459.22 4380.78 
2222 
1 -20966.333* 939.988 .000 -22927.11 -19005.55 
2 -22586.667* 939.988 .000 -24547.45 -20625.89 
11 -10468.333* 939.988 .000 -12429.11 -8507.55 
22 -8952.333* 939.988 .000 -10913.11 -6991.55 
111 -8215.333* 939.988 .000 -10176.11 -6254.55 
222 -9274.667* 939.988 .000 -11235.45 -7313.89 
1111 -571.000 939.988 .550 -2531.78 1389.78 
11111 239.667 939.988 .801 -1721.11 2200.45 
22222 1849.000 939.988 .063 -111.78 3809.78 
11111 
1 -21206.000* 939.988 .000 -23166.78 -19245.22 
2 -22826.333* 939.988 .000 -24787.11 -20865.55 
11 -10708.000* 939.988 .000 -12668.78 -8747.22 
22 -9192.000* 939.988 .000 -11152.78 -7231.22 
111 -8455.000* 939.988 .000 -10415.78 -6494.22 
222 -9514.333* 939.988 .000 -11475.11 -7553.55 
1111 -810.667 939.988 .399 -2771.45 1150.11 
200 
 
2222 -239.667 939.988 .801 -2200.45 1721.11 
22222 1609.333 939.988 .102 -351.45 3570.11 
22222 
1 -22815.333* 939.988 .000 -24776.11 -20854.55 
2 -24435.667* 939.988 .000 -26396.45 -22474.89 
11 -12317.333* 939.988 .000 -14278.11 -10356.55 
22 -10801.333* 939.988 .000 -12762.11 -8840.55 
111 -10064.333* 939.988 .000 -12025.11 -8103.55 
222 -11123.667* 939.988 .000 -13084.45 -9162.89 
1111 -2420.000* 939.988 .018 -4380.78 -459.22 
2222 -1849.000 939.988 .063 -3809.78 111.78 
11111 -1609.333 939.988 .102 -3570.11 351.45 
*. The mean difference is significant at the 0.05 level. 
 
3- Dependent Variable: DNase  LSD 
(I) Strain (J) Strain Mean Difference (I-
J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
1 
2 1.1667* .4472 .017 .234 2.100 
11 3.0000* .4472 .000 2.067 3.933 
22 4.6667* .4472 .000 3.734 5.600 
111 2.3333* .4472 .000 1.400 3.266 
222 5.1667* .4472 .000 4.234 6.100 
1111 5.5000* .4472 .000 4.567 6.433 
2222 5.1667* .4472 .000 4.234 6.100 
11111 3.3333* .4472 .000 2.400 4.266 
22222 5.8333* .4472 .000 4.900 6.766 
2 
1 -1.1667* .4472 .017 -2.100 -.234 
11 1.8333* .4472 .001 .900 2.766 
22 3.5000* .4472 .000 2.567 4.433 
111 1.1667* .4472 .017 .234 2.100 
222 4.0000* .4472 .000 3.067 4.933 
1111 4.3333* .4472 .000 3.400 5.266 
2222 4.0000* .4472 .000 3.067 4.933 
11111 2.1667* .4472 .000 1.234 3.100 
22222 4.6667* .4472 .000 3.734 5.600 
11 
1 -3.0000* .4472 .000 -3.933 -2.067 
2 -1.8333* .4472 .001 -2.766 -.900 
22 1.6667* .4472 .001 .734 2.600 
111 -.6667 .4472 .152 -1.600 .266 
222 2.1667* .4472 .000 1.234 3.100 
1111 2.5000* .4472 .000 1.567 3.433 
2222 2.1667* .4472 .000 1.234 3.100 
11111 .3333 .4472 .465 -.600 1.266 
22222 2.8333* .4472 .000 1.900 3.766 
22 
1 -4.6667* .4472 .000 -5.600 -3.734 
2 -3.5000* .4472 .000 -4.433 -2.567 
11 -1.6667* .4472 .001 -2.600 -.734 
111 -2.3333* .4472 .000 -3.266 -1.400 
222 .5000 .4472 .277 -.433 1.433 
1111 .8333 .4472 .077 -.100 1.766 
2222 .5000 .4472 .277 -.433 1.433 
11111 -1.3333* .4472 .007 -2.266 -.400 
22222 1.1667* .4472 .017 .234 2.100 
111 
1 -2.3333* .4472 .000 -3.266 -1.400 
2 -1.1667* .4472 .017 -2.100 -.234 
11 .6667 .4472 .152 -.266 1.600 
22 2.3333* .4472 .000 1.400 3.266 
222 2.8333* .4472 .000 1.900 3.766 
1111 3.1667* .4472 .000 2.234 4.100 
2222 2.8333* .4472 .000 1.900 3.766 
11111 1.0000* .4472 .037 .067 1.933 
22222 3.5000* .4472 .000 2.567 4.433 
222 
1 -5.1667* .4472 .000 -6.100 -4.234 
2 -4.0000* .4472 .000 -4.933 -3.067 
11 -2.1667* .4472 .000 -3.100 -1.234 
22 -.5000 .4472 .277 -1.433 .433 
111 -2.8333* .4472 .000 -3.766 -1.900 
1111 .3333 .4472 .465 -.600 1.266 
1 11 111 1111 11111 2 22 222 2222 22222 
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WT 15 
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WT00 
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2222 .0000 .4472 1.000 -.933 .933 
11111 -1.8333* .4472 .001 -2.766 -.900 
22222 .6667 .4472 .152 -.266 1.600 
1111 
1 -5.5000* .4472 .000 -6.433 -4.567 
2 -4.3333* .4472 .000 -5.266 -3.400 
11 -2.5000* .4472 .000 -3.433 -1.567 
22 -.8333 .4472 .077 -1.766 .100 
111 -3.1667* .4472 .000 -4.100 -2.234 
222 -.3333 .4472 .465 -1.266 .600 
2222 -.3333 .4472 .465 -1.266 .600 
11111 -2.1667* .4472 .000 -3.100 -1.234 
22222 .3333 .4472 .465 -.600 1.266 
2222 
1 -5.1667* .4472 .000 -6.100 -4.234 
2 -4.0000* .4472 .000 -4.933 -3.067 
11 -2.1667* .4472 .000 -3.100 -1.234 
22 -.5000 .4472 .277 -1.433 .433 
111 -2.8333* .4472 .000 -3.766 -1.900 
222 .0000 .4472 1.000 -.933 .933 
1111 .3333 .4472 .465 -.600 1.266 
11111 -1.8333* .4472 .001 -2.766 -.900 
22222 .6667 .4472 .152 -.266 1.600 
11111 
1 -3.3333* .4472 .000 -4.266 -2.400 
2 -2.1667* .4472 .000 -3.100 -1.234 
11 -.3333 .4472 .465 -1.266 .600 
22 1.3333* .4472 .007 .400 2.266 
111 -1.0000* .4472 .037 -1.933 -.067 
222 1.8333* .4472 .001 .900 2.766 
1111 2.1667* .4472 .000 1.234 3.100 
2222 1.8333* .4472 .001 .900 2.766 
22222 2.5000* .4472 .000 1.567 3.433 
22222 
1 -5.8333* .4472 .000 -6.766 -4.900 
2 -4.6667* .4472 .000 -5.600 -3.734 
11 -2.8333* .4472 .000 -3.766 -1.900 
22 -1.1667* .4472 .017 -2.100 -.234 
111 -3.5000* .4472 .000 -4.433 -2.567 
222 -.6667 .4472 .152 -1.600 .266 
1111 -.3333 .4472 .465 -1.266 .600 
2222 -.6667 .4472 .152 -1.600 .266 
11111 -2.5000* .4472 .000 -3.433 -1.567 
*. The mean difference is significant at the 0.05 level. 
 
 
4- Dependent Variable: Pigment  LSD 
(I) Strain (J) Strain Mean Difference (I-
J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
1 
2 -.020000* .006561 .006 -.03369 -.00631 
11 .041333* .006561 .000 .02765 .05502 
22 .025000* .006561 .001 .01131 .03869 
111 .069000* .006561 .000 .05531 .08269 
222 .016000* .006561 .024 .00231 .02969 
1111 .115000* .006561 .000 .10131 .12869 
2222 .067000* .006561 .000 .05331 .08069 
11111 .150000* .006561 .000 .13631 .16369 
22222 .049667* .006561 .000 .03598 .06335 
2 
1 .020000* .006561 .006 .00631 .03369 
11 .061333* .006561 .000 .04765 .07502 
22 .045000* .006561 .000 .03131 .05869 
111 .089000* .006561 .000 .07531 .10269 
222 .036000* .006561 .000 .02231 .04969 
1111 .135000* .006561 .000 .12131 .14869 
2222 .087000* .006561 .000 .07331 .10069 
11111 .170000* .006561 .000 .15631 .18369 
22222 .069667* .006561 .000 .05598 .08335 
11 
1 -.041333* .006561 .000 -.05502 -.02765 
2 -.061333* .006561 .000 -.07502 -.04765 
22 -.016333* .006561 .022 -.03002 -.00265 
111 .027667* .006561 .000 .01398 .04135 
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222 -.025333* .006561 .001 -.03902 -.01165 
1111 .073667* .006561 .000 .05998 .08735 
2222 .025667* .006561 .001 .01198 .03935 
11111 .108667* .006561 .000 .09498 .12235 
22222 .008333 .006561 .219 -.00535 .02202 
22 
1 -.025000* .006561 .001 -.03869 -.01131 
2 -.045000* .006561 .000 -.05869 -.03131 
11 .016333* .006561 .022 .00265 .03002 
111 .044000* .006561 .000 .03031 .05769 
222 -.009000 .006561 .185 -.02269 .00469 
1111 .090000* .006561 .000 .07631 .10369 
2222 .042000* .006561 .000 .02831 .05569 
11111 .125000* .006561 .000 .11131 .13869 
22222 .024667* .006561 .001 .01098 .03835 
111 
1 -.069000* .006561 .000 -.08269 -.05531 
2 -.089000* .006561 .000 -.10269 -.07531 
11 -.027667* .006561 .000 -.04135 -.01398 
22 -.044000* .006561 .000 -.05769 -.03031 
222 -.053000* .006561 .000 -.06669 -.03931 
1111 .046000* .006561 .000 .03231 .05969 
2222 -.002000 .006561 .764 -.01569 .01169 
11111 .081000* .006561 .000 .06731 .09469 
22222 -.019333* .006561 .008 -.03302 -.00565 
222 
1 -.016000* .006561 .024 -.02969 -.00231 
2 -.036000* .006561 .000 -.04969 -.02231 
11 .025333* .006561 .001 .01165 .03902 
22 .009000 .006561 .185 -.00469 .02269 
111 .053000* .006561 .000 .03931 .06669 
1111 .099000* .006561 .000 .08531 .11269 
2222 .051000* .006561 .000 .03731 .06469 
11111 .134000* .006561 .000 .12031 .14769 
22222 .033667* .006561 .000 .01998 .04735 
1111 
1 -.115000* .006561 .000 -.12869 -.10131 
2 -.135000* .006561 .000 -.14869 -.12131 
11 -.073667* .006561 .000 -.08735 -.05998 
22 -.090000* .006561 .000 -.10369 -.07631 
111 -.046000* .006561 .000 -.05969 -.03231 
222 -.099000* .006561 .000 -.11269 -.08531 
2222 -.048000* .006561 .000 -.06169 -.03431 
11111 .035000* .006561 .000 .02131 .04869 
22222 -.065333* .006561 .000 -.07902 -.05165 
2222 
1 -.067000* .006561 .000 -.08069 -.05331 
2 -.087000* .006561 .000 -.10069 -.07331 
11 -.025667* .006561 .001 -.03935 -.01198 
22 -.042000* .006561 .000 -.05569 -.02831 
111 .002000 .006561 .764 -.01169 .01569 
222 -.051000* .006561 .000 -.06469 -.03731 
1111 .048000* .006561 .000 .03431 .06169 
11111 .083000* .006561 .000 .06931 .09669 
22222 -.017333* .006561 .016 -.03102 -.00365 
11111 
1 -.150000* .006561 .000 -.16369 -.13631 
2 -.170000* .006561 .000 -.18369 -.15631 
11 -.108667* .006561 .000 -.12235 -.09498 
22 -.125000* .006561 .000 -.13869 -.11131 
111 -.081000* .006561 .000 -.09469 -.06731 
222 -.134000* .006561 .000 -.14769 -.12031 
1111 -.035000* .006561 .000 -.04869 -.02131 
2222 -.083000* .006561 .000 -.09669 -.06931 
22222 -.100333* .006561 .000 -.11402 -.08665 
22222 
1 -.049667* .006561 .000 -.06335 -.03598 
2 -.069667* .006561 .000 -.08335 -.05598 
11 -.008333 .006561 .219 -.02202 .00535 
22 -.024667* .006561 .001 -.03835 -.01098 
111 .019333* .006561 .008 .00565 .03302 
222 -.033667* .006561 .000 -.04735 -.01998 
1111 .065333* .006561 .000 .05165 .07902 
2222 .017333* .006561 .016 .00365 .03102 
11111 .100333* .006561 .000 .08665 .11402 
*. The mean difference is significant at the 0.05 level. 
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5- Dependent Variable: MIC   LSD 
(I) Strain (J) Strain Mean Difference (I-
J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
1 
2 -.05000000* .02043473 .031 -.0945234 -.0054766 
11 .21875000* .02043473 .000 .1742266 .2632734 
22 .21875000* .02043473 .000 .1742266 .2632734 
2 
1 .05000000* .02043473 .031 .0054766 .0945234 
11 .26875000* .02043473 .000 .2242266 .3132734 
22 .26875000* .02043473 .000 .2242266 .3132734 
11 
1 -.21875000* .02043473 .000 -.2632734 -.1742266 
2 -.26875000* .02043473 .000 -.3132734 -.2242266 
22 0E-8 .02043473 1.000 -.0445234 .0445234 
22 
1 -.21875000* .02043473 .000 -.2632734 -.1742266 
2 -.26875000* .02043473 .000 -.3132734 -.2242266 
11 0E-8 .02043473 1.000 -.0445234 .0445234 
*. The mean difference is significant at the 0.05 level. 
1 11 2 22 
COL 
GEN 
COL 
TRI 
N315 
GEN 
N315 
TRI 
 
 
6- Dependent Variable: Phage yield   LSD 
(I) Strains (J) Strains Mean Difference (I-
J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
1 
2 
-
169999999.9999999
70* 
37505555.14409388
0 
.000 
-
248235217.0999908
0 
-
91764782.90000916 
11 
73333333.33333334
0 
37505555.14409388
0 
.065 -4901883.76665747 
151568550.4333241
6 
22 
-
96666666.66666666
0* 
37505555.14409388
0 
.018 
-
174901883.7666574
7 
-
18431449.56667585 
111 
106666666.6666666
90* 
37505555.14409388
0 
.010 28431449.56667588 
184901883.7666575
0 
222 
-
136666666.6666666
60* 
37505555.14409388
0 
.002 
-
214901883.7666574
7 
-
58431449.56667585 
1111 
136666666.6666667
00* 
37505555.14409388
0 
.002 58431449.56667586 
214901883.7666574
7 
2222 
-
23333333.33333334
3 
37505555.14409388
0 
.541 
-
101568550.4333241
6 
54901883.76665746 
11111 
103333333.3333333
40* 
37505555.14409388
0 
.012 25098116.23334254 
181568550.4333241
6 
22222 
40000000.00000000
0 
37505555.14409388
0 
.299 
-
38235217.09999081 
118235217.0999908
1 
2 
1 
169999999.9999999
70* 
37505555.14409388
0 
.000 91764782.90000916 
248235217.0999908
0 
11 
243333333.3333333
00* 
37505555.14409388
0 
.000 
165098116.2333425
0 
321568550.4333241
0 
22 
73333333.33333331
0 
37505555.14409388
0 
.065 -4901883.76665750 
151568550.4333241
3 
111 
276666666.6666666
00* 
37505555.14409388
0 
.000 
198431449.5666758
4 
354901883.7666575
0 
222 
33333333.33333331
3 
37505555.14409388
0 
.385 
-
44901883.76665749 
111568550.4333241
3 
1111 
306666666.6666666
00* 
37505555.14409388
0 
.000 
228431449.5666758
4 
384901883.7666575
0 
2222 
146666666.6666666
30* 
37505555.14409388
0 
.001 68431449.56667581 
224901883.7666574
4 
11111 
273333333.3333333
00* 
37505555.14409388
0 
.000 
195098116.2333425
0 
351568550.4333241
0 
22222 
209999999.9999999
70* 
37505555.14409388
0 
.000 
131764782.9000091
6 
288235217.0999908
0 
11 1 
-
73333333.33333334
0 
37505555.14409388
0 
.065 
-
151568550.4333241
6 
4901883.76665747 
204 
 
2 
-
243333333.3333333
00* 
37505555.14409388
0 
.000 
-
321568550.4333241
0 
-
165098116.2333425
0 
22 
-
170000000.0000000
00* 
37505555.14409388
0 
.000 
-
248235217.0999908
1 
-
91764782.90000919 
111 
33333333.33333334
3 
37505555.14409388
0 
.385 
-
44901883.76665746 
111568550.4333241
6 
222 
-
210000000.0000000
00* 
37505555.14409388
0 
.000 
-
288235217.0999908
0 
-
131764782.9000091
9 
1111 
63333333.33333333
0 
37505555.14409388
0 
.107 
-
14901883.76665748 
141568550.4333241
3 
2222 
-
96666666.66666669
0* 
37505555.14409388
0 
.018 
-
174901883.7666575
0 
-
18431449.56667588 
11111 
30000000.00000000
0 
37505555.14409388
0 
.433 
-
48235217.09999081 
108235217.0999908
1 
22222 
-
33333333.33333334
3 
37505555.14409388
0 
.385 
-
111568550.4333241
6 
44901883.76665746 
22 
1 
96666666.66666666
0* 
37505555.14409388
0 
.018 18431449.56667585 
174901883.7666574
7 
2 
-
73333333.33333331
0 
37505555.14409388
0 
.065 
-
151568550.4333241
3 
4901883.76665750 
11 
170000000.0000000
00* 
37505555.14409388
0 
.000 91764782.90000919 
248235217.0999908
1 
111 
203333333.3333333
40* 
37505555.14409388
0 
.000 
125098116.2333425
3 
281568550.4333241
6 
222 
-
40000000.00000000
0 
37505555.14409388
0 
.299 
-
118235217.0999908
1 
38235217.09999081 
1111 
233333333.3333333
00* 
37505555.14409388
0 
.000 
155098116.2333425
3 
311568550.4333241
6 
2222 
73333333.33333331
0 
37505555.14409388
0 
.065 -4901883.76665750 
151568550.4333241
3 
11111 
200000000.0000000
00* 
37505555.14409388
0 
.000 
121764782.9000091
9 
278235217.0999908
0 
22222 
136666666.6666666
60* 
37505555.14409388
0 
.002 58431449.56667585 
214901883.7666574
7 
111 
1 
-
106666666.6666666
90* 
37505555.14409388
0 
.010 
-
184901883.7666575
0 
-
28431449.56667588 
2 
-
276666666.6666666
00* 
37505555.14409388
0 
.000 
-
354901883.7666575
0 
-
198431449.5666758
4 
11 
-
33333333.33333334
3 
37505555.14409388
0 
.385 
-
111568550.4333241
6 
44901883.76665746 
22 
-
203333333.3333333
40* 
37505555.14409388
0 
.000 
-
281568550.4333241
6 
-
125098116.2333425
3 
222 
-
243333333.3333333
40* 
37505555.14409388
0 
.000 
-
321568550.4333241
6 
-
165098116.2333425
3 
1111 
29999999.99999998
5 
37505555.14409388
0 
.433 
-
48235217.09999082 
108235217.0999908
0 
2222 
-
130000000.0000000
30* 
37505555.14409388
0 
.002 
-
208235217.0999908
4 
-
51764782.90000922 
11111 
-
3333333.333333343 
37505555.14409388
0 
.930 
-
81568550.43332416 
74901883.76665747 
22222 
-
66666666.66666669
0 
37505555.14409388
0 
.091 
-
144901883.7666575
0 
11568550.43332412 
222 
1 
136666666.6666666
60* 
37505555.14409388
0 
.002 58431449.56667585 
214901883.7666574
7 
2 
-
33333333.33333331
3 
37505555.14409388
0 
.385 
-
111568550.4333241
3 
44901883.76665749 
11 
210000000.0000000
00* 
37505555.14409388
0 
.000 
131764782.9000091
9 
288235217.0999908
0 
22 
40000000.00000000
0 
37505555.14409388
0 
.299 
-
38235217.09999081 
118235217.0999908
1 
111 
243333333.3333333
40* 
37505555.14409388
0 
.000 
165098116.2333425
3 
321568550.4333241
6 
205 
 
1111 
273333333.3333333
00* 
37505555.14409388
0 
.000 
195098116.2333425
3 
351568550.4333241
6 
2222 
113333333.3333333
10* 
37505555.14409388
0 
.007 35098116.23334251 
191568550.4333241
3 
11111 
240000000.0000000
00* 
37505555.14409388
0 
.000 
161764782.9000091
9 
318235217.0999908
0 
22222 
176666666.6666666
60* 
37505555.14409388
0 
.000 98431449.56667584 
254901883.7666574
7 
1111 
1 
-
136666666.6666667
00* 
37505555.14409388
0 
.002 
-
214901883.7666574
7 
-
58431449.56667586 
2 
-
306666666.6666666
00* 
37505555.14409388
0 
.000 
-
384901883.7666575
0 
-
228431449.5666758
4 
11 
-
63333333.33333333
0 
37505555.14409388
0 
.107 
-
141568550.4333241
3 
14901883.76665748 
22 
-
233333333.3333333
00* 
37505555.14409388
0 
.000 
-
311568550.4333241
6 
-
155098116.2333425
3 
111 
-
29999999.99999998
5 
37505555.14409388
0 
.433 
-
108235217.0999908
0 
48235217.09999082 
222 
-
273333333.3333333
00* 
37505555.14409388
0 
.000 
-
351568550.4333241
6 
-
195098116.2333425
3 
2222 
-
160000000.0000000
00* 
37505555.14409388
0 
.000 
-
238235217.0999908
1 
-
81764782.90000920 
11111 
-
33333333.33333333
0 
37505555.14409388
0 
.385 
-
111568550.4333241
4 
44901883.76665748 
22222 
-
96666666.66666667
0* 
37505555.14409388
0 
.018 
-
174901883.7666574
7 
-
18431449.56667586 
2222 
1 
23333333.33333334
3 
37505555.14409388
0 
.541 
-
54901883.76665746 
101568550.4333241
6 
2 
-
146666666.6666666
30* 
37505555.14409388
0 
.001 
-
224901883.7666574
4 
-
68431449.56667581 
11 
96666666.66666669
0* 
37505555.14409388
0 
.018 18431449.56667588 
174901883.7666575
0 
22 
-
73333333.33333331
0 
37505555.14409388
0 
.065 
-
151568550.4333241
3 
4901883.76665750 
111 
130000000.0000000
30* 
37505555.14409388
0 
.002 51764782.90000922 
208235217.0999908
4 
222 
-
113333333.3333333
10* 
37505555.14409388
0 
.007 
-
191568550.4333241
3 
-
35098116.23334251 
1111 
160000000.0000000
00* 
37505555.14409388
0 
.000 81764782.90000920 
238235217.0999908
1 
11111 
126666666.6666666
90* 
37505555.14409388
0 
.003 48431449.56667588 
204901883.7666575
0 
22222 
63333333.33333334
0 
37505555.14409388
0 
.107 
-
14901883.76665746 
141568550.4333241
6 
11111 
1 
-
103333333.3333333
40* 
37505555.14409388
0 
.012 
-
181568550.4333241
6 
-
25098116.23334254 
2 
-
273333333.3333333
00* 
37505555.14409388
0 
.000 
-
351568550.4333241
0 
-
195098116.2333425
0 
11 
-
30000000.00000000
0 
37505555.14409388
0 
.433 
-
108235217.0999908
1 
48235217.09999081 
22 
-
200000000.0000000
00* 
37505555.14409388
0 
.000 
-
278235217.0999908
0 
-
121764782.9000091
9 
111 3333333.333333343 
37505555.14409388
0 
.930 
-
74901883.76665747 
81568550.43332416 
222 
-
240000000.0000000
00* 
37505555.14409388
0 
.000 
-
318235217.0999908
0 
-
161764782.9000091
9 
1111 
33333333.33333333
0 
37505555.14409388
0 
.385 
-
44901883.76665748 
111568550.4333241
4 
206 
 
2222 
-
126666666.6666666
90* 
37505555.14409388
0 
.003 
-
204901883.7666575
0 
-
48431449.56667588 
22222 
-
63333333.33333334
0 
37505555.14409388
0 
.107 
-
141568550.4333241
6 
14901883.76665746 
22222 
1 
-
40000000.00000000
0 
37505555.14409388
0 
.299 
-
118235217.0999908
1 
38235217.09999081 
2 
-
209999999.9999999
70* 
37505555.14409388
0 
.000 
-
288235217.0999908
0 
-
131764782.9000091
6 
11 
33333333.33333334
3 
37505555.14409388
0 
.385 
-
44901883.76665746 
111568550.4333241
6 
22 
-
136666666.6666666
60* 
37505555.14409388
0 
.002 
-
214901883.7666574
7 
-
58431449.56667585 
111 
66666666.66666669
0 
37505555.14409388
0 
.091 
-
11568550.43332412 
144901883.7666575
0 
222 
-
176666666.6666666
60* 
37505555.14409388
0 
.000 
-
254901883.7666574
7 
-
98431449.56667584 
1111 
96666666.66666667
0* 
37505555.14409388
0 
.018 18431449.56667586 
174901883.7666574
7 
2222 
-
63333333.33333334
0 
37505555.14409388
0 
.107 
-
141568550.4333241
6 
14901883.76665746 
11111 
63333333.33333334
0 
37505555.14409388
0 
.107 
-
14901883.76665746 
141568550.4333241
6 
*. The mean difference is significant at the 0.05 level. 
 
7- Dependent Variable: Growth rate  
 LSD 
(I) Strains (J) Strains Mean Difference (I-
J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
1 
2 -.0376667 .2138752 .861 -.463292 .387959 
11 .0839778 .2138752 .696 -.341647 .509603 
22 .0873444 .2138752 .684 -.338281 .512970 
111 .0899333 .2138752 .675 -.335692 .515559 
222 .0402222 .2138752 .851 -.385403 .465847 
1111 .3797778 .2138752 .080 -.045847 .805403 
2222 .3587778 .2138752 .097 -.066847 .784403 
11111 .4028889 .2138752 .063 -.022736 .828514 
22222 .3708889 .2138752 .087 -.054736 .796514 
2 
1 .0376667 .2138752 .861 -.387959 .463292 
11 .1216444 .2138752 .571 -.303981 .547270 
22 .1250111 .2138752 .561 -.300614 .550636 
111 .1276000 .2138752 .552 -.298025 .553225 
222 .0778889 .2138752 .717 -.347736 .503514 
1111 .4174444 .2138752 .054 -.008181 .843070 
2222 .3964444 .2138752 .067 -.029181 .822070 
11111 .4405556* .2138752 .043 .014930 .866181 
22222 .4085556 .2138752 .060 -.017070 .834181 
11 
1 -.0839778 .2138752 .696 -.509603 .341647 
2 -.1216444 .2138752 .571 -.547270 .303981 
22 .0033667 .2138752 .987 -.422259 .428992 
111 .0059556 .2138752 .978 -.419670 .431581 
222 -.0437556 .2138752 .838 -.469381 .381870 
1111 .2958000 .2138752 .170 -.129825 .721425 
2222 .2748000 .2138752 .203 -.150825 .700425 
11111 .3189111 .2138752 .140 -.106714 .744536 
22222 .2869111 .2138752 .184 -.138714 .712536 
22 
1 -.0873444 .2138752 .684 -.512970 .338281 
2 -.1250111 .2138752 .561 -.550636 .300614 
11 -.0033667 .2138752 .987 -.428992 .422259 
1 11 111 1111 11111 2 22 222 2222 22222 
COL-WT 
00 
WT 15 
COL-
GEN 
WT 15 
COL-
TRI 
SCV 15 
COL-
GEN 
SCV 15 
COL-
TRI 
N315 
WT00 
WT 15 
N315-
GEN 
WT 15 
N315-
TRI 
SCV 15 
N315-
GEN 
SCV 
15N315-
TRI 
207 
 
111 .0025889 .2138752 .990 -.423036 .428214 
222 -.0471222 .2138752 .826 -.472747 .378503 
1111 .2924333 .2138752 .175 -.133192 .718059 
2222 .2714333 .2138752 .208 -.154192 .697059 
11111 .3155444 .2138752 .144 -.110081 .741170 
22222 .2835444 .2138752 .189 -.142081 .709170 
111 
1 -.0899333 .2138752 .675 -.515559 .335692 
2 -.1276000 .2138752 .552 -.553225 .298025 
11 -.0059556 .2138752 .978 -.431581 .419670 
22 -.0025889 .2138752 .990 -.428214 .423036 
222 -.0497111 .2138752 .817 -.475336 .375914 
1111 .2898444 .2138752 .179 -.135781 .715470 
2222 .2688444 .2138752 .212 -.156781 .694470 
11111 .3129556 .2138752 .147 -.112670 .738581 
22222 .2809556 .2138752 .193 -.144670 .706581 
222 
1 -.0402222 .2138752 .851 -.465847 .385403 
2 -.0778889 .2138752 .717 -.503514 .347736 
11 .0437556 .2138752 .838 -.381870 .469381 
22 .0471222 .2138752 .826 -.378503 .472747 
111 .0497111 .2138752 .817 -.375914 .475336 
1111 .3395556 .2138752 .116 -.086070 .765181 
2222 .3185556 .2138752 .140 -.107070 .744181 
11111 .3626667 .2138752 .094 -.062959 .788292 
22222 .3306667 .2138752 .126 -.094959 .756292 
1111 
1 -.3797778 .2138752 .080 -.805403 .045847 
2 -.4174444 .2138752 .054 -.843070 .008181 
11 -.2958000 .2138752 .170 -.721425 .129825 
22 -.2924333 .2138752 .175 -.718059 .133192 
111 -.2898444 .2138752 .179 -.715470 .135781 
222 -.3395556 .2138752 .116 -.765181 .086070 
2222 -.0210000 .2138752 .922 -.446625 .404625 
11111 .0231111 .2138752 .914 -.402514 .448736 
22222 -.0088889 .2138752 .967 -.434514 .416736 
2222 
1 -.3587778 .2138752 .097 -.784403 .066847 
2 -.3964444 .2138752 .067 -.822070 .029181 
11 -.2748000 .2138752 .203 -.700425 .150825 
22 -.2714333 .2138752 .208 -.697059 .154192 
111 -.2688444 .2138752 .212 -.694470 .156781 
222 -.3185556 .2138752 .140 -.744181 .107070 
1111 .0210000 .2138752 .922 -.404625 .446625 
11111 .0441111 .2138752 .837 -.381514 .469736 
22222 .0121111 .2138752 .955 -.413514 .437736 
11111 
1 -.4028889 .2138752 .063 -.828514 .022736 
2 -.4405556* .2138752 .043 -.866181 -.014930 
11 -.3189111 .2138752 .140 -.744536 .106714 
22 -.3155444 .2138752 .144 -.741170 .110081 
111 -.3129556 .2138752 .147 -.738581 .112670 
222 -.3626667 .2138752 .094 -.788292 .062959 
1111 -.0231111 .2138752 .914 -.448736 .402514 
2222 -.0441111 .2138752 .837 -.469736 .381514 
22222 -.0320000 .2138752 .881 -.457625 .393625 
22222 
1 -.3708889 .2138752 .087 -.796514 .054736 
2 -.4085556 .2138752 .060 -.834181 .017070 
11 -.2869111 .2138752 .184 -.712536 .138714 
22 -.2835444 .2138752 .189 -.709170 .142081 
111 -.2809556 .2138752 .193 -.706581 .144670 
222 -.3306667 .2138752 .126 -.756292 .094959 
1111 .0088889 .2138752 .967 -.416736 .434514 
2222 -.0121111 .2138752 .955 -.437736 .413514 
11111 .0320000 .2138752 .881 -.393625 .457625 
*. The mean difference is significant at the 0.05 level. 
 
 
 
8- Dependent Variable: Max cell  
 LSD 
(I) Strains (J) Strains Mean Difference (I-
J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
1 11 111 1111 11111 2 22 222 2222 22222 
COL-WT 
00 
WT 15 
COL-
GEN 
WT 15 
COL-
TRI 
SCV 15 
COL-
GEN 
SCV 15 
COL-
TRI 
N315 
WT00 
WT 15 
N315-
GEN 
WT 15 
N315-
TRI 
SCV 15 
N315-
GEN 
SCV 
15N315-TRI 
208 
 
1 
2 
-
2333333333.33333
3500* 
371280067.993002
950 
.000 
-
3107809983.86509
040 
-
1558856682.80157
660 
11 
-
66666666.6666669
85 
371280067.993002
950 
.859 
-
841143317.198423
90 
707809983.865089
90 
22 
300000000.000000
000 
371280067.993002
950 
.429 
-
474476650.531756
80 
1074476650.53175
690 
111 
466666666.666666
500 
371280067.993002
950 
.223 
-
307809983.865090
30 
1241143317.19842
340 
222 
699999999.999999
800 
371280067.993002
950 
.074 
-
74476650.5317570
7 
1474476650.53175
660 
1111 
1933333333.33333
3000* 
371280067.993002
950 
.000 
1158856682.80157
640 
2707809983.86509
000 
2222 
1846666666.66666
6500* 
371280067.993002
950 
.000 
1072190016.13490
960 
2621143317.19842
340 
11111 
1489999999.99999
9800* 
371280067.993002
950 
.001 
715523349.468242
90 
2264476650.53175
640 
22222 
1940000000.00000
0000* 
371280067.993002
950 
.000 
1165523349.46824
310 
2714476650.53175
700 
2 
1 
2333333333.33333
3500* 
371280067.993002
950 
.000 
1558856682.80157
660 
3107809983.86509
040 
11 
2266666666.66666
6500* 
371280067.993002
950 
.000 
1492190016.13490
960 
3041143317.19842
340 
22 
2633333333.33333
3500* 
371280067.993002
950 
.000 
1858856682.80157
660 
3407809983.86509
040 
111 
2800000000.00000
0000* 
371280067.993002
950 
.000 
2025523349.46824
310 
3574476650.53175
700 
222 
3033333333.33333
3000* 
371280067.993002
950 
.000 
2258856682.80157
660 
3807809983.86509
000 
1111 
4266666666.66666
6500* 
371280067.993002
950 
.000 
3492190016.13490
960 
5041143317.19842
300 
2222 
4180000000.00000
0000* 
371280067.993002
950 
.000 
3405523349.46824
300 
4954476650.53175
600 
11111 
3823333333.33333
3000* 
371280067.993002
950 
.000 
3048856682.80157
660 
4597809983.86509
000 
22222 
4273333333.33333
3500* 
371280067.993002
950 
.000 
3498856682.80157
660 
5047809983.86509
000 
11 
1 
66666666.6666669
85 
371280067.993002
950 
.859 
-
707809983.865089
90 
841143317.198423
90 
2 
-
2266666666.66666
6500* 
371280067.993002
950 
.000 
-
3041143317.19842
340 
-
1492190016.13490
960 
22 
366666666.666667
000 
371280067.993002
950 
.335 
-
407809983.865089
83 
1141143317.19842
390 
111 
533333333.333333
500 
371280067.993002
950 
.166 
-
241143317.198423
36 
1307809983.86509
040 
222 
766666666.666666
700 
371280067.993002
950 
.052 -7809983.86509009 
1541143317.19842
360 
1111 
2000000000.00000
0000* 
371280067.993002
950 
.000 
1225523349.46824
340 
2774476650.53175
700 
2222 
1913333333.33333
3500* 
371280067.993002
950 
.000 
1138856682.80157
660 
2687809983.86509
040 
11111 
1556666666.66666
6700* 
371280067.993002
950 
.000 
782190016.134909
90 
2331143317.19842
340 
22222 
2006666666.66666
7000* 
371280067.993002
950 
.000 
1232190016.13491
000 
2781143317.19842
400 
22 
1 
-
300000000.000000
000 
371280067.993002
950 
.429 
-
1074476650.53175
690 
474476650.531756
80 
2 
-
2633333333.33333
3500* 
371280067.993002
950 
.000 
-
3407809983.86509
040 
-
1858856682.80157
660 
11 
-
366666666.666667
000 
371280067.993002
950 
.335 
-
1141143317.19842
390 
407809983.865089
83 
111 
166666666.666666
500 
371280067.993002
950 
.658 
-
607809983.865090
40 
941143317.198423
40 
209 
 
222 
399999999.999999
760 
371280067.993002
950 
.294 
-
374476650.531757
06 
1174476650.53175
660 
1111 
1633333333.33333
3000* 
371280067.993002
950 
.000 
858856682.801576
30 
2407809983.86509
000 
2222 
1546666666.66666
6500* 
371280067.993002
950 
.000 
772190016.134909
60 
2321143317.19842
340 
11111 
1189999999.99999
9800* 
371280067.993002
950 
.004 
415523349.468242
94 
1964476650.53175
660 
22222 
1640000000.00000
0000* 
371280067.993002
950 
.000 
865523349.468243
00 
2414476650.53175
700 
111 
1 
-
466666666.666666
500 
371280067.993002
950 
.223 
-
1241143317.19842
340 
307809983.865090
30 
2 
-
2800000000.00000
0000* 
371280067.993002
950 
.000 
-
3574476650.53175
700 
-
2025523349.46824
310 
11 
-
533333333.333333
500 
371280067.993002
950 
.166 
-
1307809983.86509
040 
241143317.198423
36 
22 
-
166666666.666666
500 
371280067.993002
950 
.658 
-
941143317.198423
40 
607809983.865090
40 
222 
233333333.333333
250 
371280067.993002
950 
.537 
-
541143317.198423
60 
1007809983.86509
010 
1111 
1466666666.66666
6500* 
371280067.993002
950 
.001 
692190016.134909
70 
2241143317.19842
340 
2222 
1380000000.00000
0000* 
371280067.993002
950 
.001 
605523349.468243
10 
2154476650.53175
700 
11111 
1023333333.33333
3300* 
371280067.993002
950 
.012 
248856682.801576
40 
1797809983.86509
010 
22222 
1473333333.33333
3500* 
371280067.993002
950 
.001 
698856682.801576
50 
2247809983.86509
040 
222 
1 
-
699999999.999999
800 
371280067.993002
950 
.074 
-
1474476650.53175
660 
74476650.5317570
7 
2 
-
3033333333.33333
3000* 
371280067.993002
950 
.000 
-
3807809983.86509
000 
-
2258856682.80157
660 
11 
-
766666666.666666
700 
371280067.993002
950 
.052 
-
1541143317.19842
360 
7809983.86509009 
22 
-
399999999.999999
760 
371280067.993002
950 
.294 
-
1174476650.53175
660 
374476650.531757
06 
111 
-
233333333.333333
250 
371280067.993002
950 
.537 
-
1007809983.86509
010 
541143317.198423
60 
1111 
1233333333.33333
3500* 
371280067.993002
950 
.003 
458856682.801576
55 
2007809983.86509
010 
2222 
1146666666.66666
6700* 
371280067.993002
950 
.006 
372190016.134909
90 
1921143317.19842
360 
11111 
790000000.000000
000* 
371280067.993002
950 
.046 
15523349.4682431
6 
1564476650.53175
690 
22222 
1240000000.00000
0000* 
371280067.993002
950 
.003 
465523349.468243
30 
2014476650.53175
690 
1111 
1 
-
1933333333.33333
3000* 
371280067.993002
950 
.000 
-
2707809983.86509
000 
-
1158856682.80157
640 
2 
-
4266666666.66666
6500* 
371280067.993002
950 
.000 
-
5041143317.19842
300 
-
3492190016.13490
960 
11 
-
2000000000.00000
0000* 
371280067.993002
950 
.000 
-
2774476650.53175
700 
-
1225523349.46824
340 
22 
-
1633333333.33333
3000* 
371280067.993002
950 
.000 
-
2407809983.86509
000 
-
858856682.801576
30 
111 
-
1466666666.66666
6500* 
371280067.993002
950 
.001 
-
2241143317.19842
340 
-
692190016.134909
70 
222 
-
1233333333.33333
3500* 
371280067.993002
950 
.003 
-
2007809983.86509
010 
-
458856682.801576
55 
210 
 
2222 
-
86666666.6666666
30 
371280067.993002
950 
.818 
-
861143317.198423
50 
687809983.865090
30 
11111 
-
443333333.333333
400 
371280067.993002
950 
.246 
-
1217809983.86509
010 
331143317.198423
45 
22222 
6666666.66666674
6 
371280067.993002
950 
.986 
-
767809983.865090
10 
781143317.198423
60 
2222 
1 
-
1846666666.66666
6500* 
371280067.993002
950 
.000 
-
2621143317.19842
340 
-
1072190016.13490
960 
2 
-
4180000000.00000
0000* 
371280067.993002
950 
.000 
-
4954476650.53175
600 
-
3405523349.46824
300 
11 
-
1913333333.33333
3500* 
371280067.993002
950 
.000 
-
2687809983.86509
040 
-
1138856682.80157
660 
22 
-
1546666666.66666
6500* 
371280067.993002
950 
.000 
-
2321143317.19842
340 
-
772190016.134909
60 
111 
-
1380000000.00000
0000* 
371280067.993002
950 
.001 
-
2154476650.53175
700 
-
605523349.468243
10 
222 
-
1146666666.66666
6700* 
371280067.993002
950 
.006 
-
1921143317.19842
360 
-
372190016.134909
90 
1111 
86666666.6666666
30 
371280067.993002
950 
.818 
-
687809983.865090
30 
861143317.198423
50 
11111 
-
356666666.666666
750 
371280067.993002
950 
.348 
-
1131143317.19842
360 
417809983.865090
10 
22222 
93333333.3333333
70 
371280067.993002
950 
.804 
-
681143317.198423
50 
867809983.865090
30 
11111 
1 
-
1489999999.99999
9800* 
371280067.993002
950 
.001 
-
2264476650.53175
640 
-
715523349.468242
90 
2 
-
3823333333.33333
3000* 
371280067.993002
950 
.000 
-
4597809983.86509
000 
-
3048856682.80157
660 
11 
-
1556666666.66666
6700* 
371280067.993002
950 
.000 
-
2331143317.19842
340 
-
782190016.134909
90 
22 
-
1189999999.99999
9800* 
371280067.993002
950 
.004 
-
1964476650.53175
660 
-
415523349.468242
94 
111 
-
1023333333.33333
3300* 
371280067.993002
950 
.012 
-
1797809983.86509
010 
-
248856682.801576
40 
222 
-
790000000.000000
000* 
371280067.993002
950 
.046 
-
1564476650.53175
690 
-
15523349.4682431
6 
1111 
443333333.333333
400 
371280067.993002
950 
.246 
-
331143317.198423
45 
1217809983.86509
010 
2222 
356666666.666666
750 
371280067.993002
950 
.348 
-
417809983.865090
10 
1131143317.19842
360 
22222 
450000000.000000
100 
371280067.993002
950 
.240 
-
324476650.531756
70 
1224476650.53175
690 
22222 
1 
-
1940000000.00000
0000* 
371280067.993002
950 
.000 
-
2714476650.53175
700 
-
1165523349.46824
310 
2 
-
4273333333.33333
3500* 
371280067.993002
950 
.000 
-
5047809983.86509
000 
-
3498856682.80157
660 
11 
-
2006666666.66666
7000* 
371280067.993002
950 
.000 
-
2781143317.19842
400 
-
1232190016.13491
000 
22 
-
1640000000.00000
0000* 
371280067.993002
950 
.000 
-
2414476650.53175
700 
-
865523349.468243
00 
211 
 
111 
-
1473333333.33333
3500* 
371280067.993002
950 
.001 
-
2247809983.86509
040 
-
698856682.801576
50 
222 
-
1240000000.00000
0000* 
371280067.993002
950 
.003 
-
2014476650.53175
690 
-
465523349.468243
30 
1111 
-
6666666.66666674
6 
371280067.993002
950 
.986 
-
781143317.198423
60 
767809983.865090
10 
2222 
-
93333333.3333333
70 
371280067.993002
950 
.804 
-
867809983.865090
30 
681143317.198423
50 
11111 
-
450000000.000000
100 
371280067.993002
950 
.240 
-
1224476650.53175
690 
324476650.531756
70 
*. The mean difference is significant at the 0.05 level. 
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